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Precocious puberty, measured by thelarche or menarche, is a well-established breast
cancer risk factor. Using a unique and patented tissue engineering system we established cell
lines from 48 primary cultures of normal breast tissue from reduction mammoplasties and used
them as an in vitro model of thelarche, quantifying episphere formation and ductal differentiation.
Differential ductal formation was observed based on ancestry. In light of African American (AA)
precocious thelarche both in vivo and as we observed in vitro, we hypothesized that AA women
would exhibit an increased proportion of breast stem cells, with greater potency for
differentiation. Five AA cell lines and five European-derived white (EW) cell lines were
analyzed. AA cell lines had significantly higher percentages of breast stem cells and these stem
cells were more potent than those from EW cell lines, indicating innate differences in stem cells
might be responsible for ancestral differences in thelarche. We adapted our tissue engineering
system for xenoestrogenic assay development. The formation of epispheres was dose-responsive
with estradiol and bisphenol A. Development of a new assay is crucial for banning consumer
chemicals that cause cancer related changes in breast development. We then investigated breast
cancer cell lines for the role of Nucleotide Excision Repair (NER) in disease progression. Late
stage breast cancer cell lines (pre- or post-treatment) manifested significantly higher NER
capacity than stage I breast cancer or reduction cell lines. Increased NER capacity may be
responsible for chemotherapeutic resistance, consequential of tumor progression. We
hypothesized that the driver of higher repair capacity was due to the cancer stem cell populations
within these cell lines. Cancer stem cells were flow sorted from breast cancer-derived cell lines
and subjected to the functional Unscheduled DNA Synthesis (UDS) assay to assess NER
capacity. Cancer stem cells had increased NER capacity compared with non-stem cells from the
same cell lines. These data are consistent with breast cancer stem cells driving the increased
NER capacity in late stage breast tumors. Developing therapies specific to the breast cancer stem
cell compartment, albeit an elusive target, may provide a new treatment modality for resistant,
late stage breast tumors.
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Chapter 1
Introduction
1.1 Problem statement
1.1.1 Premature thelarche
The age of menarche (time of first period) has been decreasing for decades in the
United States and Europe. Some of this effect can be attributed to better nutrition, less
exercise and higher body mass index; however, there are indications that modulable
factors such as environmental exposures contribute as well. Menarche and thelarche (the
onset of breast development) are linked. For every year of premature thelarche, the risk
of breast cancer increases by 5-20%. African American girls in the United States
undergo menarche and thelarche an average of 2 years earlier than girls of Europeanderived White ancestry.
1.1.2 Risk factors in African American populations
Research, overall, in minority groups have lagged behind that of Europeanderived White women. The majority of large cohort studies in breast cancer have been
primarily done and are still being done on European-derived White women (Long et al.,
2013; Michailidou et al., 2015). There are known differences in breast cancer risk factors
and how they affect women of different ancestries differently. Models used to predict
and assess breast cancer risk are much less accurate and tend to underestimate the risk of
breast cancer in minority populations such as African American women (Adams-
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Campbell et al., 2009). There is a lack of scientific literature on the etiology and
treatment of African American breast cancer.
African American women have a higher incidence of breast cancer than
European-derived White women before age 40, while the opposite is true after age 40.
Although socio-economic factors have, in the past, been attributed to these differences,
data exists to support that there may be intrinsic biological differences in African
American breast tissue compared with white breast tissue. Evidence for this hypothesis
includes the fact that a higher percentage of estrogen receptor negative breast tumors are
present in African American women (Pacheco, Gao, Bumb, Ellis, & Ma, 2013).
1.1.3 Breast cancer
Breast cancer is currently the second most prevalent cancer in women and is
second in cancer-related deaths (Howlader et al., 2017). The majority of treatment
options for breast cancer are invasive requiring biopsy, surgery, radiation, and/or
chemotherapy. While recent success in targeted and hormonal therapies have helped to
improve breast cancer mortality rates, there are still tumors that are not cured. Breast
cancer recurrence after decades, and treatment of resistant tumors remain a large
problem. Certain molecular subtypes of breast cancer lack any targeted treatment and do
not respond to any hormonal therapy (Dawood, 2010). Treatment in these types of breast
cancer has seen little advancement. In fact, breast cancers without hormone and growth
factor receptors, such as triple negative breast cancer suffer from worse overall survival
rates. Studies have shown that triple negative breast cancer has a 5-year overall survival
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as low as 75%, 15% less than the current breast cancer 5-year overall survival rate of
90% regardless of type (Howlader et al., 2017; Ovcaricek, Frkovic, Matos, Mozina, &
Borstnar, 2011).
1.1.4 Treatment resistance
Recurrence in breast cancer often results in very poor outcomes and is much more
difficult to treat (Witteveen, Kwast, Sonke, IJzerman, & Siesling, 2015). Mechanisms of
resistance in cancer treatment include increased DNA repair capacity. In cells with
increased DNA repair, DNA damage caused by chemotherapy agents will be repaired
with greater efficiency and therefore cancerous cells are more likely to survive
chemotherapy treatment and continue to grow and proliferate (Helleday et al., 2008).
Nucleotide excision repair is primarily responsible for repair of DNA damage induced by
the cancer chemotherapeutic agents cyclophosphamide and doxorubicin and therefore
increased resistance (Reed, 1998; Wood, 2011). Mutations in nucleotide excision repair
genes have prognostic value, as they have been used successfully to predict the of
outcome cyclophosphamide and doxorubicin response (Andersson et al., 1996; Saffi et
al., 2010). Nucleotide excision repair deficiency is intrinsic in stage I breast cancer and
plays a role in genomic instability of early stage breast tumors (Latimer et al., 2010).
However, we know very little, if anything, about the role of nucleotide excision repair in
the progression of breast cancer.
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1.1.5 Model systems and cancer stem cells
There are over 60 commercially available cell lines that are used as surrogates to
study breast cancer in vitro. However, the use of these cell lines to represent breast
cancer overall has been called into question. The majority of these cell lines were
originally derived from late stage breast cancer metastases, whereas the current majority
of incident breast cancer is presently diagnosed as stage 1 breast cancer. The
mechanisms of resistance have been studied using these cell lines. However, the need to
explore and understand resistance mechanisms to better treat breast cancers of varying
stages still exist.
Within a tumor, there are specific cells termed cancer stem cells that are theorized
to have increased DNA repair mechanisms and exhibit increased resistance to genotoxic
insult (Pavlopoulou et al., 2016). Contradictory studies have also been published on their
supposed resistance to ionizing radiation (S.-Y. Kim et al., 2012; Yang, Sun, He, Cao, &
Jiang, 2015). Very little has been done to study the function of nucleotide excision repair
in cancer stem cells. In fact, the current literature is void of studies determining
nucleotide excision repair functional capacity in breast cancer stem cells. This is
unfortunate because, nucleotide excision repair is implicated in treatment resistance and
better characterization of breast cancer stem cells may resolve conflicting results seen in
the literature (Bowden, 2014; Holohan, Van Schaeybroeck, Longley, & Johnston, 2013).
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1.2 Purpose statement
The purpose of this dissertation research was to determine if there are differences
in stem cell behavior or number between European-derived White and African American
women. This may be pertinent to the differences in the timing of breast differentiation
witnessed in these ancestral groups. Then to develop a medium throughput assay for
human non-diseased breast differentiation for the testing of putative hormone disruptors
in culture. Using our culture model system, which produces in vitro like constructs, we
aimed to measure disruptions in secondary breast structures due to exposure to putative
estrogenic compounds. We ascertained the DNA Nucleotide Excision Repair capacity in
a survey of breast tumor cell lines commonly used as well as several developed in our
explant system (Appendix A). To further this work, our final aim was to determine DNA
repair in breast cancer stem cells within these cell lines.
1.3 Study objective and hypotheses
Hypothesis 1: There is greater percentage and/or potency of breast stem cells in African
American breast reduction explants than in European White breast reduction explants that
is biologically intrinsic. These intrinsic biological differences will drive breast
differentiation in our in vitro model of thelarche.
Specific aim 1: Determine the proportion of breast stem cells in African American and
European-derived White explants. Using flow cytometry, we will compare the
percentage of breast stem cells (CD24-, 44+, 49f+) of African American women to
European White women in these cultures to identify differences based on ancestry.
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Specific aim 2: Determine the potency of breast stem cells in these explants by sterile
flow sorting a single breast stem cell (CD24-, 44+, 49f+) into each well of a 96 well plate
for short time culture. We will also compare the ability of a single breast stem cell to
differentiate in culture to determine whether African American women have more potent
stem cells than European-derived White women.
Specific aim 3: Optimize our 3D multicellular in vitro breast differentiation system for
chemical testing that can be used to assess putative xenoestrogens. We will identify the
smallest chamber and fewest cells necessary for testing on multi-well plates and
determine the shortest possible time to determine hormone disruption. The goal will be
achieved by determining the speed and accuracy in scoring epispheres, as a measure of
changes in episphere formation.
Rationale for Aims: Minority groups are severely underrepresented in breast cancer
research. This study will help to gain insight into the etiology of breast cancer using a
model of thelarche. Thelarche is a well-established risk factor for breast cancer.
Hypothesis 2: Nucleotide excision repair functional capacity will be increased in breast
cancer stem cells compared to breast cancer non-stem cells.
Specific aim 1: Ascertain the capacity of breast cancer stem cells from early and late
stage tumor cell lines to perform nucleotide excision repair using the unscheduled DNA
synthesis assay. Then compare breast cancer stem cells to breast cancer non-stem cells to
ascertain whether breast cancer stem cells have increased nucleotide excision repair
capacity.
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Rationale for this aim: Breast cancer stem cells are more resistant to genotoxic insults
than other cells in the tumor. However, the nucleotide excision repair capacity in breast
cancer stem cells is unknown. The nucleotide excision repair pathway is a mechanism of
cancer resistance and needs to be further elucidated in breast cancer. Because of its role
in resistance, it is possible that nucleotide excision repair could be made into a drug target
for future treatment options.
1.4 Barriers, issues, limitations:
1.4.1 Thelarche, ancestry and breast stem cells
Our model system of thelarche is not completely established and we had to limit
the work to formation of specific structures seen in culture, termed epispheres. The
number of reduction mammoplasty cell lines was limited for the African American
population and we had to limit the study to 5 African American and 5 European White.
Furthermore, the number of post-menopausal cell lines was limited to 3 post-menopausal
samples for stem cell analysis. Despite a very complicated and difficult flow cytometry
process to isolate normal stem cells and culture them, we were successful in studying
both percentage and potency.
1.4.2 Cancer progression and cancer stem cells
Cancer stem cells are extremely difficult to maintain as stem cells. Most groups
are not able to do this, and they have created molecular methods of arresting
differentiation that have raised many questions about the validity of these cells
representing cancer stem cells (Sajithlal et al., 2010). In spite of this we have been
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successful at plating them directly after flow cytometry on 100% basement membrane
extract in conditioned medium and perform the biochemical Unscheduled DNA synthesis
assay 24 hours later.
1.4.3 Assumptions
In this study we have assumed that one or more of the non-diseased breast
reduction derived cell lines would be capable of reproducible episphere formation for the
development of an endocrine disruptor test system. We also assumed that with
experimental repetition that cancer stem cells would maintain their “stemness” long
enough to be assessed for nucleotide excision repair functional capacity and that the
presence of a bimodal peak of repair capacity would be evidence of differentiation.

Summary
Our study sheds light on African American women, an under-represented group,
to better understand breast differentiation and how it relates to breast cancer. We have
also developed a testing system for endocrine disruption. This testing system will fill a
gap in future breast cancer prevention strategies. We have previously determined the
nucleotide excision repair capacities in respect to stage of breast cancer cell
lines/explants. We have furthered this by determining the nucleotide excision repair
capacity in cancer stem cells. This fills a large void in the scientific literature and brings
new findings into a controversial area of cancer stem cells. Nucleotide excision repair is
a mechanism of treatment resistance that can be used by carcinogenic cells. Better
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understanding of this mechanism can lead to improved treatments for breast cancer,
especially in late stage resistant tumors.
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Chapter 2
Literature review
2.1 Breast anatomy
The breast is comprised of the mammary gland, which is a modified sweat gland
that produces milk. Lactiferous ducts and lobes make up the mammary gland (Figure
2.1) (Hoda, Bogi, Koerner, & Rosen, 2014). Lobes are made up of smaller lobules which
are the milk producing structures in the breast. Lobules and lobes are connected by a
series of branching ducts the lead milk from the back of the breast where the lobules are
located, through the lactiferous ducts to the nipple (Hoda et al., 2014). Lobules are made
up of clusters of hollow spheres called alveoli (Blackburn, 2014).
2.1.1 Microanatomy of the breast
The breast is composed of epithelial and stromal components and together, the
ducts and lobules constitute the epithelial portion. The epithelium is composed of
polarized luminal epithelial cells (Hoda et al., 2014). These cells which surround the
lumen of the ducts and lobules are the cells that secrete milk into the lumen of the alveoli
(Figure 2.1). At the base of the luminal cells that form these alveoli are basal
myoepithelial cells (Figure 2.1C) that contract and aid in the release of milk, in response
to oxytocin binding to the oxytocin receptor (Sternlicht, 2005). Lobules are immediately
surrounded by delimiting fibroblasts. Fibroblasts produce paracrine factors that support
the epithelium (Hoda et al., 2014).
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Lobules also called terminal ducal lobular unit (TDLU), are spherical in shape
due to the compact arrangement of multiple short branching’s of blind-ended ducts,
enclosed in a specialized stroma (Hoda et al., 2014). TDLUs are made up of an inner
luminal epithelial layer and an outer layer of myoepthelial cells, all enclosed by a
basement membrane. TDLUs, 20-40, are grouped together to form a single lobe (Pandya
& Moore, 2011). Each breast consists of 15-20 lobes and each lobe has its own duct
(Blackburn, 2014; Pandya & Moore, 2011). On the stromal side of the basement
membrane lie fibroblasts and loosely textured collagen, which is traversed by small blood
vessels, peripheral blood lymphocytes, macrophages, and plasma cells (Hoda et al.,
2014). The majority of the breast is fat tissu e made up of adipocytes that fills the area
around the epithelium, fat cells are necessary for the formation of epithelial structures in
explanted breast tissue into host animals (Hoda et al., 2014; Pandya & Moore, 2011).
The breast is a highly vascularized and lymphatic organ, and it contains hundreds
of lymph nodes around the lobules and ducts. The purpose of these lymph nodes is to
provide the suckling infant with antibodies and live lymphocytes before it has a working
immune system. The lymph nodes of the breast drain into over 20 axillary lymph nodes,
the lymph nodes located under the arm (Figure 2.1) (Vidi, Bissell, & Lelièvre, 2013).
There are 6 axillary lymph node groups that are recognized by surgeons (Pandya &
Moore, 2011).
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Figure 2.1 Breast anatomy. (A) The basic anatomy of the breast (B) Hematoxylin and eosin stained cross
section of a breast TDLU. A single alveolus is shown in the inset in the upper right corner, polarized
luminal epithelial cells surround an inner lumen. (C) A micrograph of a human alveolus that shows luminal
epithelial cells (white circles) surrounded by myoepithelial cells (white squares). Adapted with permission
from Vidi et al. 2013 and cancergov.org.

2.2 Breast development
2.2.1 Prenatal and perinatal development
The development of the female breast begins during embryogenesis and
undergoes massive changes throughout life. Proliferation of a pair of mammary ridges
from ectoderm in the thoracic region are the first signs of fetal breast development. The
mammary crest (also called the milk line) is formed from the thickening of epidermis on
the ventral surface in the embryo after about 5 weeks (Sternlicht, 2005). The mammary
crest atrophies and leaves behind two buds. Breast development begins from these
primary buds (Blackburn, 2014). While the development of the fetal mammary gland is
independent of hormone stimulation, B-cell lymphoma 2 protein (BCL2) plays a major
role in the inhibition of apoptosis and is expressed through prenatal development in the
breast (Nathan, Anbazhagan, Clarkson, Bartkova, & Gusterson, 1994).
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Around 15 weeks the primary buds will have penetrated into the upper dermis and
mesenchymal cells penetrate into the supportive cells of the breast (Javed & Lteif, 2013).
Secondary buds will form from the primary buds and will become the lactiferous ducts.
Both luminal and basal epithelial cells can be distinguished at this point. Growth of solid
epithelium columns will give rise to lobes in the mammary grand.
By 24 weeks, fetal breasts become apparent with tubular structure surrounded by
dense connective tissue. Around this period, the breast will become more collagenized
and less cellular and the ligaments of Cooper will form. After 28 weeks, a major
lactiferous duct will form a mammary pit, which will eventually become the nipple and
the development of branching lobule and alveolar glandular structures will take place
(Javed & Lteif, 2013). By birth, the infant will have anywhere from 15-20 lobes each
with a lactiferous duct leading to the mammary pit (Blackburn, 2014; Javed & Lteif,
2013).
Postnatally the breasts may secret colostrum and enlarge under the influence of
placental maternal hormones. This enlargement will subside in the first and second week
as hormones disappear. After this disappearance of maternal hormones, the glands will
shrink and return to an inactive state (Sternlicht, 2005). At this point, the expression of
BCL2 is also lost in the breast (Nathan et al., 1994). Lactiferous ductal structures will
persist and branch, however, no alveolar differentiation will occur. The breast remains
rudimentary until the production of estrogen and progesterone from the ovary begins at
the onset of puberty (Javed & Lteif, 2013; Sternlicht, 2005).
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2.2.2 Breast development at puberty
Thelarche or postnatal breast development occurs just before or during puberty
(Cabrera, Bright, Frane, Blethen, & Lee, 2014). Thelarche involves elongation of ducts
and thickening of the epithelium. Lobule, alveolar, and hormonally responsive periductal
stroma differentiation also occurs (Javed & Lteif, 2013). While development of the
breast at this stage is highly dependent on hormones, paracrine and autocrine signaling
are used to communicate within cells of the lobules. The start of menstruation is called
menarche and is highly associated with thelarche, which usually occurs soon after (Hoda
et al., 2014; Javed & Lteif, 2013).
A report released by Sandra Steingraber and published by the breast cancer
foundation in 2007, is a comprehensive review that highlights the drastic change seen
over the past 40 years in the age of puberty. Figure 2.2 shows that the average age of
menarche fell from 1790 to 1980 (Euling, Selevan, Pescovitz, & Skakkebaek, 2008;
Wyshak & Frisch, 1982). Currently the average age for menarche is 12.6 (range 12.4–
12.8) for white non-Hispanic girls and 12.2 (range 12.0–12.4) for African American girls.
Furthermore, the average age of thelarche in young females now rests at 10.3 for
European-derived white girls and 9.5 for African American, with many in both ancestries
beginning before the age of 8 (Cabrera et al., 2014; Euling et al., 2008; Steingraber,
2007). Decreased age of puberty has both emotional and biological implications,
including breast cancer risk.
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Figure 2.2 The falling age of puberty. Data from Europe (open white circles) and USA (closed
circles) shows the age of puberty has been in steady decline in over 200,000 patients from 1790 to
1980. Reproduced with permission from Wyshak et al., 1982, Copyright Massachusetts Medical
Society

The menstrual cycle is generally divided into 3 phases the follicular phase,
ovulatory phase, and the luteal phase (Barrett & Raybould, 2010). The follicular phase
lasts about 9 to 23 days; during this stage, estrogen increases and in the breast this signals
parenchymal proliferation of the ductal system (Ramakrishnan, Khan, & Badve, 2002).
The development of ovarian follicles occurs in this stage. The ovulatory phase lasts 1 to
3 days, and is marked with sharp increases in estrogen from the follicle. The luteal phase
lasts 13 to 14 days and during this phase progesterone levels rise. During the luteal phase
under the influence of progesterone, the breast ductal system is dilated and differentiation
of alveolar cells into secretory cells occurs (Ramakrishnan et al., 2002). If pregnancy
does not occur the hormone levels fall, and menses occurs.
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2.2.3 Pregnancy and menopause
In preparation for lactation the breast transforms during pregnancy. During the
first trimester, the alveoli and ducts increase in lobules. Due to the increase in epithelium
the breast becomes denser. Stromal vascularity increases, and the breast will become
infiltrated with mononuclear cells. In the second and third trimester, lobular growth will
continue through cellular enlargement and proliferation of cells and lobules well become
distended with secretion. After birth and breast feeding, lactation declines and the breast
lobules will undergo involution and decrease in size and density (Tiede & Kang, 2011).
There are 4 well-defined types of lobules based on how well they are developed
(Tiede & Kang, 2011). Type 1 lobules only have a single short terminal duct ending in a
cluster of alveoli. Types 2, 3, and 4 all have terminal ducts that branch into multiple
clusters of alveoli, each with progressively increasing amounts of branching and
increasing numbers of alveoli. Type 4 will eventually develop secretory acinar structures
and is only reached in women who have gone through pregnancy and breastfed (Tiede &
Kang, 2011). However, Type 4 lobules will regress to type 3 lobules following the end
of lactation (Baer et al., 2009; Tiede & Kang, 2011). In virgin and nulliparous women
type 1 lobules are the most common type (Tiede & Kang, 2011). then, during menopause
the glandular nature of the breast will become subdued with cell death in ducts and
alveoli. Finally, the breast will then become more acellular with an increase in stromal
components.
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2.3 Stem cell
2.3.1 Normal breast stem cells
Stem cells are cells that are undifferentiated and have the ability to self-renew or
differentiate into different cell types. Embryonic stem cells are omnipotent or have the
ability to differentiate into all cell types as well as self-renew. Adult stem cells are cells
that maintain some pluripotency and can differentiate into only few cell types as well as
self-renew. Adults stem cells are found throughout the body and aid in many normal
functions. In the breast, breast stem cells are thought to be located in the
myoepithelial/basal layer of the ductal architecture and give rise to both luminal epithelial
cells and myoepithelial cells. The mammary gland is unique in that it does not fully
mature, and will only undergo some ductal growth differentiation until puberty. After
puberty, it will undergo cyclical changes during menstruation and pregnancy. During the
luteal phase of menstruation, alveoli epithelial cells proliferate and are poised to begin a
pregnancy. If a pregnancy is not established, these cells die, the alveolus involutes and
calcification occurs in the place where the cells have died. During pregnancy, cells in the
breast grow and proliferate then involute when lactation is complete. This constant
remodeling of the tissue requires a source of cells that can give rise to both cell types,
luminal epithelial and myoepithelial cells, that comprise the functional unit of the gland
as well as being able to self-renew (Tiede & Kang, 2011). These special cells have been
termed breast stem cells and are necessary for the healthy development and maintenance
of the mammary gland. The existence of these cells in human breasts have been inferred
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from rodent models and in vitro studies dating back to the 1950’s (Daniel, Young,
Medina, & DeOme, 1971; Deome, Faulkin, Bern, & Blair, 1959). In syngeneic C3H
mice the mammary fat pad was cleared, and serially transplanted with normal mammary
gland. The fat pad of the host would support the normal function of the grafted
mammary cells (Deome et al., 1959). What was eventually discovered is that all portions
of the mammary gland could repopulate and become a normal functioning mammary
gland (Daniel et al., 1971). Serial transplantation involved taking the cells from one
rodent, C3H mice, and moving it to another to repopulate the second rodent. However,
this was found to be a finite process, and with normal mammary cells, 5 to 8 transplant
generations were possible. In contrast, cells transplanted from precancerous/cancerous
donors could be transplanted indefinitely (Callahan & Smith, 2000; C. W. Daniel,
Aidells, Medina, & Faulkin, 1975; Gilbert H. Smith, Pauley, Socher, & Medina, 1978).
Furthermore, Young et al. showed that age, parity, and hormonal status of the donor did
not alter the mammary regenerative potential (Young, Medina, DeOme, & Daniel, 1971).
The fact that cells from any portion of the mammary gland and from donors of
any age, all pointed to the existence of cells with a stem like capabilities. This was
eventually proven and it was shown that a single rare cell in the mouse mammary gland
can be transplanted to repopulate an entire functioning mammary gland (Shackleton et
al., 2006). Breast stem cells have been defined as a distinct cell type that is able to reestablish the mammary epithelium by asymmetric division into more differentiated cell
types, at least luminal epithelial or myoepithelial cells (Van Keymeulen et al., 2011).
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Furthermore, mammary stem cells have the ability to undergo symmetric division and
only a single daughter cell will differentiate (Chen, Liu, & Song, 2017; Knoblich, 2008).
Cells with similar capabilities have been verified in humans as well (Gudjonsson et al.,
2002; J Stingl, Eaves, Zandieh, & Emerman, 2001; John Stingl et al., 2006).
While the gold standard of identifying breast stem cells remains the ability to
reconstitute the mammary gland in xenograft mice models, the emergence of
fluorescence activated sorting (FACS) has been crucial to our understanding and
identifying breast stem cells especially in humans (Chen et al., 2017). Multiple surface
markers have been employed in the use of purification of stem cells and are summarized
in Table 2.1.
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Table 2.1 Breast stem cell markers used in flow cytometry.

Marker

Source

Associated with

Reference

Stem cell antigen1 (SCA-1)

Hematopoietic stem

Mammary progenitor
cell

Welm et al., 2002.
Gudjonsson et al.,
2002

CD24*

Sialoglycoprotein;
Cell adhesion
molecule

Cancer differentiated
cell

Hajj et al., 2002

CD44

Glycoprotein; Cell
adhesion molecule

Cancer
stem/progenitor cell

Hajj et al., 2002

Integrin beta-1
(CD29)

Cell adhesion
molecule

Mouse cancer
stem/progenitor cell

Shackleton et al.,
2007

Integrin alpha-6
(CD49f)

Cell adhesion
molecule

Bipotent
Stingl et al., 2001
luminal/myoepithelial
progenitor

Epithelial cell
adhesion
molecule
(EPCAM/ESA)

Cell adhesion
molecule

Bipotent
Stingl et al., 2001;
luminal/myoepithelial Gudjonsson et al.,
progenitor
2002

RH123 efflux

Increased efflux of
chemical dye

Bipotent
Stingl et al., 1998
luminal/myoepithelial
progenitor

Hoechst-33342
dye efflux

Increased efflux of
chemical dye

Multipotent

Zhou et al., 2001;
Smalley et al. 2003

Aldehyde
dehydrogenase
(ALDH1)

Increased enzymatic
activity

Cancer
stem/progenitor cell

Ginestier et al., 2007

*in mouse models CD24, in combination with other markers, is a positive marker for
stem/progenitor cells able to generate a functional mammary gland from a single cell
(Shackleton 2007).
**Most markers are used in combinations with multiple positive and negative markers for
stem/progenitor cells, ALDH1 is often used alone or in combination with other markers.
Markers of stem and cell type are often used in conjunction with each other.
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Early work in rodents by Welm et al. (2002) identified stem cell antigen-1 stained
cells as a mammary stem cell rich population with increased Hoechst efflux, a stem cell
characteristic (Welm et al., 2002; Zhou et al., 2001). Sting et al. (2001), discovered 3
types of human mammary progenitor cells in vitro, these progenitor cells could produce
luminal epithelial, myoepithelial, or both. Cells positive for CD49f and Epcam showed
bipotent progenitor differentiation while cells that did not express these markers showed
a decrease in potency (Stingl et al., 2001). The development of the mammosphere
culture system involved the use of ultralow attachment plates to grow and maintain
human mammary epithelial cells. These cells would grow in suspension as spherical
structures termed mammospheres (Dontu, Abdallah, et al., 2003). Mammospheres were
found to be enriched in stem cells that were maintained in their undifferentiated state.
Transcriptional profiling of these mammospheres confirmed the presence of breast stem
cells with similar gene profiles to those of earlier markers (Dontu, Al-Hajj, Abdallah,
Clarke, & Wicha, 2003; Gudjonsson, Rønnov-Jessen, Villadsen, Bissell, & Petersen,
2003).
2.3.2 Breast cancer stem cells
Eventually it was hypothesized that breast stem cells could be the origin of many
tumors and produce more heterogeneous tumors than more differentiated cells (Tu, Lin,
& Logothetis, 2002). Stem cells are also more embryonic and share marked similarities
with cancer stem cells, or tumor initiating cells such as increased differentiation potential
(Kim & Ryu, 2017). First discovered in acute myeloid leukemia (AML) it was found that

22

cancer cells are heterogeneous (Bonnet & Dick, 1997). There was a subpopulation of
cells that were more primitive or embryonic in behavior and more strongly resemble stem
cells than other cells in the tumor (Costa, Le Blanc, & Brodin, 2006). Bonnet et al.
showed that a specific subset of cells from AML with CD34 positive and CD38 negative
markers, when transplanted into non-obese diabetic/severe combined immunodeficiency
(NOD/SCID) mice would reform the original cancer population. In contrast cells that
were CD34+ 38+ could not do this. Thus, the first evidence of more potent cells with in
the tumor was found, these cells were coined cancer stem cells.
cancer stem cells are thought to be more treatment resistant and metastatic than
other cells within the tumor. After finding cancer stem cells in AML, it was later
confirmed that breast cancer stem cells also exist in breast tumors. Human breast cancer
stem cells could be grown in vivo, and when CD24-/44+/Lineage- (Lineage markers
include: CD2, CD3, CD10, CD16, CD18, CD31, CD64, and CD140b) were transplanted
into NOD/SCID mice, they could repopulate the original tumor in these mice. Cells that
did not display these protein markers, breast cancer non-stem cells, were unable to
repopulate the tumor when placed into NOD/SCID mouse (Dontu, Al-Hajj, et al., 2003).
There is evidence that stem cells can be the cell of origin in cancer as they are
possible targets for insult (Lim et al., 2009; Miller et al., 1989; Proia et al., 2011). They
have intrinsic longevity and activation of epithelial to mesenchymal transition can lead to
the formation of cancer stem cells from normal cells (Smith, 2002; Tiede & Kang, 2011).
Epithlelial to mesenchymal transition is a process where epithelial cells lose their contact
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and adhesion with other cells as well as their polarity which makes them become more
migratory, and is highly associated with cancer stem cells and invasiveness (Lee, Hwang,
& Choi, 2016). Activation of the Ras-mitogen activated protein kinase pathway via
increased oncogenes Ras or transdermal growth factor β1 or by increased expression of
transcription factors Snail and/or twist have changed normal human mammary epithelial
cells into breast cancer stem cells via an epithlelial to mesenchymal transition mediated
process.
Functionally, to be considered a cancer stem cell the putative stem cell must be
able to form a tumor in NOD/SCID mouse and then be passagable in additional mice.
Under certain stresses it is possible for differentiated tumor cells to revert into more
primitive cancer stem cells via epithelial to mesenchymal transition (Owens & Naylor,
2013). A simplified schematic of the advanced cancer stem cell model is outlined in
Figure 2.3.
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Figure 2.3 The cancer stem cell theory. In metastasis: cancer stem cells are the cells that are
believed to be responsible or have the capability to move to distant organs and create full tumors. In
Relapse: cancer stem cells are believed to be responsible or have the capability to evade cell death and
resist treatment then repopulate the tumor. In special circumstances selective pressures can trigger
(hypoxia, chemotherapy, etc.) differentiated non-cancer stem cells can undergo EMT and become
cancer stem cell (green arrows). Epithelial to mesenchymal transition (EMT), cancer stem cell (CSC).

2.4 Breast cancer
2.4.1 Breast cancer incidence and mortality
Breast cancer is a disease that occurs in one mutated cell that proliferated
uncontrollably. It is estimated that there will be about 255,180 newly diagnosed cases of
breast cancer in 2017, and 63,410 of these cases will be non-invasive carcinoma in-situ.
The Surveillance, Epidemiology, and End Results (SEER) program has been instituted by
the National Cancer Institute and has collected clinical, pathological and demographic
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data on cancer patients since 1973. Based on the most recent SEER statistics, the lifetime
risk of developing breast cancer in women is 12.32%, and while men can also develop
breast cancer, the risk is much lower at 0.13% (Desantis et al., 2016). Breast cancer is
the second leading cause of cancer-related deaths in women with an expected 40,610
mortalities in 2017 (N Howlader et al., 2017). While the mortality rate has fallen 39%
since 1989, they have remained steady in recent years for women under the age of 50.
The current breast cancer 5-year survival rate is 90% (N Howlader et al., 2017). Both the
increases in breast cancer incidence and the decline in mortality can be attributed to
introduction of mammographic screening and better treatment options (Glass, Lacey,
Carreon, & Hoover, 2007). Clinical outcome is highly dependent on early detection as as
well as other key factors including molecular type, stage, grade, and age.
2.4.2 Breast cancer risk factors
There are many factors that are either positively or negatively associated with the
risk of developing breast cancers. These factors fall into two categories, those that are
modifiable and those that are non-modifiable. Non-modifiable risk factors are those you
cannot change, such as gender, age, race, and family history. Modifiable risk factors are
those that can be adjusted such as weight, dietary intake, breastfeeding, alcohol
consumption, smoking, and pregnancy (Table 2.2). Non-modifiable breast cancer risk
factors are gender, age, race, breast density, age of menarche, genetic susceptibility,
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Table 2.2 Breast cancer risk factors
Relative risk
>4.0

Non-modifiable factor
• Age (65+ vs. <65 years, although risk
increases across all ages until age 80)
• Biopsy-confirmed atypical hyperplasia
• Certain inherited genetic mutations for breast
cancer (BRCA1 and/or BRCA2)
• Ductal carcinoma in situ
• Lobular carcinoma in situ
• Personal history of early-onset (<40 years)
breast cancer
• Two or more first-degree relatives with breast
cancer diagnosed at an early age
• Breast density >75% by area

Modifiable factor
• None

2.1-4.0
• High endogenous estrogen or testosterone
levels (post-menopausal)
• Mammographically extremely dense (>50%)
breasts compared to less dense (11%-25%)
• One first-degree relative with breast cancer

• High-dose radiation to chest

• Ashkenazi Jewish heritage
• Early menarche (<12 years)
• Height (>5 feet 3 inches)
• Late menopause (>55 years)
• Mammographically dense (26%-50%) breasts
compared to less dense (11%-25%)
• Non-atypical ductal hyperplasia or fibro
adenoma
• Personal history of breast cancer (40+ years)
• Personal history of endometrium, ovary, or
colon cancer
• Any benign breast disease

• Alcohol consumption
• Diethylstilbestrol exposure
• High socioeconomic status
• Late age at first full-term pregnancy
(>30 years)
• Never breastfed a child
• No full-term pregnancies
• Obesity (post-menopausal)/adult
weight gain
• Recent oral contraceptive use
• Recent and long-term use of
menopausal hormone therapy
containing estrogen and progestin
• Active and passive smoking

1.1-2.0

(Boyd et al., 2007; Gierch & Vogel, 2004; N Howlader et al., 2017; Yaghjyan et al., 2011)

and family history. Men can in fact develop breast cancer, however, it is very rare and
associated with a breast cancer susceptibility antigen 2 (BRCA2) mutation. The lifetime
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risk of a man having breast cancer is 1 in 1000, while the risk in females compared to
males is 100 times greater, about 1 in every 8 women will be diagnosed with breast
cancer (Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary
CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, 2013). The
most prevalent risk factor for female breast cancer is age, and the probability of
developing invasive breast cancer in the next 10 years increases with age and is greatest
in women that are 70 years old (N Howlader et al., 2017). Caucasian and African
American women have the highest incidence of breast cancer while Asian, Native
American, and Hispanic women have a lower overall risk of breast cancer (Copeland et
al., 2014; Desantis et al., 2016; Gierch & Vogel, 2004).
Breast density is the proportion of fat to fibrous and glandular tissue (dense tissue
that appears light on a mammogram) that can be seen and quantified on the mammogram.
Breasts that are more than 75% dense by area are at a 4 to 6 fold greater risk of
developing breast cancer (Boyd et al., 2007; Yaghjyan et al., 2011).
Medical history is also a risk factor with breast cancer rates being higher in
women who have been diagnosed with ductal carcinoma in situ (DCIS), lobular
carcinoma in situ (LCIS), or atypical hyperplasia (Donaldson et al., 2017). Patients who
have had previous biopsies, including number and outcome are also at increased risk for
developing breast cancer. This increase is most prevalent in women who are over the age
of 50 (Gail et al., 1989; Nichols, Lee, & Roh, 2017).
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Only about 10% of all breast cancers diagnosed are due to known inherited
genetic mutations (Figure 2.5), another 15% to 20% have family history, but no known
inherited mutation (Schrader, Sharaf, Alanee, & Offit, 2015). The most common
mutation in inherited cases is in 2-breast cancer susceptibility 1 and 2 (BRCA1, BRCA2)
genes. Both are tumor suppressor genes whose protein is involved in the double strand
break repair as well as mismatch repair (Chapman, Taylor, & Boulton, 2012; Wu, Lu, &
Yu, 2010). The risk of developing breast cancer in these patients is 72% for BRCA1
mutation carriers and 69% for BRCA2 mutation carriers BRCA2 (Kuchenbaecker et al.,
2017; Lippi, Mattiuzzi, & Montagnana, 2017).
Furthermore, there have been three founder mutations discovered in Ashkenazi
Jewish women in BRCA1 and BRCA2 genes. As many as 11% of all breast cancers in
the Ashkenazi Jewish population are due to these founder mutations, this is substantially
higher than other populations (Gabai-Kapara et al., 2014). Overall, inherited genetic
mutations make up a small number of all diagnosed breast cancers, these include the high
penetrance mutations such as BRCA1 and BRCA2. Currently breast cancer is largely a
random and exposure driven disease. Family history is another important factor and the
risk of breast cancer increases with each first-degree relative diagnosed with breast
cancer. While family history and genetic susceptibility can be very closely related due to
the inheritance of genetic mutations, they can also be due to shared environmental affects
as well.
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Modifiable factors that affect your risk for breast cancer are parity, age at first
birth, lifetime duration of breast feeding, age at menopause, body mass index, use of oral
contraceptives, use of hormone replacement therapy, smoking, and use of alcohol
(Howell et al., 2014; Morimoto et al., 2002). These factors are summarized in Table 2.2.
While the association of these factors is established with breast cancer, they do not
always hold true for different stages and types of cancers and between different
populations (Anderson, Schwab, & Martinez, 2015; Barnard, Boeke, & Tamimi, 2015;
Turkoz et al., 2013). For example, parity seems to be protective for breast cancer but
when comparisons are corrected for types of breast cancer, there may actually be an
increased risk for triple negative breast cancers and decreased risk of luminal A breast
cancers (Barnard et al., 2015; Phipps, Malone, Porter, Daling, & Li, 2008; Tamimi et al.,
2012).
Most recently, a large-scale project was put together by four consortia, the
Collaborative Oncological Gene-environment Study (COGS), to identify susceptibility
loci in breast cancer, as well as other hormone-related cancers. COGS used the Genome
Wide Association Studies (GWAS) to find areas in the genome with the greatest potential
to be associated with risk then genotyped over 200,000 single nucleotide polymorphisms
(SNP) in these areas in women of European descent. SNPs are changes in a single
nucleotide at a specific position in the DNA, or locus. By doing this, 41 novel loci were
found to be associated with breast cancer risk (Michailidou et al., 2014). Studies such as
this have contributed to the discovery of over 80 loci that are associated with breast
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cancer risk (Michailidou et al., 2015). However, these studies have been lacking
populations other than women of European descent, a major limitation. Furthermore,
precisely how these SNPs are being used to help calculate risk is still being studied (Gail,
2015; Howell et al., 2014).
These risk factors have been put together to create assessment tools that attempt
to predict breast cancer risk and give counseling to individual women as part of a
prevention strategy. The most well-known of these models is the breast cancer risk
assessment tool, or the Gail model, created by the national cancer institute (NCI)
available at https://www.cancer.gov/bcrisktool/. The tool asks eight questions based on
key breast cancer risk factors to calculate lifetime and five-year breast cancer risks.
Possible interventions can be implemented based on this model for risk reduction
including modifying lifestyle factors or even drug interventions (Howell et al., 2014;
Kushi et al., 2012; Moyer & U.S. Preventive Services Task Force, 2013). While the Gail
model is one model of risk assessment there are other models have been developed to
include more in-depth familial traits or modifiable risks, such as the Claus model, Pfeiffer
cohort study, Tyrer-Cuzik model (IBIS), and the Breast and Ovarian Analysis of Disease
Incidence and Carrier Estimation Algorithm (BOADICEA) (Antoniou, Pharoah, Smith,
& Easton, 2004; Claus, Risch, & Thompson, 1994; Pfeiffer et al., 2013; Tyrer, Duffy, &
Cuzick, 2004).
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2.4.3 Menarche, thelarche and breast cancer risk.
Menarche and thelarche are often used as surrogates of puberty to determine
breast cancer risks. Precocious menarche, generally defined as younger than eleven years
old, is associated with increased risk of developing breast cancer (Collaborative Group on
Hormonal Factors in Breast Cancer, 2012; Kelsey, Gammon, & John, 1993; Latronico,
Brito, & Carel, 2016; G. D. Mishra et al., 2017; Ritte et al., 2013). In fact, studies have
shown that each one year delay in menarche is associated with 5-10% reduction in breast
cancer risk (Collaborative Group on Hormonal Factors in Breast cancer, 2012; Hsieh,
Trichopoulos, Katsouyanni, & Yuasa, 1990). Furthermore, breast duct development is
also associated with breast cancer risk, rendering thelarche an important risk factor as
well. This is a particular concern because the age of menarche and thelarche is declining
overall in the past one hundred years (section 1.1.2). African American girls on average
begin thelarche almost a full year earlier than European white girls (Euling et al., 2008;
Steingraber, 2007).
2.4.4. Breast cancer subtypes and staging
The severity of breast cancer is defined by the pathological stage, which is based
on tumor size, lymph node status, and metastasis. Breast cancer is staged from 0-IV, as
described in Table 2.3 based on the American Joint Committee for Cancer. The
implementation of mammographic screening in 1989 has led to a decrease in late stage
breast cancer at diagnosis and incidence of invasive breast cancer, in fact, stage I breast
cancer is now the most often diagnosed stage (Siegel, Miller, & Jemal, 2016).

32

Table 2.3. Breast cancer staging system (AJCC)
TNM system

Stage
0
IA
I

IB

IIA
II
IIB

IIIA

III

IIIB

IIIC
IV

TX
T0
Tis
Tis (DCIS)
(LCIS)
Tis
(Paget’s)
T1
T1mi
T1a
T1b
T1c
T2

T

N

M

Tis

N

M

T1

N0

M0

T0

N1mi

M0

T1

N1mi

M0

T0

N1

M0

T1

N1

M0

T2

N0

M0

T2

N1

M0

T3

N0

M0

T0

N2

M0

T1

N2

M0

T2

N2

M0

T3

N1

M0

T3

N2

M0

T4

N0

M0

T4

N1

M0

T4

N2

M0

Any T

N3

M0

Any T

Any N

M1

Primary tumor cannot be assessed
No evidence of primary tumor
Carcinoma in situ
Ductal carcinoma in situ Tis
Lobular carcinoma in situ
Paget’s disease of the nipple NOT associated with invasive carcinoma and/or carcinoma
in situ (DCIS and/or LCIS) in the underlying breast parenchyma.
Tumor ≤ 20 mm in greatest dimension
Tumor ≤ 1 mm in greatest dimension
Tumor > 1 mm but ≤ 5 mm in greatest dimension
Tumor > 5 mm but ≤ 10 mm in greatest dimension
Tumor > 10 mm but ≤ 20 mm in greatest dimension
Tumor > 20 mm but ≤ 50 mm in greatest dimension
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Table 2.3 continued.

T3
T4
T4a
T4b
T4c
T4d

Tumor > 50 mm in greatest dimension
Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or
skin nodules)
Extension to the chest wall, not including only pectoralis muscle adherence/invasion
Ulceration and/or ipsilateral satellite nodules and/or edema (including peau d’orange) of
the skin, which do not meet the criteria for inflammatory carcinoma
Both T4a and T4b
Inflammatory carcinoma

Distant Metastases (M)
M0
No clinical or radiographic evidence of distant metastases

cM0(i+)

No clinical or radiographic evidence of distant metastases, but deposits of molecularly or
microscopically detected tumor cells in circulating blood, bone marrow, or other
nonregional nodal tissue that are no larger than 0.2 mm in a patient without symptoms or
signs of metastases
Distant detectable metastases as determined by classic clinical and radiographic means
and/or histologically proven larger than 0.2 mm

M1
Regional Lymph Nodes (N)
NX
Regional lymph nodes cannot be assessed (for example, previously removed)
N0
No regional lymph node metastases
N1
Metastases to movable ipsilateral level I, II axillary lymph node(s)
N2
N2a
N2b

N3
N3a
N3b
N3c

Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or
matted; or in clinically detected ipsilateral internal mammary nodes in the absence of
clinically evident axillary lymph node metastases
Metastases in ipsilateral level I, II axillary lymph nodes fixed to one another (matted) or
to other structures
Metastases only in clinically detected ipsilateral internal mammary nodes and in the
absence of clinically evident level I, II axillary lymph node metastases
Metastases in ipsilateral infraclavicular (level III axillary) lymph node(s) with or without
level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal
mammary lymph node(s) with clinically evident level I, II axillary lymph node
metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without
axillary or internal mammary lymph node involvement
Metastases in ipsilateral infraclavicular lymph node(s)
Metastases in ipsilateral internal mammary lymph node(s) and axillary lymph node(s)
Metastases in ipsilateral supraclavicular lymph node(s)
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Historically, breast cancer sub-types have been pathologically determined based
on the expression of estrogen receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor 2 (Her2Neu) (Verhaak et al., 2010). Further, molecular
subtypes of breast cancer, based on gene expression patterns of the tumor, highly overlap
with these receptor biomarkers. Breast cancer is composed of many different subtypes.
In fact, there are at least 21 histologically different types of breast cancer, with at least 5
molecular subtypes based on receptor status (Bernard et al., 2009; Blows et al., 2010;
O’Brien et al., 2010; Verhaak et al., 2010). Patient stratification into these sub-types has
led to better treatment and survival (Anderson et al., 2015).
Classifying breast cancer based on gene expression profiles has helped to further
define breast cancer in clinically relevant ways. Expression microarray has been
employed to profile breast cancers based on their intrinsic gene expression profiles. Of
these studies, the first was done by Perou et al., (2000), they defined 5 molecular
subgroups of breast cancer based on gene expression: Luminal A, Luminal B, Her2enriched, Basal-like (ER-, PR-, and HER2-), and Normal-like subtype (Perou et al.,
2000). Further gene profiling has led to the addition of “Claudin low” as a further
molecular subtype of Basal like (Bernard et al., 2009; Hu et al., 2006). The clinical
utility of these molecular subtypes has been shown, in that they respond differently to
chemotherapy and have different risks of local and regional relapses (Rouzier et al.,
2005; Voduc et al., 2010). Clinically, the expression based on immunohistochemical
staining of ER, PR, and Her2Neu have been used as surrogates of these intrinsic
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molecular subtypes and are most commonly grouped into four categories: Luminal A,
Luminal B, Her2-enriched, and Triple Negative (Howlader et al., 2014; Prat et al., 2013).
These subtypes are further described in (Table 2.4).
Table 2.4 Breast cancer subtypes.
E
R
Luminal
A

Luminal
B

Triple
negative

Her2Neu
enriched

+

+

-

-

PR

+

+

-

-

Her2
Neu
-

+/-

-

+

Prevalence

Secondary
markers

Targeted
treatment

Characteristics

73%

Ki67(-)
CK8(+)
CK18(+)

Targeted
endocrine
treatment

Favorable
prognosis

10%

Ki67(+)
CK8(+)
CK18(+/)
CCNB1(+)

Targeted
endocrine
treatment

Highly
proliferative,
intermediate
prognosis

12%

CK5(+)
CK17(+)
CD44(+)
EGFR(+/-)

No targeted
therapy

Risk at younger
age, aggressive,
further divided
into Basal like,
claudin-low, and
normal like

Ki67(+)

Targeted
monoclonal
antibodies

Risk at younger
age, highly
aggressive

5%

(Eroles, Bosch, Pérez-Fidalgo, & Lluch, 2012; Nadia Howlader et al., 2014; Lehmann et al.,
2011; Prat et al., 2013)

Luminal cancers are thought to originate in the luminal epithelial cells. Luminal
A breast cancers are positive for both ER and PR and they are negative for Her2.
Luminal A cancers are the most often diagnosed and have the most favorable prognosis.
This is due to tumor response to hormonal treatment, and the less aggressive nature of the
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tumor. Luminal B tumors differ in that they may also be HER2-positive and are highly
proliferative, as indicated by high amounts of ki67 staining and other proliferation-related
markers (Cheang et al., 2009; Tran & Bedard, 2011). Her2-enriched tumors are negative
for both ER and PR, but highly express Her2. While these tumors are highly proliferative
and aggressive, targeted treatment against Her2-positive tumors have drastically
improved patient outcomes (Blows et al., 2010). Triple negative breast cancers are
negative for ER, PR, and Her2, and the majority are of the Basal-like subtype based on
their gene expression profile (Cheang et al., 2008). Triple negative breast cancer
generally has poorer outcomes, lacks targeted treatment, and is highly associated with
pre-menopausal breast cancer. Furthermore, African American women are more likely to
be diagnosed with this type of breast cancer, as well as Ashkenazi Jewish women and
those that carry the BRCA1 mutation (Dawood, 2010; Desantis et al., 2016; Lehmann et
al., 2011; Rosenthal, Moyes, Arnell, Evans, & Wenstrup, 2015).
2.4.5 Breast cancer and ancestry
The five racial ethnic groups reported in the Surveillance, Epidemiology, and End
Results Program database include European-derived White, African American,
Asian/Pacific Islander (API), Hispanic, and American Indian/Alaskan Natives (AI/AN).
There are distinctive differences in both incidence rates and mortality in breast cancer
based on ancestry (Figure 2.4).
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Figure 2.4 Breast cancer incidence and mortality rates among 5 ancestral categories. Average
annual rate per 100,000, age adjusted to the 2000 US standard population. *Incidence rates, 20092013: North American Association of Central Cancer Registries (NAACCR), 2016. **Mortality
rates, 2010-2014: National Center for Health Statistics (NCHS), Centers for Disease Control and
Prevention, 2016

From 2008 to 2012, the incidence rates of breast cancer have increased for both
African American women and Asian/Pacific Islanders, while there was no significant
change in the other ancestral categories (Desantis et al., 2016). Furthermore, African
American and European-derived White women incidence rates have converged in 2012.
Overall mortality rates have declined in all but AI/AN women, where it remains
unaffected, however, rates in AI/AN are not as consistent due to the lack of high quality
data such as is available for the other ethnic groups. While African American and
European White women now share similar incidence rates, the long-term mortality rate in
African American women is 42% greater than that of European White (Desantis et al.,
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2016). The median age of both diagnosis (58) and mortality (62) of breast cancer is
lower in African American women when compared to European White (62 and 69,
respectively).

Figure 2.5 Frequency of breast cancer subtypes based on 5 ancestral
categories. NH indicates non-Hispanic; API, Asian/Pacific Islander;
HR, hormone receptor; HER2, human epidermal growth factor receptor
2; TNBC, triple-negative breast cancer. Source: North American
Association of Central Cancer Registries CiNA Analytic File, 1995 to
2012. From Desantis et al., (2016), reprinted with permission.

The lower age of mortality in African American women is due to many
contributing factors including access to health care, socio-economic status (Bradley,
Given, & Roberts, 2002), increased diagnosis of advanced stage tumors (Desantis et al.,
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2016), and higher incidence of triple negative breast cancers (Bradley et al., 2002; Carey
et al., 2006; Lund et al., 2010; Morris et al., 2007; Stark et al., 2010; Stead et al., 2009).
The Carolina breast cancer study is a population study of women diagnosed with invasive
breast cancer in North Carolina. The study began phase one in 1993 and was the first
study to find increased incidence of triple negative breast cancer in African American
women (Carey et al., 2006; Newman et al., 1995). Most recent SEER data shows that the
frequency of triple negative breast cancer is 22% in African American and 12% in
European White women from 1995 to 2012 (Figure 2.5) (Desantis et al., 2016).
It is important to note that while differences in the frequency of triple negative
breast cancer are significant and have been well verified in several studies, the overall
survival of patients with regard to ancestry are inconsistent. While studies do show
mortality rates are increased in African American women, they do not all control for
prognostic markers such as triple negative breast cancer (Woodward et al., 2006). There
are studies that show when comparing triple negative breast cancer of African American
women to European White women there is no significant difference in mortality
(Dawood, 2010; O’Brien et al., 2010; Pacheco et al., 2013; Sturtz, Melley, Mamula,
Shriver, & Ellsworth, 2014). In contrast, increased hazard ratios in matched ER status
breast cancers of different ancestries showed African American women had increased
mortality when controlled for subtypes (Albain, Unger, Crowley, Coltman, & Hershman,
2009). The interaction was strongest in patients with ER-positive breast cancers: African
American ER-positive breast cancer showed higher mortality than ER-positive European-
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derived White breast cancer. However, no interaction was significant in this study.
Another study by Lund et al also showed increased mortality when triple negative breast
cancers of African American women were compared to triple negative breast cancers of
European White women, with a hazard ratio of 2.0 (CI 95% 1.0-3.7) after controlling for
other variables (Lund et al., 2009). They also showed that triple negative breast cancer
tumors in African American women had increased expression of p16, p53, Cyclin E, and
low Bcl-2 and Cyclin D (Lund et al., 2009). In 2007 a study based on the California
cancer registry from 1999 to 2003 showed that at each stage triple negative breast cancer
had the worst survival. Overall, African American women had the poorest 5-year relative
survival for triple negative breast cancer in stages II-IV when compared to Europeanderived White women triple negative breast cancer with the same stages (Bauer, Brown,
Cress, Parise, & Caggiano, 2007). In summary, triple negative breast cancers
consistently have the worst survival outcomes, and African American women with triple
negative breast cancer suffer from worse survival than European-derived White women
with triple negative breast cancer.
Contributing factors for breast cancer that have been shown to be significantly
different between African American and European White women include age of first
parity, multiparity, breast feeding, contraceptive use, education, smoking, caffeine intake,
alcohol consumption, and obesity (Table 2.5) (Carey et al., 2006; Hall, Moorman,
Millikan, & Newman, 2005). Multiple childbirths and earlier age of first child are
frequently seen in African American women and may increase their risk of breast cancer
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(Danforth Jr, 2013; Hall et al., 2005). Breast feeding is a risk factor that is inversely
related to triple negative breast cancer risk, and multiple studies show African American
women breast feed significantly less than European White women (Hall et al., 2005;
Millikan et al., 2008; Sturtz et al., 2014). Not only do African American women differ in
which risk factors affect them the most, but how the risk factors affect them also differs
(Table 2.5).
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Table 2.5 Risk factors prevalence and odds based on ancestry
AA compared AA compared to AA EW compared to
to EW
controls
EW Controls
Age at first
Younger
No association with
Later pregnancy
full-term
risk
increases BC Risk
pregnancy
Parity

Less likely to
be nulliparous

Breast
feeding

Waist to hip
ratio
Education
level
Alcohol
consumption
Smoking

More likely to
never have
breast fed
Longer use of
contraceptive
Larger body
mass index
Large waist/hip
ratio
Lower levels of
education
Less alcohol
consumption
Less smoking

Age at
menarche

Younger age of
menarche

HRT

No difference

1st degree
family
member
Induced
abortion
Miscarriage

No difference

Increased risk in postmenopausal
Increased risk

No difference
No difference

Oral
contraceptive
Body size

In pre-menopausal
nulliparous slightly
decreases BC risk
Reduced BC risk

Pattern of
risk
Different

Nulliparous increases
BC risk

Different

Not significantly
associated with
reduced BC risk
Slight increase in BC
risk
No association with
risk
Larger ratio increases
BC risk
No association with
risk
No association with
risk
Prior smoking not
associated with risk
Decreased age
increases BC risk
(not to the same
degree as AA)
No association

Different

Increased risk

Same

No association

No association

Same

No association

No association

Same

Slight increase in BC
risk
No association with
risk
Larger ratio increases
BC risk
No association with
risk
No association with
risk
Prior smoking
increased risk
Decreased age
increase BC risk

Same
Same
Same
Same
Same
Different
Same

Different

AA women have greater prevalence of certain risk factors as well as relatively higher odds of BC
from risk factors. African American (AA), European White (EW), breast cancer (BC). (Dietze,
Carolina, Carolina, & Seewaldt, 2017; Hall et al., 2005; Sturtz et al., 2014)

43

Many risk factors that have been shown to be associated, either positively or
negatively, with breast cancer in European White women may have no effect or an
inverse affect among African American women. These include average age of menarche,
age of first child, nulliparous, hormone replacement therapy, as shown in Table 2.3 (Hall
et al., 2005). Caffeine intake was found to be associated with decreased pre-menopausal
breast cancers in European White but not African American women (Baker et al., 2006;
Boggs et al., 2010). Multiparity was correlated with increased breast cancer risk in
African American but not in European-derived White women and hormone replacement
therapy was inversely related to breast cancer risk in African American women but not in
European-derived White women (Hall et al., 2005).
Understanding risk factors and how they are applicable to different populations is
a complex problem. The Gail or Claus models of breast cancer risk do not accurately
assess breast cancer risk in African American women (Adams-Campbell, Makambi,
Palmer, & Rosenberg, 2007; Adams-Campbell et al., 2009). The Gail model, originally
created in 1989, was restricted to European White women because the African American
sample size was too small. Since then, the model has been validated in multiple
European-derived White populations but has not been validated for African American
populations. Risk prediction models, such as the Gail and Clause models underestimate
risk in African American women (Adams-Campbell et al., 2007; Newman, 2005). The
Women’s Contraceptive and Reproductive Experiences (CARE) model has been
implemented to better assess risk in African American women, however, it still tends to
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underestimate breast cancer risk (Lucile L Adams-Campbell et al., 2009; Gail et al.,
2007). More research is therefore needed in this area.
It was originally thought that the disparity seen in African American woman
compared to European White women in breast cancers was due mainly to non-biological
factors such as access to health care. However, African American women had similar if
not slightly higher rates of mammographic screening in 2012 (Desantis et al., 2016).
While lifestyle choices and differences in known risk factors may play a role, recent
studies suggest there might be inherent biologic differences within these ancestries that
contribute to the disparities seen in African American breast cancer. As previously
mentioned, GWAS have identified SNPs that are associated with breast cancer, and these
studies have been primarily conducted on European White populations. Only 10% of the
SNP index related to breast cancer are replicated in African American (Long et al., 2013).
In African American women SNPs are identified at higher rates that are associated with
triple negative breast cancers (Palmer et al., 2013). Therefore, African American women
possess a unique genetic makeup that may make them susceptible to different cancers as
seen in the epidemiological and biological data.
2.5 Breast cancer treatment
There are three main treatment modalities in breast cancer and they are: surgery,
radiation, and chemotherapy. The most common treatment guidelines followed are by
the American Society of Clinical Oncology (ASCO), European Society for Medical
Oncology (ESMO), and the National Comprehensive Cancer Network (NCC). Treatment
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regimens are highly dependent on cancer stage and to a lesser extent age, overall health,
biomarkers, gene expression, and risk for recurrence. For stages 0-III, surgery is
performed first, often followed with radiation therapy and neoadjuvant chemotherapy
depending on the particular patient. Stage IV breast cancer has already metastasized to
other parts of the body and surgery is only done as a palliative procedure. Chemotherapy
is always recommended for stage IV and recurrent breast cancers. Treatment options by
stage are summarized in Table 2.6.
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Table 2.6 Breast cancer treatment guidelines.
Treatment
Options

Treatment to the Breast

Treatment to the Lymph Nodes

Chemotherapy

Hormonal
Therapy

Targeted Therapy

STAGE 0

prophylactic total mastectomy
OR
lumpectomy plus radiation
OR
lumpectomy alone (radiation only for a
limited subset of women)
total mastectomy
OR
lumpectomy plus radiation

none required

generally, none
required

hormonereceptorpositive
cancers

no current role

sentinel lymph node biopsy, also
known
OR axillary lymph node biopsy

may be given to
reduce the risk
of recurrence

total mastectomy
OR
lumpectomy plus radiation, in some cases
following chemotherapy to shrink a large
single cancer

commonly
recommended

STAGE
IIIA and
Operable
IIIC

total mastectomy followed by radiation
OR
lumpectomy plus radiation following
chemotherapy to shrink a large single
cancer
chemotherapy to shrink tumor and/or
lymph nodes, followed by total
mastectomy that may require removal of
other nearby tissues involved with the
tumor
AND radiation after mastectomy
surgery, radiation, or both may be used,
depending on many individual factors
(usually palliative)

sentinel lymph node biopsy,
OR
axillary lymph node biopsy
AND possible radiation to
supraclavicular and/or internal
mammary lymph nodes
axillary lymph node removal by
traditional approach
AND
possible radiation to supraclavicular
and/or internal mammary lymph nodes
axillary lymph node removal by
traditional approach
AND
possible radiation to supraclavicular
and/or internal mammary lymph nodes

targeted therapy may
be used for women
with cancers that have
certain characteristics
targeted therapy may
be used for people
with cancers that have
certain characteristics

N/A

STAGE
IIA and IIB

hormonereceptorpositive
cancers
hormonereceptorpositive
cancers

almost always
recommended

hormonereceptorpositive
cancers

targeted therapy may
be used for people
with cancers that have
certain characteristics

N/A

almost always
recommended

hormonereceptorpositive
cancers

targeted therapy may
be used for people
with cancers that have
certain characteristics

N/A

Palliative treatment of lymph nodes

almost always
recommended

hormonereceptorpositive
cancers

targeted therapy may
be used for people
with cancers that have
certain characteristics

Palliative
surgery
AND/OR
radiation

STAGE IA
and IB

Stage IIIB
&
Inoperable
IIIC

Stage IV

Treatment
to Other
Parts of
the Body
N/A

N/A
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2.5.1 Surgery
Surgery in breast cancer can be divided into two categories, breast conserving
surgery and mastectomy. The overall trend over the last 30 years has been towards breast
conserving surgery with a vast majority of patients undergoing this procedure (Senkus et
al., 2015). Breast conserving surgery or lumpectomy involves removing the tumor while
leaving as much of the breast as possible, and is always followed with radiation therapy
(Darby et al., 2011). Studies show that radiation therapy reduces the recurrence rate by at
least half and improves overall survival (Early Breast Cancer Trialists’ Collaborative
Group (EBCTCG) (Darby et al., 2011). Mastectomy is carried out when there is an
inability to define clear surgical margins, when there are contraindications to radiation
therapy, there is a large tumor size, or there are multiple centers of origin, or by patient
choice (Association of Breast Surgery at Baso 2009, 2009; Senkus et al., 2015).
Mastectomy involves removal of the entire breast. Mastectomy may avert the need for
radiation therapy, however in some patient’s radiation therapy is still necessary. Survival
in patients with breast conserving surgery followed by radiation therapy versus
mastectomy are the same (De La Cruz et al., 2016; van Maaren et al., 2016). Slightly
higher rates of recurrence have been observed in patients who undergo breast conserving
surgery followed by radiation therapy in the past however, currently it is at least as good
as mastectomy (Fischer et al., 2002). There seems to be no difference in African
American and European White women that have equal access to health care in rates of
lumpectomy (Enewold et al., 2012).
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2.5.2 Radiation therapy
In breast cancer radiation therapy ionizing radiation is used to eradicate cells in a
specific area or in the entire breast (whole breast radiation therapy). These high energy
rays destroy cells by either directly damaging the genome or via production of free
radicals caused via ionization of water within the cells (Baskar, Dai, Wenlong, Yeo, &
Yeoh, 2014). Radiation therapy after breast conserving surgery is always indicated, as
cancer cells may be left behind. Radiation therapy tends to kill cancer cells more
selectivity as their genomes are replicating (Pavlopoulou et al., 2016).
There are multiple pathways dedicated to the maintenance and repair of the
genome. In breast cancer cells DNA repair pathways are often mutated and inefficient in
repairing the genome. This leads to increased amounts of both double and singlestranded breaks and in turn more selective eradication of cancer cells compared to nondiseased cells with competent repair mechanisms (Mohseni-Meybodi, Mozdarani, &
Mozdarani, 2009; Parshad, Tarone, Price, & Sanford, 1993; Shahidi, Mozdarani, &
Bryant, 2007). Based on previous unpublished data one in our laboratory, DNA repair
deficient non-tumor adjacent cells will also be killed by radiation therapy. Radiation
therapy triggering of cellular adaptive responses of cancer cells allowing them to
overcome cell death, remains a problem with treatment. Inherent or acquired increases in
DNA repair mechanisms of cancer cells are sources of resistance to radiation therapy
(Baskar et al., 2014; Toulany & Rodemann, 2013).
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2.5.3 Systemic treatments
Chemotherapy
In addition to surgery and radiation therapy, systemic treatments are often used in
breast cancer, these include chemotherapy, hormone therapy, and targeted therapy. The
use of these treatments is highly dependent on the stage and characteristics of the tumor.
Chemotherapy is always recommended in late stage breast cancer and triple negative
breast cancer and can be used in stage II breast cancers upward (Table 2.8).
Chemotherapy is usually given with more than one chemotherapeutic agent and the most
common regimen consisting of Adriamycin and Cyclophosphamide (AC). However,
cytotoxicity to the heart may be a limiting factor of this regimen and often anthracyclines
(Adriamycin) may be substituted for a different class of chemotherapies (Minotti, Menna,
Salvatorelli, Cairo, & Gianni, 2004). In late stage breast cancer a single chemotherapy
agent such as gemcitabine is often utilized (Dawood, 2010). Chemotherapeutic agents
work to eradicate cancer cells in a variety of ways that are summarized in Figure 2.6.
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Figure 2.6. Chemotherapeutic drug classes and mechanisms of action. Adriamycin and
cyclophosphamide are the most common chemotherapeutic agents utilized in first line treatment of breast
cancer. Cyclophosphamide is a nitrogen mustard that is no cell cycle specific. Adriamycin is an
anthracycline that blocks topoisomerase function. Gemcitabine is commonly used in late stage treatment
as a monotherapy and is an antimetabolite that inhibits DNA synthesis (Reprinted with permission from
My Cancer Genome https://www.mycancergenome.org/content/molecular-medicine/pathways/cytotoxicchemotherapy-mechanisms-of-action, Copyright 2018 by Vanderbilt University.).

The main mechanism of action of chemotherapy drugs is that they preferentially
target actively dividing cells with improperly functioning cell cycle checkpoints, which
makes them more selective for cancer cells (Swift & Golsteyn, 2014). Inherent or
adaptive chemotherapeutic resistance in cancer cells is a major obstacle to breast cancer
treatment (Housman et al., 2014). Figure 2.7 outlines the known mechanisms of
resistance to chemotherapy; as shown increased DNA repair is again an important
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mechanism to be considered in chemotherapeutic treatment, because it can repair damage
caused by the common breast cancer treatments (Holohan et al., 2013).

Figure 2.7 Cancer resistance. Drug Efflux, drug inactivation, target alterations, increased DNA repair
pathways, cell death inhibition, EMT, epigenetic changes, and changes in stroma are all resistance
pathways. Cancer cells often utilize multiple pathways to evade eradication. Examples of changes in these
pathways are in purple. The process of EMT seems to develop an inherently more resistant and mobile
(metastatic) cell.
ATP binding cassette (ABC), breast cancer resistant protein (BCRP), multidrug drug resistant protein 1
(MDR1), glutathione-S-transferase (GST), cytochrome p450 (CYP450), topoisomerase IIA (TOP2A),
epithelial to mesenchymal transition (EMT)
Adapted with permission, Copyright © 2014 by the authors; licensee MDPI, Basel, Switzerland. Adapted
from Housman et al. (2014) under the terms and conditions of the Creative Commons Attribution
license.

Hormone therapy
Hormone therapy is used to interfere with estrogen and estrone (from fat)
signaling in tumors that rely on estrogenic signaling for proliferation and growth.
Hormone therapy is given to patients whose tumors express high amounts of estrogen
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receptor, are primarily Luminal type tumor. Hormonal therapy is not effective against
estrogen receptor negative cancers. Drugs used for hormone therapy fall into two main
categories selective estrogen receptor modulators (SERMs) and aromatase inhibitors.
SERMs work at the receptor as an antagonist at the estrogen receptor. Aromatase
inhibitors work to reduce the amounts of estrogen in the body by blocking the conversion
of androgen to estrogen. Aromatase inhibitors are preferred for use in post-menopausal
treatment of breast cancer because they cannot stop the production of estrogen from the
ovaries of pre-menopausal women (Abdulkareem & Zurmi, 2012; Kwan et al., 2017).
Tamoxifen, originally developed as a contraceptive in the late 1960s, is the prototypical
SERM and still widely utilized for estrogen receptor positive breast cancers (Maximov,
Lee, & Jordan, 2013). Resistance to hormone therapy is common and is due to many
factors, two being the activation of an altered growth signaling pathway, or the loss of
hormone receptor expression. While increased levels of circulating estrogen are indeed
correlated with increased risk of breast cancer via DNA repair suppression, the role of
DNA repair with regards to hormone therapy resistance is unclear, if any at all (Caldon,
2014).
Targeted therapy
Breast cancer treatment has helped to revolutionize all cancer treatments with the
development of targeted therapies. Patients with Her2 positive breast cancers have
benefited the most from these types of treatment, which comprise 12% of all newly
diagnosed breast cancers (Nadia Howlader et al., 2014). Trastuzumab is a monoclonal
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antibody that specifically targets the HER2/neu protein and inhibits its activation, which
in turn inhibits mitogen activated protien kinase and PI3K/Akt pathways. Both of these
pathways contribute to cell growth and proliferation. Trastuzumab also has beneficial
indirect effects on tumor cells. Trastuzumab increases the tumor suppressor protein
PTEN levels and activity and induces cell cycle arrest via restoration of the P27 gene
product (Vu & Claret, 2012). Trastuzumab also attracts immune cells to the tumor to
eradicate cancer cells via an antibody-dependent cellular toxicity mechanism (Vu &
Claret, 2012). While Trastuzumab has had a tremendous impact on the treatment of Her2
positive breast cancers, inherent or acquired resistance frequently develops (Gajria &
Chandarlapaty, 2011; Zhang et al., 2011). Mutations in the structure of HER2 are
implicated in one pathway of resistance, DNA repair and tumor suppressor proteins are
implicated in other resistance mechanisms to trastuzumab (Zhang et al., 2011). Other
emerging targeted therapies are being developed that use antibodies as well as small
molecule inhibitors. These novel drugs not only target the HER2/neu protein but other
unique proteins within cancer cells such as interleukin 5, CD275 (PDL-1), and vascular
endothelial growth factor to name a few (Shepard, Phillips, Thanos, & Feldmann, 2017).
2.6 DNA repair
Maintaining the integrity of the genome is essential to life, our cells and their
DNA are under constant extrinsic and intrinsic insult (Jeggo, Pearl, & Carr, 2015). DNA
damage, if not repaired, results in mutations in the daughter strand and permanent
alterations to the genome. Over time, this genomic instability and accumulation of
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mutations lead to cancer (Helleday, Eshtad, & Nik-Zainal, 2014). The progression to
cancer involves several different theories. Knudson et al. developed the two-hit theory
that cancer could occur in a cell in as few as two steps and highlighted the importance of
tumor suppressor genes, with each hit involving a mutation (either inherited or developed
over time) (Knudson, 1971). Vogelstein et al., theorized that mutations accumulate over
time in a single cell lineage to produce clonal tumors that exist as discrete pathologies
(Fearon & Vogelstein, 1990). Furthermore, Vogelstein et al., showed carcinogenesis also
requires activation of specific genes that can increase cell growth and proliferation, called
proto-oncogenes, as well as deactivation of tumor suppressors (Fearon & Vogelstein,
1990; Lengauer, Kinzler, & Vogelstein, 1998). Eventually this theory has advanced to
involve the accumulation of mutations, or alternatively, epigenetic alterations that mimic
genetic mutations leading to cancer. The multiple theories of carcinogenesis highlight
the importance of maintaining the genome by DNA repair pathways. Furthermore, it has
been known that mutations in DNA repair pathway genes themselves contribute to
genomic instability by speeding up mutational rates, and shifting cancer incidence to
younger ages (Hornsby, Page, & Tomlinson, 2007; Rauth Doll, 1954).
2.6.1 Repair pathways
There are five major DNA repair pathways, base excision repair (BER), mismatch
repair (MMR), nucleotide excision repair (NER), homologous recombination (HR), and
non-homologous end joining (NHEJ). These DNA repair pathways are responsible for
repairing specific types of damage to DNA, however, there is considerable overlap
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between the types of repair performed by these pathways. The pathways are summarized
in Figure 2.8. NER is the most versatile pathways, not only repairing single strand helix
distorting damage, but also working with HR proteins to repair inter-strand crosslink
damage and as a backup for both the MMR and BER pathways (Bret, Klein, & Moreaux,
2013; Reed, 1998).
2.6.2 Single strand repair pathways
BER corrects the non-helix-distorting single nucleotide damages to the DNA. It
involves the use of specific DNA glycosylases to recognize and remove the damage,
which forms an abasic site or a site that lacks a pyrimidine or purine. This site is then
cleaved by endonucleases and repaired by either “short-patch” or “long-patch” BER,
where the single damaged nucleotide or a sequence of 2-10 nucleotides around the
damage are replaced, respectively (Zharkov, 2008). Mismatch repair, like NER, is
another single strand repair pathway that happens post-replication. MMR machinery
removes incorrectly incorporated nucleotides that have been incorporated during
transcription, as well as removing insertion and deletion loops developed during the
replication process. MMR proteins use
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Figure 2.8 The 5 major DNA repair pathways. Base excision repair, nucleotide excision repair, double strand break repair, and mismatch
repair are the 5 major pathways. Homologous end-joining and non-homologous end joining are two different pathways that repair double
strand breaks. Adapted with permission from Jalal et al. (2011).
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the parent strand of DNA as a guide to recognize, remove, and replace the incorrectly
incorporated DNA base in the daughter strand.
2.6.3 Double strand repair pathways
HR is used to correct damage that lead to double strand breaks, however, it also
has a role in meiosis to produce genetic variability in gamete cells. HR proteins repair
these large-scale damage by utilizing the undamaged sister chromatid to accurately
restore the DNA, therefore, it is mostly used during replication in S-phase and shortly
after in G2 phase when sister chromatids are nearby. HR proteins involved include both
ATP dependent chromatin remodeling complexes and histone-modifying enzyme to
initiate repair. Then removal of the damage begins on the 5’ end creating a 3’ overhang
that is used to search for homology with the sister chromatid. A DNA heteroduplex, or
D-loop, is formed with the sister chromatid and both strands are extended accurately
using the undamaged sister chromatid as a template. Finally, the D-loop is disassembled,
and the two independent DNA double helixes are restored (Jasin & Rothstein, 2013).
NHEJ also repairs double strand breaks to the DNA. Because it does not utilize a
homologous sister chromatid as a template, such as in HR, repair is done with much less
accuracy. NHEJ is a key component of the non-DNA repair pathway, V(D)J
recombination, that adds diversity to the products of immune cells.
NHEJ utilizes Ku proteins to detect double strand breaks by recognizing broken
ends, then “tethers” them together. The ends are processed by removal of the damage or
nucleotides by nucleases and refilled by DNA polymerases. Finally DNA ligation occurs
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using specific ligases, most notably DNA ligase IV, finishing the repair (Davis & Chen,
2013; Derbyshire, Epstein, Young, Munz, & Fishel, 1994; Mahaney, Meek, & LeesMiller, 2009; Weterings & Chen, 2008)
2.6.4 Nucleotide excision repair
NER is most commonly known for repairing DNA lesions caused by ultraviolet
light (UV), however it is not limited to UV light damages. The NER pathway repairs any
damage that distorts the periodicity of the DNA helix or causes bulky DNA adducts.
Cyclobutane pyrimidine dimers (CPDs) and pyrimidine-(6,4)-pyrimidone products (64PP) caused by UV light as well as bulky adducts, and intra-strand crosslinks such as
those caused by chemicals and chemotherapeutic agents are repaired by NER (Bowden,
2014; Friedberg, 2001; Reed, 1998). Furthermore, NER proteins work in conjunction
with BER to repair oxidative damage and NER proteins have been found to regulate the
BER pathway (Melis, van Steeg, & Luijten, 2013). Finally, the NER pathway works
with HR to repair interstrand crosslinks (Minotti et al., 2004; Saffi et al., 2010; Wood,
2011).
NER has 5 major steps, (1) recognition, (2) DNA unwinding, (3) dual incision and
excision, (4) strand synthesis, and (5) ligation (Figure 2.9) (Costa, 2003; Schärer, 2013).
NER is divided into global genomic NER (GG-NER) and transcription coupled NER
(TC-NER). TC-NER repairs DNA that is actively being transcribed and GG-NER repairs
all genomic DNA in all phases of the cell cycle. The two types differ only in the first
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step in which GG-NER proteins scan and find DNA lesions TC-NER is brought about by
stalled RNA polymerase II (RNA polII) (Melis et al., 2013).

Figure 2.9 Nucleotide excision repair pathway. A schematic of the nucleotide excision repair pathway
shows global genome repair the left and transcription coupled repair to the right. Image Copyright © 2015
Manova and Gruszka, open access under the terms of the Creative Commons Attribution License (Manova
et al., 2015).

There are more than 30 proteins involved in all steps of NER and a minimum of
20 proteins are required for complete DNA repair. The first step in the NER pathway is
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recognizing the damage. In TC-NER this begins with stalling of the DNA polymerase,
and temporary dissociation of the polymerase. The CSB protein localizes to the lesion
and recruits CSA, ring-box 1 (RBX1) and cullin 4A (CUL4A). This complex, in turn,
recruits XPA binding protein 2 (XAB2) for chromatin remodeling. Transcription factor
II H (TFIIH) is then brought in to begin the unwinding process. In GC-NER, recognition
occurs via either the XPC/RAD23B complex or the DDB1 and DDB2 proteins that scan
the genome for smaller damage. DDB1 and DDB2 recruit the XPC complex, while the
XPC complex can initiate GG-NER on its own, having a greater affinity towards bulkier
adducts. The XPC protein contains multiple binding domains for DNA and other
proteins including TFIIH. TFIIH recruitment begins the next step of the pathway and at
this point the TC and GG NER pathways converge. TFIIH forms a complex with 10
other proteins, XPB, XPD, p62, p52, p44, p34, p8, and the CDK-activating kinase (CAK)
complex: MAT1, CDK7, and Cyclin H. In both TC and GC-NER this complex forms
around the DNA and begins the unwinding process forming a bubble structure in the
DNA, via DNA helicases XPB and XPD. XPA, RPA, and XPG are also recruited and
verify that the lesion on the correct strand as well as initiating the dual incision process.
RPA interacts with endonucleases ERCC1, in a complex with XPF, to make the 5’
incision and XPG makes incision at the 3’ end of the bubble. This results in the removal
of a patch 20-30 nucleotides long and the gap is then filled by DNA polymerase δ, ε, or κ,
in conjunction with proliferating cell nuclear antigen (PCNA), replication factor C
(RFC), and RPA. The DNA replication machinery uses the undamaged strand as a
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template to correctly restore the damaged strand of DNA. Finally, DNA ligase I in
replicating cells or ligase IIIα with X-ray repair cross complementing-1 (XRCC1) in nonreplicating cells seals the 3’ nick to fully restore the DNA helix and sequence (R. Costa,
2003; Melis et al., 2013).
2.7 Nucleotide excision repair in cancer
Nucleotide excision repair is a double-edged sword in cancer. Nucleotide
excision repair genes clearly act as tumor suppressors, however, deficient repair
mechanisms in cancer etiology lead to increased genomic instability and cancer incidence
at younger ages. On the other hand, overexpression of nucleotide excision repair genes
and increased function of the pathway results in increased drug resistance in late stage
cancer cells (Jeggo et al., 2015).
2.7.1 Nucleotide excision repair inherited diseases
There are several diseases that result from inherited mutations in genes within the
nucleotide excision repair pathway including Xeroderma Pigmentosum (XP), Cockayne
Syndrome (CS), and Trichothiodystrophy (TTD). XP is a rare autosomal recessive
genetic disorder that results from mutations in the XP genes of the nucleotide excision
repair pathway and affects 1 in 250,000 people of all ancestries (Lehmann, McGibbon, &
Stefanini, 2011). There are 8 complementation groups in XP that result in deficient

nucleotide excision repair function. The more deficient the nucleotide excision repair
function the more severe the disease, and this is highly dependent on the specific
mutation in XP. The disease is characterized by sensitivity to UV light and increased the

62

likelihood to develop cancers. In fact, XP patients are more than 2,000 time more likely
to develop skin cancers than DNA proficient normal people (Bradford et al., 2011). This
disease and it’s phenotype demonstration the importance of nucleotide excision repair
and its role in protection against cancer.
CS is an autosomal recessive disorder that results from mutations in either the
CSB or CSA genes of the nucleotide excision repair pathway. These gene products are
involved in transcription coupled nucleotide excision repair and are the root cause of the
neurodegenerative disorder CS. The disease is characterized by photosensitivity,
impaired development of the nervous system, and premature aging. While the disease
does affect TC-NER, it does not lead to a predisposition to cancer as would be expected
of DNA repair defects (Nance & Berry, 1992).
TTD is another autosomal recessive disorder that results from mutations in the
nucleotide excision repair genes, XPB, XPD, and TTD (Theil, Hoeijmakers, &
Vermeulen, 2014). All three of the genes are subunits of the TFIIH complex, critical for
the nucleotide excision repair pathway. The disease has a variety of phenotypes
including photosensitivity, ichthyosis, brittle hair and nails, intellectual impairment,
decreased fertility, and short stature (Theil et al., 2014). The severity of symptoms is also
highly variable with the most severe cases resulting in early mortality. The disease
results in deficient nucleotide excision repair function but not elevated risks for cancer.
In both TTD and CS it is likely that the blocking of RNA polymerases leads to extreme
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cell toxicity and results in cell death, therefore mutations are not accumulated and there is
no predisposition to cancer (de Boer & Hoeijmakers, 2000; Theil et al., 2014).
2.7.2 Nucleotide excision repair in breast cancer
Nucleotide excision repair is also implicated in breast cancer. Multiple studies
have shown that that lymphocytes in breast cancer patients have deficient nucleotide
excision repair compared to non-diseased controls (Kovacs, Stucki, Weber, & Müller,
1986; Ramos et al., 2004; Shi et al., 2004). Furthermore, these studies showed that
decreased nucleotide excision repair capacity is associated with increased risk of
developing breast cancer (Ramos et al., 2004; Shi et al., 2004). These studies, however,
utilized lymphocytes as surrogates for breast tissue. Latimer et al. (2010) has shown that
in stage I breast cancer explants there is an intrinsic deficiency in the nucleotide excision
repair pathway. Not only were DNA expression and protein expression under-expressed
when compared to normal breast cultures, but functional DNA repair capacity, as
measured by the Unscheduled DNA Synthesis assay was also deficient (Latimer et al.,
2010). Unscheduled DNA synthesis functional analysis further revealed that compared to
the same patient’s non-tumor adjacent explant the nucleotide excision repair function was
also decreased in unpublished data created by our laboratory. The connection between
cancer and DNA repair is evident.
2.8 Model systems
Studying DNA repair in breast cancer involves the use of different model
systems. One important model are breast cancer-derived cell lines. Established breast
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cancer cell lines have enriched our knowledge of breast cancer features such as
proliferation, invasion, angiogenesis, metastasis, and drug resistance (Holliday & Speirs,
2011). There are currently more than 60 commercially available breast cancer cell lines,
20 of which are widely used in breast cancer research (ATCC 2017). They provide an
unlimited regenerative source of breast tumor cells and possess a high degree of
homogeneity within each cell line. However, there are several disadvantages to utilizing
these cell lines. Most are derived from late stage metastatic breast cancer derived from
pleural effusions, therefore they may not reflect qualities of the primary tumor or even
the heterogeneity of the primary tumor (Burdall, Hanby, Lansdown, & Speirs, 2003;
Cailleau, Olivé, & Cruciger, 1978; H D Soule, Vazguez, Long, Albert, & Brennan, 1973).
Furthermore, because the cell lines are based on stage IV tumors, they may not reflect the
stage I breast cancers that now represent the majority of breast tumors diagnosed in the
United States (Howlader et al., 2017). Adaptation to culture of these cell lines may also
cause fundamental changes in cellular and genetic characteristics not representing the
primary tumor (Bahia et al., 2002). It is also clear that these cell lines continue to evolve
in culture, such that genetically and functionally different sublines can be identified that
have characteristics not found in the original tumor (Wenger et al., 2004). The work in
this dissertation utilizers original cell lines from different stages and also from the nondiseased state, some of the well-known breast cancer cell lines derived from stage IV
tumors are included as a means of comparison with the vast majority of breast cancer
studies in the literature.
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The Latimer laboratory has developed an organotypic tissue engineering system
for the development of both non-diseased breast tissue from reduction mammoplasties as
well as tissue derived from tumors. Non-diseased tissues came from a variety of sources
including women of different ages (pre-, peri, and post-menopause) and ancestries.
Using this method breast tumors have been successfully cultured from all stages of breast
cancer including the various types.
An overview of our tissue engineering system derived from non-diseased female
patients is shown in Figure 2.10. Fresh minced tissue pieces attach to a 1:1 dilution of
basement membrane extract (Trevigen®) to DMEM within 24-48 hours, typically
rendering the medium acidic and yellow in color. The cells are maintained in a
specialized medium that had been adapted from embryonic stem cell culture called
MWRI. Within 3 days, living attached cells appeared as monolayer outgrowths of
multiple cell types from freshly severed 3 dimensional pieces of tissue edges. These
attached cells include both epithelial and fibroblastic cells. After 10-11 days in culture a
marked increase in cell populations becomes apparant, due to both cell migration and
proliferation, with cells becoming visible microscopically in the areas of the dish not
obscured by tissue pieces.
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Reduction/
Tumor

Figure 2.10 Tissue engineering schematic. Non-diseased and tumor cell lines created
through the Latimer tissue engineering system. The primary is passaged into extended
explants. After passage 13 we consider them cell lines.

The formation of epispheres in vitro is the first recognizable three-dimensional
epithelial architecture formed in our culture system (Figures 2.11, and 2.12a, b).
Epispheres develop as early as 24 hours after initial establishment of primary cultures.
Epispheres, through a process of epithelial cell migration and proliferation, give rise to
ductal structures over a period of 2-3 weeks in culture. With greater time in culture (2-5
weeks), linear ductal structures may form and become longer, progressively branching to
form ductal networks (Figure 2.13b). Mature ducts manifest lumen containing secreted
milk proteins with a diameter consistent with interlobular ducts in vivo (40-70 µm).
Finally, the formation of intra-ductal lobular structures (Figure 2.11) and TDLUs (Figure
2.13) is also manifested in at least 40% of these long-lived cultures.
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Figure 2.11 Latimer tissue engineering system. This timeline shows the progressive differentiation
manifested by non-diseased breast reduction mammoplasties placed into primary culture

Episphere and subsequent ductal formation are active processes of cellular
aggregation and recruitment rather than an artifact of the disaggregation method.
Epispheres in this system are 3-dimensional clusters of 20-100 epithelial cells, with
intimate contact between rounded epithelial cells and the lowest layer of cells in contact
with a Matrigel substratum (Figure 2.12). Ductal structures are luminal as shown by the
pattern and outline of cytokeratin-19 staining and DRAQ5-stained nuclei (Figure 2.13d,
e).
One of the critical features of an organotypic culture system is the production of
proteins that are related to organ function. Beta-casein is a milk protein that is rarely
expressed in any primary epithelial cell culture system (Kim, Oberley, & Clifton, 1993),
although it is expressed in approximately 17% of human breast tumors (Monaco,
Bronzert, Tormey, Waalkes, & Lippman, 1977). In our cultures, this milk protein is
expressed in the lumen of mammospheres and ductal structures (Figure 2.13f, g).
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Figure 2.12 Epispheres in culture. (A) Scanning electron micrograph (SEM) of a normal epithelial
epispheres after 2 days in culture. These cells remain in close contact via desmosomes, and retain normal
epithelial tissue architecture and polarity. (B) Confocal microscopy image of a episphere, showing a view
of the luminal interior of the episphere. Nucleoli are stained with acridine orange (green) and
Mitochondria are stained with mitrotracker red (red).

Figure 2.13. Ductal systems in culture. Electron micrograph (a) and DIC images (b) of duct-like
structures arising from the culture of non-diseased human breast reduction epithelium, showing the
elevation of the structures above the substratum and the branching nature of the ductal network. These
ducts stain with CK-19 (d), and contain lumen. DRAQ5 stains the nuclei (blue) to show the luminal
space between the hollow columns of cells. Functional secretion of beta casein is observed (f, g), and
generation interstitial and terminal lobular structures (arrows). Higher power electron micrographs of
more advanced lobular structures are given in (h) and (i).
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Using this same tissue engineering system, the Latimer laboratory has also
developed 60 tumor cell lines, without the use of any transforming agents. This contrasts
with the most commonly used cell lines that generally use transforming agents. It is often
not known how these agents can affect DNA repair, and more research is needed to
assess the DNA repair in established cell lines (Burdall et al., 2003).
2.9 Nucleotide excision repair in cancer treatment
While DNA repair works to maintain a healthy genome in non-diseased cells,
these same mechanisms in tumor cells often contribute to tumor resistance to genotoxic
chemotherapy. Advanced stage cancer cells often show increased expression/function of
DNA repair mechanism proteins to remediate damage from genotoxic insults (Helleday,
Petermann, Lundin, Hodgson, & Sharma, 2008). The core of many chemotherapeutic
agents is to damage the cancer cell enough to render it unable to replicate or force
apoptosis. If DNA repair mechanisms remediate this damage as opposed to triggering
apoptosis, the cell can escape death or continue proliferating. Cisplatin is the
prototypical drug remediated by nucleotide excision repair. It causes 1,2-intrastrand
cross-links between purine bases. Increased expression of nucleotide excision repair
genes, most notably XPC, has been shown in many cisplatin resistant cancers (Lai et al.,
2011; Rosell et al., 2003; Wang, Dombkowski, Chuang, & Xu, 2004). Furthermore,
down regulation of excision repair cross-complementation group 1 (ERCC1) in prostate
cancer cells has been shown to sensitize these cells to cisplatin (Cummings et al., 2006).
In breast cancer treatment anthracyclines and cyclophosphamide are heavily used and
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studies have shown that increased expression of nucleotide excision repair genes is also
associated with chemotherapeutic resistance (Andersson et al., 1996; McHugh,
Spanswick, & Hartley, 2001; Müller, Thomale, Rajewsky, & Seeber, 1998).
2.9.1 Nucleotide excision repair in cancer stem cells
There is a particular lack of information on the role of nucleotide excision repair
in cancer stem cells. In fact, the literature seems to have conflicting results regarding
DNA repair in cancer stem cells. Cancer stem cells are thought to be more resistant cells
that can regenerate the tumor after treatment, contributing to both metastases and
reoccurrences. Several studies have shown that stem cells are more resistant to
chemotherapy, as well as ionizing radiation (Phillips, McBride, & Pajonk, 2006; Tanei et
al., 2009; Yang et al., 2015). Other studies have shown that stem cells have shown
sensitivity to the antibiotic salinomycin and, contradictorily, ionizing radiation (An et al.,
2015; S.-Y. Kim et al., 2012). A major drawback of these studies has been the use of
commercially available cell lines including MCF7 and MDA MB231, which have high
levels of nucleotide excision repair. Only Tanei et al., (2009) used primary tumor
information and they showed that tumors with high amounts of CD24- 44+ aldehyde
dehydrogenase positive cells were resistant to paclitaxel and epirubicin. These studies are
summarized in Table 2.6. There is a clear lack of information regarding nucleotide
excision repair in cancer stem cells with virtually no relevant data in the breast cancer
literature.
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Reference

Insult

Model System

Stem Cell Definition

Characteristic

Phillips et al., 2006

Ionizing Radiation

MCF 7

CD24- 44+

Resistant

Yang et al., 2015

Ionizing
Enhanced CHK1/2

MCF 7

CD24- 44+

Resistant

Tanei et al., 2009

Paclitaxel
Epirubicin

Primary

CD24- 44+
aldehyde dehydrogenase 1

Resistant

*Pavlopoulou, et al., 2016

Review

Sajithlal et al., 2010

Adriamycin
Etoposide
5-fluorouracil
Cis-platinum
Methotrexate
Taxol
Ionizing

MCF 7
MDA MB231
MDA MB453
JL BTL-12

CD24-/44+
OCT3/4 blocked

Mixed depending
on cell line.
All cancer stem
cells were sensitive
to Taxol.

MDA MB231
MDA MB453

CD24- 44+
OCT3/4 blocked

sensitive

Kai et al., 2015

LBH589
Salinomycin

aldehyde dehydrogenase 1

Sensitized by
Salinomycin

Vazquez-Martin et al., 2011

Metformin

HCC1937,
MDA-MB-231,
MCF7, and SK-BR-3
MDA MB231,
SKBR3,
MDA MB468

Mammosphere formation

Sensitized by
metformin

Kim et al., 2012

Table 2.7. Cancer stem cells resistance and sensitivity.
*selected review describing resistance in stem cells

Resistant
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2.10 Summary
This dissertation is separated into three sections. First, we discovered differences
in ductal formation of non-diseased breast explants in culture between African American
women and European derived white women in a unique culture system. We then set out
to determine if there are differences in African American women and European derived
White women breast stem cells. Differences in stem cells, either proportion or potency,
could explain why we see differences in the timing of ductal formation. This is relevant
because the timing of ductal formation in our culture system seems to mimic the
epidemiological evidence that there is a decrease in age of thelarche. This decrease in
thelarche is exaggerated in African American women and we will show that this is also
seen in our unique culture system. Furthermore, a decrease in puberty is a breast cancer
risk factor, therefore this puts African American women at an increased risk for breast
cancer. The second section focuses on the development of a medium throughput assay
using this same unique culture system. This assay will be vital for replacing outdated
assays such as the E-screen in testing for chemicals that can putatively disrupt breast
structure formation. Finally, the third section focuses on breast cancer stem cells.
Previous laboratory data has shown that there is an increase in gene expression and
function on nucleotide excision repair (Appendix A). Based on these findings, we sought
to determine the nucleotide excision repair in breast cancer stem cells of early and late
stage cell lines. Breast cancer stem cells are believed to be a more resistant cell in a
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tumor. Establishing the nucleotide excision repair capacity in these cells may lead to
future drug targets.
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Chapter 3
Breast cultures from African American women manifest higher stem cell
percentage and potency than those from European derived white women

3.1 Introduction
3.1.1 Breast remodeling and stem cells
The breast is a tissue that undergoes constant remodeling until death. The
development of the breast, known as thelarche, signifies the start of puberty and is
followed shortly by menarche (Cabrera et al., 2014). As the breast undergoes normal
changes in response to milestones like puberty and lactation, or cyclical monthly changes,
it requires specialized cells that can self-renew and differentiate into the luminal
epithelial and myoepithelial cells that together make up the plumbing system of the breast
(Tiede & Kang, 2011). Breast stem cells have been the ideal model for all stem cell
research because of their sheer prevalence in the tissue (Tiede & Kang, 2011). In fact,
the first cloning of a sheep, Dolly, was accomplished by using a stem cell from the
mammary gland (Campbell, McWhir, Ritchie, & Wilmut, 1996).
3.1.2 Thelarche and ancestry in the U.S.
Both genetic and non-genetic can affect the onset of puberty (Cabrera et al., 2014;
Mishra et al., 2017). Genetics, race, maternal body mass index, prematurity or low birth
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weight, fatherlessness, environmental pollutants, and percentage body fat are all factors
that influence the timing of puberty (Daniel & Balog, 2009; Day et al., 2017; Flom et al.,
2017; Kelly, Zilanawala, Sacker, Hiatt, & Viner, 2017; Li et al., 2017). Studies of
familial traits in monozygotic twins and close relatives have shown that only about half
of the variation in the age of menarche are attributed to genetics (Morris, Jones,
Schoemaker, Ashworth, & Swerdlow, 2011; Towne et al., 2005). The age of menarche
has been falling since the 1800s until the present (Cabrera et al., 2014; Euling et al.,
2008; Steingraber, 2007) (Figure 2.2). This decrease in age of menarche is more
dramatic in African American girls and it is consistent with the falling age of thelarche
(Figure 3.1). African American girls go through thelarche at 9.5 years old compared to
10.3 years old in European-derived white girls (Cabrera et al., 2014; E. Daniel & Balog,
2009; Euling et al., 2008; Steingraber, 2007).

Figure 3.1. The falling age in menarche and thelarche in the United States by ancestry. Data from
multiple sources in both the United States and Europe shows the age of both menarche and thelarche have
decreased. The decline is more dramatic in African American girls. Reproduced with permission from
BCPP, www.bcpp.org (The falling age of puberty in U.S. girls, Steingraber, 2007)
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The reason for ancestral disparity in thelarche and menarche is not well understood.
African American women manifest factors that correlate with early menarche such as
increased body mass index (Daniel & Balog, 2009; Spencer et al., 2013). Genetic factors
have also been shown to play a role. Single nucleotide polymorphism analysis has shown
a polymorphism, rs11604207, just upstream of remodeling and spacing factor 1 (RSF1)
(Spencer et al., 2013), that correlates with decreased age of menarche. RSF1 has been
implicated in both ovarian and breast cancers.
3.1.3 In vitro models of mammary differentiation
The Bissel group has developed a relevant in vitro culture system, which mimics in
vivo differentiation. Using mouse mammary cells cultured under a laminin-rich basement
membrane, breast alveoli with functional milk secretion has been shown (Lelièvre,
Weaver, & Bissell, 1996). These alveoli do not form ductal structures but remain blindended circular hollow structures that die as the matrix degrades over time.
The Latimer laboratory has developed and published a novel culture system for
human mammary epithelial cells that is a model of thelarche (Figure 2.12). This system
allows for unusually long-term (three months or longer) establishment of normal primary
cultures that begin as three-dimensional “epispheres,” which are structures made up of
20-100 epithelial cells. These epispheres subsequently differentiate into complex
organotypic branching ducts and lobules that demonstrate Epithelial Specific Antibody
(ESA) staining, cytokeratin -18 and -19 staining, the presence of hollow lumen, polarized
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epithelial nuclei, desmosomes along the lateral surfaces of the epithelial cells, and
microvilli on the apical (secretory) surfaces of the polarized luminal epithelial cells.
Myoepithelial cells that are also present demonstrate cytokeratin 14 staining and can be
located at the basal surface of the luminal epithelial cells (Figure 3.2), or more rarely as
colonies in the area around the organotypic structures. Tumor cells, in contrast, manifest
a continuum of behaviors in this culture system, but completely lack the ability to form
these collaborative epithelial architectures.

Figure 3.2 Confocal image of breast architecture
in culture. (A) Single image from a confocal stack
of a breast reduction primary culture stained with
both cytokeratin 14 (Texas red conjugated CK 14)
myoepithelial cells and cytokeratin 18 (FITC
conjugated CK 18 green) luminal epithelial cells.
The myoepithelial cells have formed a basal layer as
expected under the luminal epithelial cells that have
formed a lumen. Intense CK 18 staining is seen
along the interior of a large ductal structure that is in
part luminal (hollow) but still forming. Nuclei are
chemically stained (blue) with DRAQ5.

B. Single image from a confocal stack of the
Non-immune control of a similar structure from a
chamber slide cultured and stained at the same
time with the same explant.
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3.1.4 Thelarche, menarche, and breast cancer
Thelarche and menarche, as surrogates for puberty, are well established breast
cancer risk factors (Collaborative Group on Hormonal Factors in Breast cancer, 2012;
Kelsey et al., 1993; Latronico et al., 2016; Mishra et al., 2017; Ritte et al., 2013). Early
menarche can increase breast cancer risk by as much as 10% for each year of precocious
menarche (Collaborative Group on Hormonal Factors in Breast cancer, 2012; Hsieh et al.,
1990). This is particularly worrisome in the African American community, where early
menarche is more common and this phenomenon may also play roles in the types of
breast cancer common in African American, or in the age of onset of breast cancer,
frequently pre-menopausal in African American populations.
Menarche is more often used as opposed to thelarche for age of puberty because
of its relatively ease to recall. However, thelarche is the start of breast growth, the first
stage of puberty. Menarche generally follows close after thelarche, however,
environmental chemicals may affect them differently, and timing between thelarche and
menarche may increase (Kaplowitz & Oberfield, 1999). The uncoupling of menarche
and thelarche increases breast cancer risk when there is a greater than two years in
between (Bodicoat et al., 2014). Timing of thelarche also affects breast cancer risk.
Girls who undergo thelarche at ten years of age or younger have been shown to have an
increased breast cancer risk as much as 20% higher than girls who undergo thelarche
between the ages of eleven and twelve (Bodicoat et al., 2014).
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In recent years, African American and European-derived white women breast
cancer incidence rates have become similar (Desantis et al., 2016). However, AfricanAmerican women are more likely than white women to die from the disease (Bach, 2002;
Desantis et al., 2016). Breast cancer survival at five years after initial diagnosis is only
81% among African-American women compared to 92% among European-derived white
women (Siegel et al., 2016). Furthermore, African American women are less likely to be
diagnosed with smaller tumors (less than or equal to 2.0 cm, stages I and II) and more
likely to be diagnosed with larger tumors (greater than 5.0 cm) and at later stages than
white women of the same age (Desantis et al., 2016; Siegel et al., 2016). Although in the
past these differences have largely been attributed to socio-economic factors, data exists
to support the hypothesis that there may be intrinsic biological differences in African
American breast tissue compared with white breast tissue (Wieder, Shafiq, & Adam,
2016). The first piece of evidence for this hypothesis is that thelarche occurs earlier in
African American populations which invokes the idea that breast differentiation has an
earlier onset. Secondly, the known hormonal risk factors for breast cancer are not
accurately predicted by the Gail and Klaus models for African American women
compared with European White women. Lastly, a higher percentage of African
American breast cancers are seen in pre-menopausal women compared with European
White women who manifest more generally as post-menopausal estrogen receptor
positive breast cancers. In summary, breast development, breast cancer risk and breast
cancer types are generally different between African American and European White
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women. The question of socioeconomic status, access to insurance and urban versus
suburban lifestyle could still be factors in the U.S. However, Nigerian women living in
Nigeria have been shown to also manifest a high proportion of triple negative breast
cancers (Abdulkareem & Zurmi, 2012; Adisa et al., 2012)
In this chapter we will test the hypothesis that intrinsic biological differences
between African American and European White breast tissue may be a contributing
factor for the differing age of thelarche using our in vitro model of thelarche. We are able
to use an in vitro system to test this hypothesis because when Dr. Latimer’s laboratory
originally placed reduction mammoplasties into the model system, they were unaware of
ancestry, BMI age, menopausal status and other patient characteristics. It was observed
that some cultures formed ductal structures much earlier than other cultures. After
extensive multivariate analyses, it was discovered that ancestry was one of the main
factors involved in this in vitro disparity in ductal formation with African American
samples forming the ducts before European White patients. This will be described in the
following sections.
Because differentiation of cells in culture into ductal structures requires the
support of breast progenitor cells, we hypothesize that there is an intrinsic difference in
either the percentage of breast stem cells and/or the potency of breast stem cells between
African American women and European White women. Indeed Nakashatri et al. (2015)
showed that African American women have significantly higher proportions of CD24-
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/44+ and PROCR+/EpCAM- cells (both are marker sets that distinguish stem cell
populations in non-diseased breast) than European-derived White women (Nakshatri,
Anjanappa, & Bhat-Nakshatri, 2015). Therefore, there is precedent in the literature
justifying the search for differences in the size of the stem cell compartment in the breast
based on ancestry. Our study differs in that we are also studying the differentiation
potential of stem cells derived from African American and European-derived White
subjects. Differentiation potential, also known as “stem cell potency,” was determined
using the CD 24-/CD44+ markers as well as CD49f+, a third marker for breast stem cells
(Lloyd-Lewis, Harris, Watson, & Davis, 2017; Stingl et al., 2001).
3.2 Materials and methods
3.2.1 Non-diseased primary tissue processing
Primary human mammary epithelial cultures were established from all 48 breast
reduction mammoplasty tissues obtained from the Magee-Womens Hospital of
University of Pittsburgh Medical Center (UPMC). These tissues were derived from 36
pre-menopausal, 6 post-menopausal and 6 peri-menopausal (ages 45-55) and were all
verified to be within the range of normal histology. 12/48 (25%) of the tissue donors
were African American women matched in socioeconomic status with the white women
(middle class). Magee-Womens Hospital is a tertiary care hospital that generally serves
insured patients, so the question of socioeconomic status is not a confounding factor in
this study.
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Primary tissues were processed as described in section 2.8. Freshly obtained
tissues were minced upon arrival then platted on two-chamber slides that were coated
with 1:1 diluted basement membrane extract (Trevigen®) with DMEM. Minced tissue
was plated in MWRI medium and incubated in a humidified cell culture incubator at
37oC and 5% CO2. Two-chamber slides were inspected microscopically for episphere
formation and ductal formation daily.
3.2.2 Multivariate analysis of primary non-diseased tissues in culture
All of the cultures formed epispheres; however, 23 (47.9%) of these cultures
formed ductal structures within 11 days. Intrinsic factors were correlated with the ability
to differentiate in culture. Clinical and basic demographic and medical information were
obtained on all the anonymized subjects under internal review board number 0504117.
Thirteen factors were analyzed: age, gravida (pregnancy), para (live birth), ancestry,
weight, body mass index, height, hormone use for contraception or hormone replacement,
family history of cancer, previous lesions, time in culture, S-phase index, and menopausal
status. Two multivariate analyses were performed using Minitab software. The first
(n=48) using ductal formation (yes/no) as the dependent variable and the second (n=23)
using time to ductal formation as a dependent variable.
3.2.3 Microarray
Microarray was completed with two African American samples, JL BRL-01 (n=1)
and JL BRL-02 (n=3), and two European White samples, JL BRL-23 (n=1) and JL BRL-
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14 (n=3) to assess differences in overall gene expression between ancestries in these
cultures. RNA and microarray data previously generated from Latimer et al., (2010)
were processed using Genespring software and analyzed in different ways. Files were
normalized together using the PLIER16 algorithm (Therneau & Ballman, 2008). Results
from two African American and two European White samples were averaged together,
and probes representing the same gene, when available, were also averaged together.
Unsupervised hierarchical clustering analysis was completed, and significance was
measured using a moderated t-test with Benjamini-Hochberg multiple testing correction.
A supervised analysis of 42 genes and markers of “stemness” was also analyzed.
3.2.4 Established non-diseased breast tissue cultures for flow cytometry
We selected 10 non-diseased breast reduction mammoplasty cultures derived
from the Latimer tissue engineering system for this study (Latimer, 2002, US patent
6,383,805). Each of these cell lines was originally examined by a pathologist to confirm
the absence of histological abnormalities. Five are of self-declared African American
descent, five are self-declared European White, and all 10 of these are pre-menopausal
samples. Patients did not significantly differ in age, height or weight; however, 2/5
African American women had given birth (were parous) compared to all nulliparous
subjects in the European-derived White cohort. Samples were maintained and expanded
using the Latimer culture system (Latimer et al., 2003). One African American postmenopausal patient and two European White post-menopausal patients were also
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analyzed and compared separately (Table 3.2). Breast-reduction mammoplasty tissues
were obtained and processed for culture as previously described (Jean J Latimer et al.,
2003). Cells were incubated at 37 °C and 10% CO2, media was replaced at least 3 times
a week using MWRI.
3.2.5 Flow cytometric staining
Flow cytometry was utilized to quantify stem cell compartments based on CD24,
CD44, and CD49f expression (Table 1.1). Cells were disaggregated with 0.25% trypsin
containing EDTA (Hyclone), suspended in 1 mL of Hanks Buffered Saline Solution
(HBSS, Hyclone) with 2% fetal bovine serum (FBS, Hyclone), and counted with a
hemocytometer. Cells were washed twice with HBSS 2% FBS and resuspended in 50 uL
of HBSS (Hyclone) and 2% FBS (Hyclone).
Live cells were incubated with 20 uL of FITC-conjugated mouse anti-human
CD24 (Clone ML50, BD), PE rat anti-human CD49f (BD), and APC-conjugated mouse
anti-human CD44 (Clone G44-26, BD) antibodies for every 106 cells, for 1 hour on ice,
protected from light. Cells were then washed twice with HBSS. After washing, cells
were resuspended in 0.5mL of HBSS 2% FBS containing propidium iodide (SigmaAldrich®) at a concentration of 10 ug/mL for every 106 cells.
Cells where then immediately analyzed on a BD Accuri™ C6 flow cytometer. To
determine appropriate gating and fluorescent compensation, a fluorescent minus one
(FMO) strategy was utilized for each sample. Compensation and instrument set up and
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sensitivity were also verified and determined using BD CaliBRITEtm FITC, PE, and APC
beads (BD). Gating was determined from unstained samples and positive gates created
had less than 99.99% of events in unstained samples for each antibody.
3.2.6 Assessment of stem cell compartments
To quantify stem cell compartments FCS files created on the BD Accuri™ C6
were analyzed using the latest version of the FlowJo software. Cells were first gated on
forward and side scatter to select appropriate cellular population. Then cells that
excluded propidium iodide were selected and gated upon. Doublets were excluded based
on area versus height. CD24-/CD44+/49f+ (a more stringent definition of breast stem
cells) and CD24-/44+ (the simplest definition of stem cells) populations were quantified.
Stem cell proportions were determined in triplicate for each sample, then were averaged.
Results from African American and European-derived White women were compared
using a two-way t-test with significance determined at p<0.05 for each set of stem cell
markers. Then the samples were grouped together based on menopausal status without
regard to ancestry and stem cell proportions for pre-menopausal and post-menopausal
were compared using a student’s t-test. Then European-derived White pre-menopausal
samples were compared to European White post-menopausal samples using a t-test.
Finally, African American pre-menopausal women were compared to a single African
American post-menopausal woman. Because significance cannot be assessed based on a
single sample using a t-test we evaluated whether the single African American post-
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menopausal sample differs from the pre-menopausal population using a z-test. All
differences were considered significant at p<0.05.
3.2.7 Flow sorting and clonal plating of single stem cells
Single cell sorting was completed using the same staining technique as was used
for stem cell quantification. Once the staining was complete, cells were immediately
sorted using a BD FACSJazz Cell Sorter. Cells with the staining pattern: CD24/44+/49f+ were sorted directly into 96 well plates (Corning®). The chambers of these
plates were coated with a 1:1 dilution of basement membrane extract (Trevigen®) and
cultured using MWRI medium supplemented with 20% conditioned media for each
respective sample. Cells with the staining pattern: CD24-/44+/49f- from 5 African
American and 5 European White samples were also single cell sorted. Prior experiments
showed that cells grew significantly better in 20% conditioned MWRI rather than MWRI
alone or MWRI with increased amounts of serum.
3.2.8 Assessment of cloning efficiency
Cells were inspected microscopically within 12 hours to verify the presence of a
single cell per well (and to identify and eliminate any wells with more than one cells)
then twice a week (Monday and Friday) for 4 weeks using a Zeiss Axiovert 100 inverted
microscope. Images were captured under DIC optics using a Hamamatsu camera and in
vitro software. Sorting efficiency was determined based on the number of wells out of 96
that were microscopically verified to contain a single viable cell. Cloning efficiency is
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the number of wells that contained multiple cells. African American cloning efficiency
was compared to European white cloning efficiency using a student’s t-test (p<0.05).
3.2.9 Assessment of potency
Potency was determined as the proportion of cells that produced visibly different
cell types based on morphology upon proliferation. Potency was assessed in two cell
types CD24-/44+/49f+ (breast stem cell) and CD24-/44+/49f- (non-breast stem cell).
Duplicate runs for each sample (and when possible triplicate) were averaged together.
Data for single cell sorts from CD24-/44+/49- cells was also assessed from one run for
each sample and averaged together for each ancestry. Sorts with low sort efficiency were
excluded from calculations. JL BRL-21 CD24-/44+/49- cells had no viable cells after
sorting and was not included. African American women were compared to European
White women using a two-way t-test with significance at p<0.05. Stem and non-stem
cell potencies were compared within each ancestry using a student’s t-test for
significance (p<0.05). JL BRL-02 flow cytometric and sorting data was obtained from
prior work completed at UPMC.
3.3 Results
3.3.1 Primary tissue characteristics and multivariate analysis
When comparing the ability for form ducts, six significant multivariate models
were found, the most significant being a 7-factor model that yielded an R2 = 0.51 and
p=0.032 (Table 3.1, Model 1A). The simplest significant model contained only two
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variables that correlated with ductal formation: gravida and the S-phase index (Table 3.1,
Model 6A). Gravida, or the number of times a woman has been pregnant, had a negative
association with ductal formation. S-phase index, a measure of the proportion of
proliferative cells in a culture, had a positive association with ductal formation.
A second multivariate analysis using the time (in days) to ductal formation as the
response variable (n=23) yielded two different significant models. Model 1B yielded an
R2 = 0.78 (p<0.001) and model 2B yielded an R2 = 1 (p=0.005), Table 3.1. In model 1B,
age, previous benign lesions, and hormone use were all positively associated with time to
ductal formation. Parity, however, was negatively associated with time to ductal
formation. Both models involved age, previous lesions, and family history. In the
second significant regression model for time to ductal formation, 2B, family history and
height had positive associations with timing to ductal formation. Age, any previous
lesions, gravida, S-phase index, and ethnicity were all negatively associated with time of
ductal formation. In model 2B, African American decent decreased the time it took to
form ductal structures in culture by a factor of 63.9. The two models shared age and
previous lesions in common, but in different directions.

Table 3.1 Multivariate models.
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Ductal formation (n=48):
Model
#
1A

DF =

2.83

2A

DF =

3.14

3A

DF =

2.94

4A

DF =

3.15

5A

DF =

3.15

6A

DF =

0.39

0.515
G
0.504
G
0.473
G
0.382
G
0.425
G
0.444
G

+
0.0111
SPI
+
0.0107
SPI
+
0.0106
SPI
+
0.0146
SPI
+
0.0152
SPI
+
0.0156
SPI

0.0404
H
0.0448
H
0.0422
H
0.0462
H
0.0433
H

+
0.0130
TIC
+
0.0126
TIC
+
0.0151
TIC
+
0.0122
TIC

+
0.470
PL
+
0.471
PL
+
0.455
PL

+
0.290
FH
+
0.302
FH

+
0.072
HU

R2

P

51.4%

0.032

51.0%

0.016

49.1%

0.007

41.4%

0.008

36.4%

0.007

29.1%

0.010

78.5%

<0.001

100.0%

0.005

Time to ductal formation (in days) (n=24):
1B
2B

TDF
=
TDF
=

5.05
766

+0.8
A
-2.26
A

-4.43
P
-19.8
G

-20.8
FH
+36.4
FH

+17.7
PL(B)
- 27.6
PL(A)

+13.9
HU
-63.9
E

+15.6
H

- 1.82
SPI

DF= ductal formation, TDF = time to ductal formation, A = age (years), P = para (absolute number), G =
gravida (bivariate yes/no), FH = family history (non-breast), PL(B) = previous lesions (breast), PL(A) =
previous lesions (any), HU = hormone use, E = ethnicity (bivariate European White/African American), H
= height (inches), SPI = S-phase index (% labeled cells), TIC = time in culture (days)

Based on multiple regression model’s, African American descent is associated
with a decreased time to ductal formation. We therefore compared the time to ductal
formation of primary cultures derived from African American women to Europeanderived women. We found that African American women primary explants formed
ductal structures on average after 10.4 days in culture significantly earlier than European

90

White primary explants, which formed ductal structures at 22.61 days (p=0.028) (Figure
3.3).

Figure 3.3. Time to ductal formation based on ancestry. It took
European White women (n=18) 22.31 days to form ducts in culture, while
African American (n=5) women’s cultures formed ducts in 10.4 days
(p=0.028).

3.3.2 Microarray analyses
Unsupervised and supervised analyses of gene expression from microarray using
cell lines established in the Latimer laboratory (Breast Tumor Lines, BTL and Breast
Reduction Lines, BRL), as well as some of the commonly used commercially available
cell lines were performed. Foreskin fibroblasts (FF) were also included as non-diseased
explant cultures. All 38,500 human genes on the Affymetrix chip were included for
unsupervised hierarchal clustering. Two major clusters are shown: stage IV cell cancer
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cell lines in the middle and far right containing HeLa and MDA MB231, MCF7 and
SKBR3, and one on the left containing FF (normal) as well as several of our reduction
mammoplasty cell lines (BRLs) and some stage I cell lines. BTL-8,-33,-4 are all derived
from stage I breast tumors and have very subtle karyotypic abnormalities compared with
the cell lines on the right (Figure 3.4). Furthermore, karyotypic analysis of cell lines
shows we are studying non-transformed tissues (Figure 3.5).

Unsupervised

Figure 3.4. Unsupervised hierarchical clustering of cell lines. Breast reduction
lines do not cluster with transformed late stage breast cancers.
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Figure 3.5 Normal Karyotype
JL BRL-14. Representative
normal karyotypes of JL BRL14 (Cell lines not shown but
also karyotyped are JL BRL06, -23, 24)

Unsupervised analysis of microarray on two African American versus two
European White women derived reduction mammoplasty cell lines showed that two
genes were significantly different in unsupervised analysis of the entire chip. Interleukin
33 (IL33) was significantly under expressed in African American samples by a fold
change of 10.55 (p(corr)=0.01). RP5-944M2.2 was significantly over expressed by a fold
change of 3.26 in comparison to European White samples (p(corr)=0.04) (Figure 3.6)).
IL33 plays a role in immune system regulation. RP5-944M2.2 is a long non-coding
RNA.
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Figure 3.6 Unsupervised microarray
analysis of African American and
European White reduction cell lines.
The resultant Volcano plot is shown
comparing African American (n=2)
and European White (n=2) women
gene expression. Two genes are
significantly different. Interleukin 33,
IL33, (blue) has 10.55-fold greater gene
expression in European White than
African American women (corrected
p=0.013). RP5-944M2.2 (red) is a long
intergenic non-coding RNA that is
expressed 3.26 times greater in African
American than European White women
(corrected p=0.046).

We also looked specifically at 42 genes that are most related to stem characters
and markers. A dendrogram was created to show differences in relative expression
between African American and European White women for these genes (Figure 3.7). We
found that CD24 was expressed at a low level in both races but more so in African
American samples. CD44 was highly expressed in both samples with relatively little
differences. CD49f (ITGA6) was markedly increased in African American samples. It is
important to note that there are two cell lines in each group.
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Figure 3.7 Supervised microarray
analysis of genes related to
stemness. Dendrogram comparing
African American (n=2) to European
White (n=2) women. Red is
overexpressed and blue
underexpressed, yellow is in between.
Genes in blue boxes, CD24, CD44,
and ITGA (CD49f) are markers used
in our study for stem cells (CD24/44+/49). African American samples
showed overall slightly higher
expression in stem cell markers.
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3.3.3 Stem cell staining patterns of individual explants
Ten pre-menopausal and three post-menopausal cell lines were selected for stem
cell analysis by flow cytometry. These cell lines are summarized in Table 3.2.
Table 3.2. Extended explants characteristics.
Extended
explant

Ancestry

Type

Age

Grava

Para

Height
(inches)

Weight
(lbs.)

JL BRL-2
JL BRL-1

Pre-menopausal
AA
R
AA
R

19
35

0
2

0
0

59
64

110
170

JL BRL-24
JL BRL-12
JL BRL-15
JL BRL-23
JL BRL-14
JL BRL-08

AA
AA
AA
EW
EW
EW

R
R
R
R
R
R

33
37
33
22
25
26

1
2
0
0
0
0

1
1
0
0
0
0

65
68
66
66
62
60

227
190
245
120
180
135

JL BRL-18
JL BRL-21

EW
EW

R
R

32
35

0
UNK

0
UN
K

63
67

230
219

JL BRL-36

Post-menopausal
AA
R

65

3

1

63

230

Karyot
ype

Ductal
formation in
1º culture
Yes
No

46, XX

46, XX
46, XX

Yes
No
Yes
Yes
No
Yes
Yes
Yes

Yes

JL BRL-13
EW
R
57
2
2
62
136
Yes
JL BRL-06
EW
R
62
4
4
54
158
Yes
AA = African American, EW = European White, R = non-diseased breast reduction, UNK = unknown,
Grava = gravidity, Para = parity

Flow cytometry dot plots were created for CD24/44/49f staining of non-diseased
cultured breast cells in each sample. First, live cells were compared for their expression
on CD24. Cells that did not show positivity in CD24 were selected (Figure 3.8A).
Overall, cells in our reduction mammoplasty culture system did not show high expression
of CD24. Dot plots for the CD24 negative only cells were created and the expression of
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CD44 and CD49f markers were compared (Figure 3.8B). Most cells expressed CD44
markers with most cells staining positive for this marker. CD49f showed the most
variation in expression with some samples having less than one percent and others with
over 30% of the population expressing this marker. Overall, there were increased levels
of CD44 cells in both African American and European White women and low to no cells
with CD24 positivity.

97

A CD24-

B. CD24-/44+/49f+

Figure 3.8 Flow cytometry profiles of CD24/44/49f stained cells. Individual dot plots for (top row)
4 African American, JL BRL-01, JL BRL-24, JL BRL-12, and JL BRL-15, (middle row) 5 European
White, JL BRL-23, JL BRL-14, JL BRL-08, JL BRL-18, JL BRL-21, and (bottom row) 3 postmenopausal samples, JL BRL-36 (African American), JL BRL-13 (European White), and JL BRL-06
(European White). (A) Dot plots represent the cells with CD24 surface proteins versus side scatter
(SSC). Cells in the lower left quadrant are CD24 negative. (B) CD44 versus CD49f markers of each
individual sample, plots are gated to only include cells that are CD24-. The upper right quadrant of
each plot represents cells that are positive for both CD44 and CD 49f, i.e. the stem cells. JL BRL-02
data not shown.
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Samples were then quantified for the proportion of stem cells, CD24-/44+, i.e. the
simplest definition of a stem cell, and CD24-/44+/49+, the more stringent definition of a
stem cell (Stingl et al., 2001) in the whole population of cultured cells (Figure 3.9A and
B). JL BRL-18, pre-menopausal European White-derived sample, showed the lowest
proportion of these stem cells, with only 53.01% CD24-/CD44+ cells. JL BRL-24
showed the highest percent of CD24-/44+ cells at 99.34%. CD24-/44+/49f+ stem cells
were lowest in JL BRL-36 (0.48%), a post-menopausal European-derived White derived
sample, and highest in JL BRL-01 (33.40%), a pre-menopausal African American
derived sample.
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A

B

Figure 3.9 Percent of stem cells for individual cell lines. (A) Percent of stem cells based on CD24-/44+
expression pattern for each individual sample. (B) Percent of stem cells based on CD24-/44+/49f+
expression pattern for each individual sample.

3.3.4 Stem cell percentages in African American versus European White derived samples.
We first compared the CD24-/44+ populations between African American and
European White-derived women. There was no significant difference between African
American women and European White women in proportions of CD24-/44+ cells
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(p=0.11). Although they did not reach significance, African American samples did
overall have increased amounts of CD24-/44+ cells with an average of 95.32% compared
to 80.40% in European White-derived samples (Figure 3.10). The European-derive
White-derived samples showed somewhat higher interindividual variability in staining
patterns for these markers.

% CD 24-/44+ Stem Cells vs. Ancestry
120.00%

CD 24- CD44+ (%)

100.00%
80.00%
60.00%
40.00%
20.00%
0.00%

AA

EW

Figure 3.10. Percentage CD24-/44+ cells based on race. The average of
CD24-/44+ cells is higher in African American samples (n = 5) at 95.32%
than in European White (n = 5), 80.40%, cells, but not significant (p=0.11)

CD24/44/49f staining of non-diseased cultured breast cells showed relatively high
levels of interindividual variation across both ancestries. Overall, African American
women had significantly higher proportions of cells with CD24-/44+/49f+ patterns than
European White women (p=0.04). African American women showed that on average
23.73% of cells stained with a CD24-/44+/49f+ pattern, whereas, European-derived
White women’s cells averaged only 10.73% (Figure 3.11).
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% CD24-/44+/49f+ vs. Ancestry

CD24-/44+/49f+ cells (%)

30.00%
25.00%
20.00%

*

15.00%
10.00%
5.00%
0.00%

Premenopause AA

Premenopause EW

Figure 3.11 Percentage CD24-/44+/49f cells based on race. The average of CD24/44+/49f+ cells is significantly higher in pre-menopausal African American (n=5) than
in pre-menopausal European White cultures (p=0.02) (n=5). The average percent of
African American CD24-/44+/49f+ stem cells was 23.73% and in European White it
was 10.73%.

Samples from post-menopausal women also gave distinct patterns in cultured
cells. Three menopausal women (one African American and two European White) were
compared to the 10 pre-menopausal women. In post-menopausal women-derived cells,
the average proportion of CD24-/44+ cells were 94.31% consistent with the 87.86%
found in pre-menopausal samples (p=0.48). Due to their only being a single African
American post-menopausal-derived sample, significance was evaluated within this
ancestry using a z-test. African American post-menopausal-derived cells did not differ
from pre-menopausal African American derived cells in the CD24-/44+ compartment
(p=0.91). European White post-menopausal-derived cells also did not differ from
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European White pre-menopausal-derived cells (p=0.42). Overall, there was no
significant differences in patterns for CD24-/44+ percentages for these cells (Figure
3.10A). However, post-menopausal-derived cells did have significantly lower
proportions of CD24-/44+/49f+ cells when compared to pre-menopausal women
(p=0.03). When the one African American post-menopausal derived sample was
compared to pre-menopausal African American derived cells there was a significant
decline (based on the z-test) in the percentage of CD24-/44+/49f+ cells (p<0.001),
however, a similar decline was not seen in European White-derived cells. In fact,
European White women had no significant difference in pre/post-menopausal
percentages of these progenitor cells (p=0.238) (Figure 3.12B).
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Differences in % CD24-/44+ stem cells versus menopausal status & ancestry

A
120.00%

% CD24- CD44+ cells

100.00%
80.00%
60.00%
40.00%
20.00%
0.00%
All samples

AA
Premenopause

EW

Postmenopuase

Differnces in % CD24-/44+/49f+ stem cells versus menopausal status &
ancestry

B

% CD24- CD44+ CD49f+ cells

30.00%
25.00%
20.00%
15.00%
10.00%
5.00%

*

**

0.00%
All samples

AA
Premenopause

EW

Postmenopause

Figure 3.12 Percentage of CD24-/44+ and 24-/44+/49f+ cells based on menopausal status and
ancestry. (A) percentages of cells that are CD24-/44+ are not significantly different regardless of
ancestry or menopausal status. (B) Post menopausal cultures have significantly lower percentages of
CD24-/44+/49f+ cells (p=0.03) (n=3). **The single African American sample had a significantly lower
percentage of breast stem cells after menopause than African American premenopausal women,
signficance is measured by z-test (p<0.001).
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3.3.5 Stem cell potency in ancestries
When comparing cloning efficiency between African American women and
European White women we found that there was no difference in the efficiency, that is
cells that grew from a single viable cell after sorting, in either CD24-/44+/49f+ (p=0.252,
Figure 3.13). CD24-/44+/49f- cells also showed no difference in cloning efficiency
based on ancestry (p=0.240). The ability of African American and European Whitederived cells exhibited no differences in their ability to grow after single cells were
sorted. Therefore, potency is measured in equally proliferating colonies.

Differences in CD24-/44+/49f+ stem cell cloning efficiency based on
ancestry
60.00%

% clones

50.00%
40.00%
30.00%
20.00%
10.00%
0.00%

CD24-/44+/49f+ cloning in AA

CD24-/44+/49f+ cloning in EW

Figure 3.13 Cloning efficiency based on ancestry. (A) Cloning efficiency defined as the
percentage of cells that attached in 96 wells that have been plated with a single cell during flow
cytometric delivery, shows that there is no signficant difference in cloning efficiency based on
ancestry (p=0.252).

When comparing the potency of CD24-/44+/49f+ cells, samples from African
American women exhibited significantly higher proportions of bipotent cells than
European White women (p=0.02). African American women showed bipotent CD24-
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/44+/49f+ cells in 10.45% of the colonies compared to only 2.91% of colonies in
European White women (Figure 3.14). Individual results for each cell line for stem cell
percentages and potency are summarized in Table 3.3.
A

B
CD24-/44+/49f+ SC potency based
on ancestry
14.00%
12.00%

potency (%)

10.00%
8.00%

*

6.00%
4.00%
2.00%
0.00%

AA

Figure 3.14 Stem cell potency based
on ancestry. (A) DIC bright field
imaging of a single fibroblastic cell at
100X (left), and a cell that has
developed into two different types
displaying bipotency (right), i.e.
fibroblastic on the left and epithelial
on the right. Both photos were taken
after a single cell was originally
verified in the first 12 hours in each
well. (B) Among CD24-/44+/49f+
flow sorted single cells that were
plated as single cells and monitored
over time, African American (n=5)
samples exhibited almost twice as
much bipotent differentiation as
European White (n=5) (p=0.04).

EW

3.3.6 Stem cell potency in cell types.
To assess the difference in potency between CD24-/44+/49f+ (stem) and CD24/44+/49f- (non-stem) cells we compared the two groups regardless of ancestry and we
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found that potency did not significantly differ (p=0.36) based on cell type. When CD24/44+/49f+ (stem) African American cells were compared to CD24-/44+/49f- (non-stem)
African American cells, there was a significant reduction in potency (p=0.03). In
contrast, there was no significant differences between European White CD24-/44+/49f+
and European White CD24-/44+/49f- cell potency. This was driven by one cell line that
showed some potency in CD24-/44+/49f- cells while no others did.
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Table 3.3 Individual results for stem cell characteristics.
Non-diseased
breast
epithelium
donor

Age Ancestry

Microarray
gene expression
pattern

Ductal
Formation in
1º culture

CD24/CD44+

CD24/CD44+/CD49F+

Cloning after
sorting of 24/44+/ CD49f+
cells

Multicellular
Phenotypes in
clones (potency)

JL BRL-02

19

AA

Normal

Yes

87.14%

20.50%

ND

11.00%

JL BRL-01

35

AA

Normal

No

95.19%

33.40%

48.48%

7.14%

JL BRL-24

33

AA

Normal

Yes

99.34%

22.24%

54.35%

8.00%

JL BRL-12

37

AA

ND

No

96.33%

31.57%

63.56%

16.20%

JL BRL-15

33

AA

Normal

Yes

98.60%

10.94%

21.43%

10.00%

JL BRL-23

22

EW

Normal

Yes

91.51%

8.23%

17.90%

3.00%

JL BRL-14

25

EW

Normal

No

71.75%

0.84%

29.70%

0.00%

JL BRL-08

26

EW

ND

Yes

87.75%

20.37%

27.78%

0.00%

JL BRL-18

32

EW

ND

Yes

53.01%

16.60%

18.33%

0.00%

JL BRL-21

35

EW

ND

Yes

98.00%

7.63%

63.65%

11.54%

JL BRL-36

65

AA

Normal

Yes

98.27%

0.48%

JL BRL-13

57

EW

ND

Yes

93.45%

2.39%

JL BRL-06

62

EW

Normal

Yes

91.20%

3.50%

African American = AA, European White = EW

Post-menopausal
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3.4 Discussion
When comparing the global gene expression of two African American women to
two European White women derived cultures we found two genes with significant
differences. IL33 is part of the IL-1 cytokine family and RP5-944M2.2 is a long noncoding RNA. There is little information known about RP5-944M2.2 function as a noncoding RNA however, it’s expression is increased in African American women. IL33 is
a potent stimulator of both innate and adaptive immunity, it is expressed in preadipocytes as well as immune cells and we found it’s expression to be lower in African
American women. Since our cultures do not visibly contain immune cells, we have to
assume we may have progenitor cells that include pre-adipocytes, which would be logical
in cultured breast tissue. Supervised microarray-based gene expression patterns, showed
African American gene expression was lower for CD24 and higher for CD44 and CD49f
than European-derived White cultures which is consistent with the flow cytometry data
on stem cell compartments.
The expression of CD24-/44+ cells is the simplest definition of a breast stem cell
or a breast cancer stem cell (Sajithlal et al., 2010). In our study of non-diseased breast
cultures, we found a high percentage of these cells in general. In non-diseased primary
explants, Nakashatri et al. (2015), found an increase in the stem cell compartments in
African American women compared to European-derived White women using CD24/44+ to identify them; however, we did not find significant differences in our cultures for
these markers (Nakshatri et al., 2015). It is possible that this is an adaptation to our
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unique culture system that is highly supportive of stem cells in general. Basement
membrane substrates are often used to support stem cell growth and maintain
undifferentiated cells (Takahashi et al., 2007). MWRI medium is also adapted from
embryonic stem cell culture and is supportive of stem cells. Therefore, it is likely that we
have selected for these cells or that the expression of CD24-/44+ cells is supported by
these factors.
When comparing the more stringent definition of stem cells, i.e. the proportion of
CD24-/44+/49f+ staining cells from African American cultures to European-derived
White cultures, we found that African American women contain significantly more of
these breast stem cells. These data are consistent with a difference in earlier thelarche in
the African American population and they are also consistent with the most prevalent
breast cancer in the African American population is a “stem-like” cancer. The cell type
of origin in breast cancers of African American patients may more frequently be a stem
cell, because breast stem cells are present in higher numbers in African American than in
European White breast samples.
Post-menopausal culture data suggests that European-derived White women
breast stem cell proportions may not change from pre- to post-menopausal status
(although this is based upon only two post-menopausal cultures). The African American
women had a decline in the percentage of breast stem cells after menopause (although
this is based on only one culture). Based on these data we postulate that African
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American women have decline in stem cell percentages after menopause in their breast
that is not seen in European white women. However, this would require more samples to
confirm.
European-derived White women have no change in breast stem cell proportions
from pre- to post-menopause in their non-diseased breast samples based on our limited
post-menopausal data. There is no decline because compared to African American
women, they already have considerably lower breast stem cell proportions even in their
pre-menopausal breast tissue. Post-menopausal breast cancers, most commonly
diagnosed in European White women, are most often ER+ with incidence rates highest in
luminal type breast cancers at around 50 years old (Howlader et al., 2017). This type of
cancer is not associated with “stemness”.
The form of breast cancer most associated with “stemness” is triple negative
breast cancer (ER-. PR-, Her2-). This type is most common in young African American
women (Bauer et al., 2007). Our results show that stem cell percentages are highest in
pre-menopausal African American and that African American women have higher stem
cell percentages in their non-diseased breast in general. It is important to note that we
only have a single sample from a post-menopausal African American patient and only
two from European White patients, a limitation of this study. Therefore, post-menopausal
breast stem cells from these groups should be replicated and further evaluated.
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We also find that not only do African American women have higher percentages
of breast stem cells in these cultures, but they are intrinsically more potent as well. This
is a new finding that was not shown in Figure 3.12.
One benefit of using this culture system is that it can establish differentiated
structures reminiscent of the mammary gland. We found that African American primary
cultures tend to form ductal structures faster than European White cultures. This reflects
what epidemiology tells us about the falling age of puberty; not only has the overall age
been decreasing over the past century, but currently African American girls go through
puberty at younger ages as well. This is particularly worrisome since early menarche is
associated with increased breast cancer risk. Menarche is characterized by an explosion
of growth and requires breast stem cells to support major changes. We now find intrinsic
differences in both the proportion and potency of stem cells in tissue samples from nondiseased breasts of African American women. These differences may increase the risk
for certain breast cancers, either directly by being a target for insult, or indirectly by
modulating risk factors. Risk factors in African American women are still poorly
understood relative to information relevant to European White women. Further
characterization of the basic biology of African American breast growth and
differentiation will help to better recognize risk factors affecting this minority group.
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Chapter 4
In vitro model of thelarche for testing putative chemicals disruptive to breast
development
4.1. Introduction
4.1.1. Brief history of the creation of breast cell lines as model systems
Tumor Cell lines

The use of breast tumor cell lines has been an invaluable tool for research dating
back to the 1950s with the creation of BT-20 (Lasfargues & Ozzello, 1958), a stage IVbreast cancer-derived cell line. Tumor cell lines provide a cost efficient and unlimited
supply of cells that are relatively easy to use. Since their inception, thousands of cells
lines have been created and utilized to further our knowledge and understanding of many
aspects of breast cancer. However, even with the creation of all these cell lines there
seems to be an overwhelming use of a particular few, especially MCF7, in the breast
cancer field. Originally created in 1973 by the Michigan cancer foundation, MCF7 was
adapted into an estrogen response model because it was extremely sensitive to estrogen
(Levenson & Jordan, 1997; Soto, Sonnenschein, Chung, & Fernandez, 1995).
Non-Diseased Cell Lines
Non-diseased breast cell lines have been considerably more difficult to create
because they do not replicate immortally but manifest a version of the Hayflick
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phenomenon (Hayflick, 1965). Most non-diseased breast explants/cell lines double
between 10 and 20 times and then cease to replicate. As we will describe below, attempts
at immortalizing these cells have been made with the carcinogen benzo[a]-pyrene
(Martha R Stampfer, Bartley, & Rubin, 1985), more recently by stable transfection with
the telomerase gene (Shay, Reddel, & Wright, 2012). These methods utilized enzymatic
digestion of tissues (both normal and tumor) to the point of single cells. This
disaggregation may be one of the reasons for the short lifespan of non-diseased cells in
culture that rely heavily upon signaling from direct contact with other cells (juxtacrine
interactions).
4.2. Cell lines used as surrogates for “normal” breast cells
4.2.1. E-SCREEN
The E-SCREEN or Estrogenic Screen assay was developed to test for
environmental pollutants (Soto, 1995). The E-SCREEN assay utilizes a late stage cancer
cell line that was created from a pleural effusion, MCF-7. MCF-7 has over 100 copies of
the estrogen receptor gene and is exquisitely sensitive to the effects of estrogen or
estrogen-like compounds (xenoestrogens). MCF-7 responds to estrogens by replicating
at increased rate(Brooks, Locke, & Soule, 1973).
The E-SCREEN assay involves using serial dilutions of the test compound with
17β-estradiol is used as the positive control and the standard for comparison. After six
days of growth and exposure, the relative proliferation rates are measured, and the
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estrogenic activity of a compound is determined. However, there are major drawbacks of
the ES-CREEN assay. Chemicals tested using this system may not be relevant to nondiseased tissue or cancer prevention. Testing how xenoestrogenic chemicals may disrupt
normal cellular behavior cannot be evaluated using this and other models like it.
Furthermore, the only end point measured is cell proliferation. In fact, most assays used
today in vitro, still only use rudimentary end points such as cell death or growth rates.
This is unfortunate because the disruption of development by chemicals has been shown
to alter breast cancer risk.
4.2.2. MCF10A
MCF10A is a cell line produced from a non-malignant proliferative breast tissue
(Herbert D Soule et al., 1990). It is characterized by epithelial cells that grow in a
monolayer. It also exhibits secondary hollow spheroids when grown on MatriGelTM
together with collagen I, similar to what is seen in the in vivo breast (Debnath & Brugge,
2005; Debnath, Muthuswamy, & Brugge, 2003). MCF10A is often used as a
representative for normal breast epithelial development (Qu et al., 2015).
However, recent studies suggest that the MCF10A cells have a unique expression
pattern that is not seen in normal breast epithelium (Qu et al., 2015). Furthermore,
unpublished data from our own laboratory has shown MCF10A expression patterns to be
less like normal breast epithelium explants and more like tumor. The use of this cell line
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for an abnormal early stage of breast cancer casts some doubt on its validity as a model
system for non-diseased breast.
4.2.3 Transformed lines
To study toxicological effects, human and mouse mammary epithelial cells were
grown in culture. Stampfer and Bartley developed a system using human non-diseased
mammary epithelial cells that were transformed with benzo[a]pyrene (Stampfer et al.,
1985). These cells do not form tumors in nude mouse but do show properties of tumorderived cells. The original transformed line 184A1 was licensed a company called
“Clonetics” and sold by the microscope slide ($400 per slide) as normal human
mammary cells. Furthermore, multiple derivatives of this transformed line have been
created by further transformation. These include 184A1-RF, further transformed with
Raf-1, 184AaMY1-5, further transformed with c-myc, 184A1-GSE22, further
transformed with GSE22, and 184A1-hTERT(12p), and further transformed with hTERT
(Garbe et al., 2014; Olsen, Gardie, Yaswen, & Stampfer, 2002; Stampfer et al., 2001).
4.2.4 “Organoids” as model systems for the non-diseased breast
The growth of breast cells in 3-deminsional culture has been pioneered by Mina
Bissell. Bissell, and her group have shown the importance of extracellular matrix for
creating organotypic models in culture. A basement membrane purified from EngelbrethHolm-Swarm (EHS) excreting tumors, is used to mimic breast extracellular matrix in cell
culture flaks. Murine cells were embedded in the basement membrane extract in culture

116

and shown to differentiate into functional breast-like structures (Lee, Kenny, Lee, &
Bissell, 2007). These structures were spherical with some polarization of epithelial cells,
they also produced milk. This system was eventually adapted to human mammary cells
then into an assay for differentiating between normal and malignant mammary cells, as
malignant cells respond differently both in gene expression and morphology (Kenny et
al., 2007). While functional breast like spheroid structures have been developed in the
Bissel technique, none of these models differentiate into complex ductal systems.
4.3 Breast cancer etiology: from “normal” to cancer
Breast cancer is the most common type of cancer in American women after skin
cancer (Howlader et al., 2017). Early puberty, expressed as age of menarche, is a wellestablished risk factor for breast cancer and is included in the most widely used risk
assessment model (Gail, 2015; Gail et al., 1989). A one-year difference in age of
menarche affects overall breast cancer risk by as much as 10% (Collaborative Group on
Hormonal Factors in Breast cancer, 2012; Hsieh et al., 1990; Ritte et al., 2013). This
factor has widely been interpreted as a simple estrogenic effect on proliferation in normal
breast epithelium contributing to carcinogenesis, and particularly on proliferation of
newly transformed cells, promoting their growth into a tumor. A second factor in the
Gail model, age of first live birth, suggests another interpretation for these “hormonal”
risk factors. There is evidence that there is a critical window of vulnerability for the
breast between puberty and pregnancy wherein committed but not completely
differentiated epithelium are susceptible to transformation (Russo, Hu, Yang, & Russo,
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2000). These data suggest that breast cancer susceptibility is intricately linked to the
complex development of the breast and the cycling it undergoes to prepare for puberty
and pregnancy. In this way, even in the adult, the breast continues to be a developing
tissue every month and at the critical milestones of puberty, pregnancy and menopause.
The breast should therefore be considered from the context of developmental toxicity.
4.3.1. Developmental models of mammary epithelial cells for transformation
The mammosphere assay (Stem cells)
The laboratory of Clarke performed in vitro isolation of purified mouse epithelial
cells via Epithelial Specific Antigen (ESA)-directed flow cytometric cell sorting followed
by culture as aggregates or organoids (Smalley et al., 1999). This system showed that
mouse mammary like structures can be produced in vitro. Further work from this
laboratory by Dontu et al. (2003) led to the development of a system that involves the
establishment of spherical floating aggregates of cells, or "mammospheres” (Dontu,
Abdallah, et al., 2003). This technology was marketed as “the mammosphere formation
assay”. The assay is used to culture breast stem cells, which are important for the
development of the breast, and is still widely used today. The floating mammosphere
assays can investigate the subset of stem-like breast cancer cells that survive in
suspension conditions and show enhanced tumorigenesis when implanted into mice
(Charafe-Jauffret et al., 2009; M. Kai et al., 2015). This protocol provides a convenient
in vitro measure of sphere-forming ability, a proxy for in vivo tumorigenesis.
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Primary Human Breast Culture
Dairkee et al. (2003), demonstrated that bisphenol A-induced genomic changes in
short-term primary non-tumor adjacent epithelial explant cultures resembled those found
in aggressive breast tumors (Dairkee et al., 2008). The exposures were for seven days
and the cultures senesced shortly after testing. Other than this work, development of
models to test putative chemicals in non-diseased and non-transformed human tissue
development is currently lacking. However, the Latimer tissue engineering system
provides us with a unique ability to be able to test putative xenoestrogens and how they
affect secondary structure in vitro.
4.3.2. Chemicals in the environment
Millions of synthetic chemicals have been developed over the last century, with
~100,000 currently in commercial or industrial use (Wilson & Schwarzman, 2009).
Recent advances in combinatorial chemistry are likely to increase this number,
exponentially, in near future. Toxicity testing has lagged badly behind production and
has concentrated on genotoxicity, since this has been the property most clearly associated
with carcinogenesis. Non-genotoxic carcinogenicity is well recognized, however, and
includes estrogenic effects, but has not been widely mandated for testing. Few of these
chemicals have been tested for developmental toxicity (Wilson & Schwarzman, 2009).
In addition, naturally occurring substances often have significant toxic properties and
these have not been extensively and systematically tested. The classical toxicological
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approach to human exposures has been to analyze the chemicals, as we have proposed for
agents affecting breast differentiation. Increasingly, however, a molecular
epidemiological approach has been applied successfully, wherein evidence of toxic
exposure is first detected in patients or the population, and then backtracked to the cause
(Grant, 2001). The positive aspect of exposure-induced changes to human health is that
often the effects can be ameliorated or even reversed by removing the source of the
exposure.
It is clear that a fast and cheap yet accurate and informative test for substances
that affect breast development could have far-reaching implications for the health and
breast cancer risk of American women. We will therefore investigate the suitability of
explants derived from the Latimer tissue engineering system to establish a mediumthroughput assay for human non-diseased breast ductal differentiation for the testing of
suspicious hormone disruptors. This chapter reflects the start of optimization of such a
medium throughput assay for hormone disruptors of breast tissue.
4.4 Methods
4.4.1 Experimental design: chronic exposure of breast reduction explants
Testable Outcome: Number of Epispheres formed in the presence of the chemical
or the vehicle.
Two unique cell lines were tested to develop a non-diseased model for testing
putative xenoestrogens: JL BRL-6 (post-menopausal, run three times) and JL BRL-14
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(pre-menopausal, run twice). Cells were plated on glass four chamber slides (Nunc)
coated with basement membrane extract (Trevigen) at 3,000 cells per well in MWRI
medium as previously described in (Latimer, 2002; Latimer et al., 2010). Chemicals
used in testing included bisphenol A and estradiol that were dissolved in dimethyl
sulfoxide (DMSO) and added to MWRI medium before each experiment.
Doses were developed using previous literature and our previous experiences with
episphere formation (Dairkee et al., 2008; Welshons et al., 2003). Physiological doses of
estrogen range from 0.4nM to full saturation of the estrogen receptor at 10 nM (Welshons
et al., 2003).

Table 4.1 Experimental design of chemical testing.
Slide 1 BPA

100 nM

1,000 nM

10,000 nM

No Treatment

Slide 2 BPA
(Replicate)

100 nM

1,000 nM

10,000 nM

No Treatment

Slide 3 Estradiol

4 nM

40 nM

400 nM

Slide 4 Estradiol
(Replicate)

4 nM

40 nM

400 nM

DMSO Control
4 nM
DMSO Control
4 nM

DMSO Control
40 nM
DMSO Control
40 nM

DMSO Control
400 nM
DMSO Control
400 nM

DMSO Control
100 nM
DMSO Control
100 nM
DMSO Control
1000 nM
DMSO Control
1,000 nM

DMSO Control
l000 nM

DMSO Control
10,000 nM

BLANK

BLANK

Slide 5 DMSO Controls
Slide 6 DMSO Controls
(Replicate)
Slide 7 DMSO Controls

*Testing of JL BRL-06 also included duplicate slides of fulvestrant at doses 0.01 nM, 0.1 nM and 1 nM with

matching vehicle controls, as well as diethylstilbestrol (DES) at doses 100 nM, 1,000 nM, and 10,000 nM with
matching vehicle controls for each experiment. Bisphenol A (BPA) dimethyl sulfoxide (DMSO).
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Episphere formation was scored visually using a Zeiss microscope at 100X under
phase microscopy. First, treatment was given 24 hours after plating, bisphenol A,
estrogen, vehicle control (DMSO), and vehicle treated were all run concurrently. Each
well received a chemical at a specific dose and slides were run in duplicate for each
experiment (Table 4.1). Continuous treatment of cells continued until significant cell
death was observed. Media containing each treatment agent was replaced every Monday
and Friday. Epispheres were counted in each well by dividing the well into nine fields
and counting from top to bottom (sum of nine fields equals total epispheres per well).
4.4.2. Statistical analysis
Multiple regression was utilized to test for correlations to episphere counts in our
system. The chemical, dose, experiment, passage, and duration were all used as
independent variables. Pearson’s correlation coefficient (R2) was used to test for
correlations between episphere count and these factors. The model was considered
significant at p<0.05). Minitab software was utilized to perform the regression analysis.
Episphere counts were plotted at each time point to show the effect of time for
each dose on JL BRL-14. Counts for each time point from duplicate slides were
averaged together. Each time point was compared to its vehicle control and significance
was measured using t-test at p<0.05. Episphere counts for each dose were averaged
together from all time points and plotted against dose to create dose curves. Episphere
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counts were compared to vehicle control for each matching dose in duplicate experiments
and significance was measured using a t-test at p<0.05.
4.4. Results
4.4.1 Standardization of non-diseased breast cultures for chemical testing
To assess the ability of our non-diseased cell cultures to be used as a testing
model we assessed using the response of two noon-diseased cell lines generated through
the Latimer tissue engineering system as previously described. We began with JL BRL06 (post-menopausal) and JL BRL-14 (pre-menopausal) because these cell lines (>13
passages) retained the ability to form epispheres despite passaging. Multiple regression
models were created for each test model. JL BRL-06 and JL BRL-14 test models both
showed estrogen responses (the positive controls) that were positively correlated with
episphere formation (p=0.011, p<0.001). However, JL BRL-14 was determined to be the
most reproducible cell line with regard to episphere formation, as JL BRL-06 showed
increased variability between experiments (Table 4.2). In testing model JL BRL-14, the
adjusted coefficient of determination is 26.3%, therefore our model is able to explain
26% of the variability in episphere counts using these factors. The effect of estrogen and
time were significant at p < 0.001 and were the strongest predictors of episphere number
in this model. Time had a negative effect with a decrease of 7.9 epispheres for each
increase in one unit of time. Estrogen had a positive effect with an increase of 5.1
epispheres for each unit increase of estrogen.
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The vehicle control (DMSO) and bisphenol A dose were also significantly
correlated, p = 0.027 and p = 0.02, respectively, but were in the opposite directions. The
DMSO vehicle had an increase of 2.2 epispheres per unit increase, bisphenol A had a
negative effect with a decrease of 2.33 epispheres per unit increase of bisphenol A. The
constant was also significant; this was expected as we see epispheres in these cultures
almost immediately. Therefore, the regression line does not intercept the origin.
The factors of slide number and experiment number were put into the model as
internal controls and showed no significant correlation with episphere count, however, JL
BRL-06 showed significant differences in our internal controls. This indicated that our
system, using JL BTL-14 is reproducible as there was no difference in the combined
experiments or slide replicates. Due to confounding factors such as batch variability of
the basement membrane extract, we expect to see some variation between replicates and
experiments. However, this was not significant between different experiments with JL
BRL-14.
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Table 4.2 Multiple regression models of chemical exposures
(A) JL BRL-06
Predictor

Coef

Constant

564.550
-38.768
DURATION
-2.639
DMSO VEHICLE
-0.002
FULVESTRANT
-25.030
ESTROGEN
0.148
BISPHENOL A
0.005
DIETHYLSTILBESTROL
0.005
PASSAGE
-12.975
EXPERIMENT

Stdev

52.220
6.814
1.992
0.002
22.960
0.057
0.003
0.003
1.703

t-ratio

p

10.810
0.000
-5.690 <0.001
-1.330
0.187
-0.960
0.339
-1.090
0.277
2.580
0.011
1.750
0.083
1.730
0.086
-7.620 <0.001

s = 62.90 R-sq = 34.8% R-sq(adj) = 31.7%

(B) JL BRL-14
Predictor

Coef

Constant

105.590
3.705
-1.601

47.100
5.798
0.204

2.240
0.026
0.640
0.523
-7.860 <0.001

1.727
0.002
0.100

3.147
0.001
0.020

0.550
0.584
2.220
0.027
5.090 <0.001

-0.002

0.001

EXPERIMENT
DURATION
SLIDE
DMSO
ESTROGEN
BISPHENOL A

Stdev

t-ratio

-2.330

p

0.020

s = 35.88 R-sq = 27.7% R-sq(adj) = 26.3%

4.4.2. Estrogen response in JL BRL-14
Continuing with JL BRL-14, the more reproducible line, we analyzed the effect
over time of these chemicals. Evidence of a significant dose response to estrogen was
found as early as 16 days of treatment (p=0.018). Estrogen exposure time curves showed
significant increases over vehicle control in all 3 doses. At 4 nM, a significant increase in
episphere count was observed at 23 days (p=0.025), while at 40 nM a significant effect
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was observed at 28 days (p=0.018), and at 400 nM significant increases occurred at 13,
16, 20, 23, and 32 days (p=0.029, p=0.015, p<0.001, p=0.48, and p=0.021, respectively)
(Figure 4.1A). Treatment with 100 nM of bisphenol A showed no significant difference
at any time point. Significant increases in bisphenol A over vehicle was observed at
1,000 nM doses at 16, 20, 23, 32, and 37 days (p=0.035, p=0.008, p=0.011, p=0.021, and
p=0.011, respectively) (Figure 4.1B). However, a decline in episphere formation
compared to vehicle control at 28 days was observed with 10,000 nM bisphenol A
(p=0.058). Both time courses shown are based on a single experiment. In both
experiments, significant declines were seen after 44 days.
To further investigate the model, we also looked at which doses of estrogen and
bisphenol A had the most significant effect over control. Both estrogen and BPA showed
significant increases on episphere number over vehicle control (Figure 4.2). Estrogen at
doses of 40nM and 400nM showed significant increases over vehicle controls (p=0.036
and p<0.001) (Figure 4.2A). Bisphenol A doses of 100 nM and 10,000 nM showed a
significant increase in episphere number over vehicle (p=0.002 and P<0.001), the highest
dose of 10,000 nM showed an overall decrease (P<0.001) (Figure 4.2B).
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A

B

Figure 4.1. Episphere response over time in JL BRL-14. (A) Response to estradiol over 44 days in JL
BRL-14 versus DMSO vehicle control. In 4nm of estradiol there is significant increase over DMSO
control at 23 days (p=0.025). in 40 nM at 28 days (p=0.018) and in 400 nM at 13, 16, 20, 23, 32, 37 days
(p=0.029, p=0.015, p<001, p=0.048, p=0.021, respectively). (B) Response to Bisphenol A over 44 days
in JL BRL-14 versus DMSO vehicle control. In 0.1 μm exposure of BPA there was no significant
exposure over DMSO control. In 1 μm there are significant increases at 16, 20, 23, 32, and 37 days
(p=0.035, p=0.008, p=0.011, p=0.021, p=0.011). In 10 μm doses there is a significant decrease in
episphere formation at 28 days (p=0.054)
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A

B

Figure 4.2. Dose response curves for JL BRL-14 episphere formation. (A) Dose response curves of
estrogen and matched DMSO vehicle control over 44 days. Significant increases in episphere formation
in medium (40 nM) and high (400 nM) exposures of estrogen over DMSO control (p=0.036 and p<0.001
respectively). (B) Dose response curves of bisphenol A and matched DMSO vehicle control. There are
significant increases over control in low (0.1 μm, p=0.002) and medium (1 m p<0.001) doses. There is a
significant decline in epispherses at the high dose of 10,000 nM of BPA over matched DMSO control
(p<0.001)

4.5. Discussion
We first sought to determine the suitability of cell cultures derived using the
Latimer tissue engineering system for a medium throughput assay of breast development.
We scored cultures in vitro for the ability to form secondary structures, termed
epispheres, after being exposed to estrogen and estrogen-like compounds. We first used
JL BRL-06, which showed a significant positive correlation with episphere formation and
estrogen exposure. However, significant differences with experiment number (between
experiments) and passage were seen. JL BRL-06 is a post-menopausal derived cell line
and may therefore be less able to form secondary structures in culture and therefore yield
less consistent responses. Post-menopausal women may have utilized their
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differentiation potential, something that may be required for continuous formation of
secondary structure in passaged cells. We choose to perform chronic exposures to
chemicals because the formation of epispheres may take days. To evaluate their
formation, their maintenance and their disappearance would take a matter of weeks.
Based on these data however, stopping the experiments at two weeks is sufficient to see
the initial impact of the chemical.
We then focused on JL BRL-14, which showed no significant differences between
experiments. JL BRL-14 episphere formation showed a statistically significant positive
correlation with estrogen, and a significant negative correlation with bisphenol A. We
therefore showed evidence that secondary structure in vivo can be manipulated in a dose
responsive and measurable manner. While we do see a negative overall correlation with
bisphenol A, the highest dose of 10,000 nM is the only dose to significantly decrease the
number of epispheres. This dose may be toxic to the cells and is driving this correlation
as smaller doses showed an increase in epispheres. This is an interesting point to note, as
the ability of JL BRL-14 to respond differently to different doses may actually be more
reflective of the in vivo situation.
Often, cell lines are exposed to various chemicals and apoptosis or cell death is
measured. However, doses below what would be required to cause apoptosis may still be
measured, and their effect quantified in this system. Dairkee et al. (2008) showed that
BPA at 10-7 mol/L induced a pre-tumor profile in non-malignant contralateral breast
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explants based on gene expression after exposure (Dairkee et al., 2008). The Dairkee
group chose to use tissue that was pre-disposed to becoming malignant in order to detect
possibly tumorigenic changes by expression microarray. In contrast, we developed a
functional model of breast epithelial differentiation. RNA will be isolated in future
studies and assessed with RNAseq rather than expression microarray because it is a more
sensitive technique for gene expression that is low.
We also showed that BPA interferes with normal development of breast structure
in vitro. In vivo, alterations in normal breast development such as the falling age of
puberty or failure of breast epithelium to involute after lactation, are known breast cancer
risk factors (Bodicoat et al., 2014; Euling et al., 2008; Radisky & Hartmann, 2009;
Wyshak & Frisch, 1982). We may be able to use this system to test the ability of
chemicals to affect normal breast development.
Increased lifelong exposure to estrogen is a well known cancer risk factor,
especially in post-menopausal women (Burstein & Winer, 2000; Dall & Britt, 2017). Our
test system allows for the measurement of the effects of putative xenoestrogens to
discover how estrogenic the chemical may be in normal breast epithelium. This is
especially important because assays such as the E-SCREEN utilize breast cancer derived
cell lines that may not translate to an in vivo situation.
This test system utilizes a non-diseased breast epithelium in culture to measure
secondary structure over a period of 4 weeks. This is a relatively chronic exposure as
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opposed to an acute exposure. Adapting this technique to a high throughput assay may
prove difficult. It would require the use of advanced cell culture as well as expensive
high content platforms for imaging and analysis. The use of platforms such as the
Arrayscan or Cell insight CX7 would make it feasible to adapt this system into a medium
throughput assay for normal breast tissue. The Center for Collaborative Research and
Nova Southeastern University now possesses a Cell Insight CX7 with automated stage,
so these experiments will be considerably easier to perform now than they were.
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Chapter 5
The role of nucleotide excision repair in breast cancer stem cells.
5.1 Introduction
Before 2000, cancer researchers and clinicians were taught that solid tumors were
de-differentiated mature cells that had undergone accumulated somatic mutation
(Knudson, 1971). Tumor cells were closer to the embryo than to the mature tissuespecific cell types from which they came. Tumor cells were originally considered to each
be capable of forming another tumor by metastasizing to a new site in the body. Around
the year 2000, the cancer stem cell theory became popular (Bonnet & Dick, 1997; Lim et
al., 2009; Miller et al., 1989). That theory cast into doubt whether each cell in a tumor
could actually form another tumor because it was hypothesized that only the “cancer stem
cell” was capable of doing this. The cancer stem cell theory has been partially proven but
remains controversial because it has more recently been shown that non-stem cells in a
tumor can become cancer stem cells, i.e. de-differentiate, when they are under duress
from hypoxia, radiation, chemotherapy, etc. (Mani et al., 2008; Morel et al., 2008; Owens
& Naylor, 2013).
5.1.1 Cancer stem cells
Tumors are heterogeneous. Within each tumor resides a subset of cells called
cancer stem cells. Cancer stem cells share many common characteristics with embryonic
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stem cells. In the field of breast cancer, work by Al-Hajj et al. (2003) confirmed the
presence of these cells. They showed that CD24-/44+ cancer stem cells can repopulate a
tumor when grown and subsequently passaged in non-obese diabetic/severe combined
immunodeficient mice (NOD/SCID) (Al-Hajj, Wicha, Benito-Hernandez, Morrison, &
Clarke, 2003). This part of the cancer stem cell theory is true. That is these cells are
capable of being passaged in immunodeficient mice and creating a new tumor, whereas,
non-stem cells may grow initially in the first mouse but are not capable of being passaged
to another.
5.1.2 Cancer stem cell isolation and detection
While many definitions of breast cancer stem cells have been proposed, the gold
standard to verify “stemness” remains the ability to be passaged in NOD/SCID mice (AlHajj et al., 2003; K. Kai, Arima, Kamiya, & Saya, 2010; Owens & Naylor, 2013).
However, other methods have been discovered and utilized to detect and isolate cancer
and non-cancer stem cells. The mammosphere formation assay developed by Dontu et al.
(2003) demonstrated that normal stem cells can be grown in suspension as spherical
structures (Dontu, Abdallah, et al., 2003). When plated on bacteriological plastic round
dishes, stem cells will form spherical clusters that are suspended in culture because they
cannot attach to bacteriological plastic (which is not positively charged as is a cell culture
plate). While originally developed from terotocarcinoma culture, this assay has also been
used to describe and purify breast cancer stem cells, which also form spherical clusters on
non-adherent dishes (Dontu, Abdallah, et al., 2003).
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Breast cancer stem cells are most often detected and isolated by the proteins they
express. By far the most common definition of breast cancer stem cells are cells that are
CD24 negative and CD44 positive (CD24-/44+) (Kai et al., 2010; Phillips et al., 2006;
Tannishtha, Morrison, Clarke, & Weissman, 2001; Yin & Glass, 2011). However, many
proteins have been investigated and are utilized for the detection of breast cancer stem
cells (Table 1.1). Functional markers of stem cells have also been developed based on
key characteristics of stem cells. One such marker, aldehyde dehydrogenase, is an
enzyme that has increased activity in cancer stem cells (Croker et al., 2009). This
observation has led to the development of the aldefluor assay which is used to detect and
select for increased activity of the aldehyde dehydrogenase (ALDH+) in cancer stem cells
(Ginestier et al., 2007). PKH26 is a membrane dye that is retained in breast cancer stem
cells. PHK26+ cells have also been utilized to detect and isolate breast cancer stem cells
(Owens & Naylor, 2013; Pece et al., 2010). These markers are used in conjunction with
flow cytometric methods, to flow sort and isolate stems based on their presence or
absence.
Breast cancer stem cells can also be prevented from differentiating by transfection
with of OCT3/4 promoter. Cancer stem cells transfected with the OCT3/4 promoter
showed all the characteristics of cancer stem cells and could be passaged in NOD/SCID
mice (Sajithlal et al., 2010). Dr. Latimer’s laboratory in concert with Dr. Prochownic at
the University of Pittsburgh showed this with one of her advanced stage cell lines JL
BTL-12, as well as several conventional breast cancer cell lines. Breast cancer stem cells
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developed in this manner have also been used to test for mechanisms of ionizing radiation
resistance in cancer stem cells (S.-Y. Kim et al., 2012). The exact mechanism of this
differentiation “blockage” is currently unknown.
5.1.3 Cancer stem cell mechanisms of resistance
One proposed hallmark of breast cancer stem cells is that they are inherently more
resistant to treatment (Chang et al., 2015). Some of the same characteristics or proteins
that are taken advantage of in detection of stem cells directly contribute to their treatment
resistance. Aldehyde dehydrogenase is an enzyme that converts aldehydes to less toxic
carboxylic acids. In this way cancer stem cells are capable of detoxifying
chemotherapeutic agents such as cyclophosphamide (Abdullah & Chow, 2013; Croker et
al., 2009; Januchowski, Wojtowicz, & Zabel, 2013). Associations with ABC transporters
and ALDH+ cells indicate they may function cooperatively to increase drug resistance in
these cells (Januchowski et al., 2013).
Cell death pathways are also implicated in cancer stem cell resistance. BCL2,
FLIP and BCL-Xl are all anti-apoptotic genes and have been shown to have increased
expression in cancer stem cells (Abdullah & Chow, 2013; G. Liu et al., 2006;
Pavlopoulou et al., 2016; Safa, 2016). Nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB ), a gene that promotes inflammation and inhibition of apoptosis
plays a role in breast cancer stem cell survival (Safa, 2016).
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The activity of checkpoint kinases (CHK1/2) have been shown to contribute to
ionizing radiation resistance in breast cancer stem cells. CHK1/2 is a serine/threonine
protein kinase that performs the rate-limiting step in cell cycle arrest in response to DNA
damage (Yang et al., 2015). Multiple studies have shown association and increased
expression in DNA repair genes including EGFR, MGMT, ATR, ATM, CDKN2A,
PDGFRA, RAD51, and BRCA1 in breast cancer stem cells (Cabarcas, Mathews, &
Farrar, 2011; Eyler & Rich, 2009; Y. Liu et al., 2017; Maugeri-Saccà, Bartucci, & De
Maria, 2012; Sciuscio et al., 2011; Verhaak et al., 2010).
More specifically single strand break repair has also been shown to be
functionally increased in breast cancer stem cells. MCF7 mammospheres have shown
increased activity in response to 4 Gy of radiation, using the comet assay, when
compared to non-stem monolayers of MCF7 (Karimi-Busheri, Rasouli-Nia, Mackey, &
Weinfeld, 2010). Also, protein expression was increased in Apurinic-Apyrimidinic
Endonuclease 1 (APE1), a multifunctional gene involved in DNA base excision repair
pathway.
5.1.4 Conflicting evidence in therapy resistance for cancer stem cells.
Even though there are multiple mechanisms of treatment resistance in cancer stem
cells, conflicting results have also been shown. MCF7 stem cells defined by CD24-/44+
surface marker patterns have been shown to be resistant to ionizing radiation (Phillips et
al., 2006; Yang et al., 2015). However, Kim et al. (2012) showed that MDA MB231 and
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MD MB453 CD24-/CD44+ and OCT3/4 blocked stem cells were sensitive to ionizing
radiation than cancer non-stem cells(Kim et al., 2012). These contradictory outcomes are
unresolved.
Chemotherapy resistance to paclitaxel and epirubicin was associated with breast
cancer stem cells in ALDH1+ tumors. However, this association was not found in
histologically stained CD24-/44+ breasts tumors (Tanei et al., 2009). One study showed
that MCF7 CD24-/44+ OCT3/4 blocked stem cells were resistant to adriamycin,
etoposide, 5-flourouracil, cis-platinum, and methotrexate, however, they were sensitive to
Taxol (Sajithlal et al., 2010). MCF7, MDA MB231, MDA MB453, and JL BTL-12
CD24-/44+ OCT3/4 blocked stem cells showed differing responses to chemotherapeutic
agents depending on the cell line (Sajithlal et al., 2010). MDA MB453 cancer stem cells
were resistant to 5-fluorouracil, MDA MB231 and JL BTL-12 were resistant to
adriamycin as well as 5-flurouracil.
In different studies, both the antibiotic salinomycin and the diabetic drug
metformin seemed to sensitize cancer stem cells to cytotoxic agents. Metformin seemed
to work synergistically with herceptin to inhibit self-renewal, in a mechanism that is not
been defined (Vazquez-Martin, Oliveras-Ferraros, Del Barco, Martin-Castillo, &
Menendez, 2011). Salinomycin, in conjunction with histone deacetylase inhibitors,
seems to sensitize cancer cells via induction of apoptosis and cell cycle arrest (Kai et al.,
2015).
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5.1.5 DNA repair in breast cancer stem cells
No specific functional analyses for the 5 major DNA repair pathways have been
performed on breast cancer stem cells. Many of the mechanisms of resistance in cancer
stem cells seem to be shared, however, there is a great deal of variability in response
(Table 2.6). Cancer stem cell surface markers/isolation method, as well as the biological
origin of the cancer stem cell are likely to play a role in this variability. Conflicting
results in breast cancer stem cell resistance highlights our lack of understanding of cancer
stem cells. Many DNA repair genes have been implicated in cancer stem cell resistance,
however, functional assays have not been tested (Karimi-Busheri et al., 2010; MaugeriSaccà et al., 2012).
Nucleotide excision repair function has not been specifically tested in cancer stem
cell and the corresponding non-stem cells of tumor cell lines. This is surprising as
nucleotide excision repair plays a role in both chemotherapeutic resistance as well as
ionizing radiation (Kelley, Logsdon, & Fishel, 2014; Martin, Hamilton, & Schilder, 2008;
Michailidou et al., 2015; Stordal & Davey, 2007). Furthermore, no information is
available on the stage specificity in cancer stem cell behavior. We therefore propose that
increased nucleotide excision repair capacity measured by the unscheduled DNA repair
assay will be displayed in breast cancer stem cells.
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5.2 Methods
5.2.1 Cell culture
Three cell lines were used for this experiment MDA MB231 (ATCC), JL BTL-12,
and JL BTL29. MDA MB231 is a triple negative stage IV breast cancer cell line
obtained from a 51-year-old patient pleural effusion. The JL BTL cell lines were created
using the Latimer tissue engineering system (US Patent 6,383,805). JL BTL-12 is a stage
III breast tumor cell line obtained from a 35-40 year-old patient with luminal A breast
tumor. JL BTL-29 is a stage II hormone negative breast tumor cell line obtained from a
35-40 year-old patient (Table 5.1). Both JL BTL cell lines were chemo naïve, MDA
MB231 (ATCC) is a chemotherapy resistant cell line. BTL cell lines were grown and
maintained in MWRI medium at 37 °C with 5% C02, as described in previous sections.
MDA MB231 was grown in DMEM with 10% FCS with the same incubator conditions.
Table 5.1 Cell line characteristics for stem cell analysis
Molecular characteristics
Cell line/culture explants

Stage and site of isolation

Patient age and race
ER

PR

MDA-MB-231

IV, pleural effusion

51, Caucasian

-

-

JL BTL-12

III, primary breast tumor

35-40, Caucasian

+

+

JL BTL-29

II, primary breast tumor

35-40, Caucasian

5.2.2 Stem cell staining
Cells were disaggregated with 0.25% trypsin containing EDTA (Hyclone),
suspended in 1mL of Hanks Buffered Saline Solution (HBSS, Hyclone) with 2% fetal
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bovine serum (FBS, Hyclone), and counted with a hemocytometer. Cells were washed
twice with HBSS containing 2% FBS and resuspended in 50 uL of HBSS (Hyclone) with
2% FBS (Hyclone).
Live cells were incubated with 20 uL of FITC conjugated mouse Anti-human
CD24 (Clone ML50, BD) and APC conjugated mouse Anti-human CD44 (Clone G44-26,
BD) antibodies for every 106 cells, for 1 hour on ice, and protected from light. Cells
were then washed twice with HBSS. After washing, cells were resuspended in 0.5 mL of
HBSS 2% containing FBS and propidium iodide (Sigma-Aldrich®) at a concentration of
10 ug/mL for every 106 cells.
5.2.3 Cell sorting and optimization of sample preparation
Before each sort, compensation, instrument set up and sensitivity were verified
and determined using BD CaliBRITEtm, FITC, PE, and APC beads (BD, Cat No.
340486). Gating was determined from unstained samples and positive gates created had
less than 99.99% of events in unstained samples for each antibody.
Once the staining was completed, cells were immediately sorted using the BD
FACSJazz Cell Sorter. Cells with the staining pattern: CD24-/44+ (stem) and CD23/44- (non-stem) cells were sorted directly into separate 5 mL polypropylene tubes. Tubes
were prefilled with 4 mL of warm MWRI medium. Cells were then moved to 2-well
slides at 1 mL per well (Nunc). The chambers of these slides had previously been coated
with a 100% basement membrane extract (Trevigen®, Cat#3432-005-01) for both JL
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BTL-12 and JL BTL-29. MDA MB231 cells were plated directly on the glass slides.
Cells were incubated at 37 °C with 5% CO2 for 24 hours, then were ready to be analyzed
by the unscheduled DNA synthesis assay. Preliminary experiments done with a 48 hour
incubation before beginning the unscheduled DNA synthesis resulted in bimodal peaks in
grain counts of nuclei. This finding is evidence that multiple cell types, most likely due
to differentiation of cells during that time or possible contamination of other cell types
maybe causing the bimodal peaks. We also found that diluted 1:1 basement membrane
extract (Trevigen®) was not sufficient for supporting attachment of cancer stem cell and
non-stem cells after sorting. We therefore decreased the incubation time to 24 hours
prior to beginning the unscheduled DNA synthesis assay and coated 2-chamber slides
with undiluted basement membrane extract (Trevigen®).
5.2.4 Unscheduled DNA synthesis assay
The unscheduled DNA synthesis assay was performed as previously described
(Latimer et al 2003; 2010). Cancer stem cells, non-stem cells and unsorted parental cell
lines were all ran concurrently. Control foreskin fibroblast cells were plated 24-48 hours
prior to experiments onto glass 2 chamber slides (Nunc).
On the day of the unscheduled DNA synthesis assay, all medium was removed,
and slides were placed into an irradiation chamber with the well closest to the ground
glass protected from UV. The other chamber was exposed to a total of 14 Joules/m2 of
254 nm UVC irradiation. Immediately following irradiation, cells were incubated in
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DMEM supplemented with 10% FBS and 10 μCi/ml [H3] methyl-thymidine
(PerkinElmer Life Sciences®) for two hours in a Forma Series II Water Jacketed CO2
incubator that is dedicated to radioactive treated cultures at 37 °C in 5% CO2. Labeling
was followed by a two hour chase with DMEM medium supplemented with 10% FBS
and 10mM thymidine (Sigma-Aldrich®). Slides were then washed with 1X sodium
citrate (Sigma-Aldrich®) in PBS, then fixed in 33% acetic acid (Fisher Scientific®) in
ethanol (Sigma-Aldrich®) for 15 minutes, then 70% ethanol in distilled water for 15
minutes. Slides were left overnight to dry, then dipped in a photographic emulsion
(Caresteam®). Slides were then sealed in light tight slide boxes wrapped in foil to protect
them from light and left in complete darkness for 11 days at 4 °C. After 11 days, two
tester slides, that had been packaged separately, were developed first in Kodak®
developer then in Kodak® fixer. If adequate exposure of emulsion had occurred in
controls (50 grains per nucleus for FF), the remaining slides were then developed and
stained with Giemsa (Sigma-Aldrich®), rinsed, and counted. Counting was done on Zeiss
Axioskop microscope at 1,000X with oil immersion lens.
Quantification of silver grains on 100 nuclei from unirradiated and irradiated
chambers was done by trained laboratory personnel and local background was subtracted
from each nucleus. Cells that had greater than 80 grains per nuclei were considered to be
in S-phase and were excluded. The mean grains per nucleus was calculated for both sides
of the slide. Then the unirradiated mean was subtracted from the irradiated mean, to
remove background. The remaining value was divided by the same value calculated for
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the positive control Foreskin Fibroblast cells. Duplicate slides were compared. Total
number of cells in S-phase per field were also recorded to calculate the S-phase index of
each cell line.
5.2.5 Statistics
The average DNA repair capacity was obtained from the unscheduled DNA
synthesis assay. cancer stem cells were compared to both non-stem and the parent line
within each cell line. Non-stem cells were also compared to the parent line. Significance
was determined using a two-way t-test (p<0.05).
5.3 Results
The unscheduled DNA synthesis assay was used to determine the nucleotide
excision repair capacity of three cell lines. Table 5.1 summarizes the cell line
characteristics. All three cell lines had similar stem cell percentages. MDA MB231 had
the highest percent of CD24-/44+ cells and JL BTL12 had the lowest percent of CD24/44+ cells. When a third marker, CD49f, was added we still saw very few differences
between the three cell lines. For the sake of sorting speed, we used only CD24-/44+. JL
BTL-12 had the highest percent of cells that are CD24-/44+/49f+ and JL BTL-29 has the
lowest (Table 5.2).
Table 5.2 Cell line stem cell percentages in cell lines.
Cell line/culture explants

Percent CD24-/44+

Percent CD24-/44+/49f+

MDA-MB-231
JL BTL-12
JL BTL-29

95.99%
85.76%
95.73%

80.69%
82.55%
76.89%
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Individual dot plots for each cell line to calculate percentages are provided in Figure 5.1.
Overall, all three cell lines stained strongly for the CD44 antibody with little variation in
any cell line. Unstained cells are provided in each plot for reference. These cell lines are
high in stem cell percentages for both CD24-/44+ and CD24-/44+/49f+ cells.

Figure 5.1 Cancer cell lines stem cell staining patterns. Stained cells for CD24, CD44, and CD49f
(blue) are shown with accompanying unstained cells (red) for each cell line. (A) Dot plot represents
CD24 vs. side scatter, increases on the y-axis of stained cells over unstained indicate cells positive for
CD24. Overall there is very little expression of CD24 across all cell lines (bottom left quadrant). (B)
Stained cells for CD44 vs. CD49f show increases over unstained population for both markers. Cells in
top right quadrant are positive for both markers.
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5.3.1 Nucleotide excision repair capacity in stem and non-stem cells
The nucleotide excision repair capacities based on flow sorted stem cells (CD24/44+) and non-stem cells (CD24-/44-) showed differences. The original parent line was
not sorted and is used to compare stem cells to the overall heterogeneous population of
cells in each cell line. MDA MB231 demonstrated a very high nucleotide excision repair
capacity, 106.69% of foreskin fibroblasts. The nucleotide excision repair capacity in the
stem cells of MDA MB231 was similarly high, 117.13% of FF, and the non-stem
nucleotide excision repair capacity was considerably lower, 64.15% of FFs. JL BTL-12,
the nucleotide excision repair capacity of the parent cell line was 48.12% of FFs. The
stem line was again similar, 48.60% of FFs, however the non-stem cell lines were lower
with only 26.24% of FFs. Finally, in JL BTL-29 the nucleotide excision repair capacity
in the parent line was 50.63% of FFs. The stem cell compartment has a nucleotide
excision repair capacity that was 44.68% of FFs, and the non-stem was slightly lower at
37.70% of FFs. Overall, the trend shows that breast cancer stem cells were considerably
higher in nucleotide excision repair capacity than the remaining cells in the cell line, i.e.
the cancer non-stem cells, as measured by the functional unscheduled DNA synthesis
assay. The fact that the parental lines were similar to the cancer stem cells in repair
capacity reflects the high percentage of cancer stem cells in these cell lines. These results
are summarized in Figure 5.2.
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Stem cells show increased NER capacity compared to
non-stem cells
NER capacity relative FF
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Figure 5.2 Nucleotide excision repair capacity of stem and non-stem cells. CD24-/44+ cells are
considered cancer stem cells and CD24-/44- cells are considered non-stem cells. DNA Nucleotide
Excision Repair in the cancer stem cells (RED) is higher than in the non-stem cells (BLUE) from each
cell line. The parental line (GRAY) represents the unsorted original cell line. MDA MB231 is a stage IV
cell line that is chemotherapy resistant and it manifests the highest DNA repair. JL BTL-12 is a stage III
cell line that is chemotherapy naïve. Both show a similar pattern in the cancer stem cells having higher
repair than the non-stem cells. JL BTL-29 is a stage II cell line that is chemotherapy naïve and the
significance is unclear without further experiments. Both of the chemotherapy naïve cell lines are on the
whole are lower in DNA repair than MDA MB231. nucleotide excision repair capacities are based on
duplicate slides from a single experiment. Standard error is calculated between slides.

5.4 Discussion
Based on a single experiment, we did not see significant changes in nucleotide
excision repair capacity in cancer stem versus cancer non-stem cells. However, we do
see that in all three cell lines breast cancer stem cells have increased nucleotide excision
repair capacity compared to the cancer non-stem cells. More experiments are needed to
confirm these results and measure significance; a second experiment is currently being
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analyzed. Functional assay of nucleotide excision repair has never been shown on cancer
stem cells probably because they differentiate very rapidly, and it is a challenge to sort
them, get them to attach in culture and run the unscheduled DNA synthesis biochemical
assay while they are still stem cells.
MDA MB231 is a highly aggressive tumor that displays high levels of stem cells
as shown both here. Furthermore, MDA MB231 was derived from a patient that had
undergone genotoxic chemotherapy, therefore it is likely that selection for more resistant
cells occurred in vivo. JL BTL-12 is also derived from a late stage cancer; however, it is
chemotherapy naïve. Interestingly, its cancer stem cells are lower in nucleotide excision
repair capcity than MDA MB231; the lack of chemotherapy induction may play a role in
this.
JL BTL-29 is also a chemotherapy naïve cell line but it was derived from a stage
II (early stage) tumor. Therefore, it is not surprising we see little differences in the parent
and breast cancer stem cell nucleotide excision repair capacity as the majority of cells in
the parent unsorted population are already very stem like.
Comparisons of the nucleotide excision repair capacities in breast cancer stem
cells compared to breast cancer non-stem tells gave interesting results. The trend in all
three cell lines shows that nucleotide excision repair capacity of non-stem cells is lower
than stem cells from the same cell lines. The difference was most dramatic in stem cells
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from MDA MB231 and JL BTL 12. Both cell lines showed that stem cells had almost
twice the repair capacity of non-stem cells.
Nucleotide excision repair has been shown to be a mechanism of tumor resistance
(Ferry, Hamilton, & Johnson, 2000; Martin et al., 2008; Rosell et al., 2003). Increased
nucleotide excision repair capacity in stem cells would be very much in line with a
majority of literature, as most studies have shown cancer stem cells to be generally
resistant to toxic injury (K. Kai et al., 2010). One contradictory study provided evidence
that breast cancer stem cells can actually be more sensitive to ionizing radiation (S.-Y.
Kim et al., 2012). This study, while intriguing, used OCT3/4 “blocked cells” in addition
to CD24/44 markers. The introduction of the OCT3/4 into cells is known to make
dramatic changes in cells (Rizzino, 2009). Our study uses no such transforming agent,
furthermore we see the same trend across stages II-IV. Future experiments will include
stage I. This may indicate that there is in intrinsic difference in nucleotide excision repair
in cancer stem cells. Furthermore, while chemotherapeutic induction of nucleotide
excision repair was a possibility, our JL BTL cell lines still show a difference in breast
cancer stem cell nucleotide excision repair over the rest of the cells in the cell line. This
indicates that chemotherapeutic selection may not be responsible for these differences.
The cell lines used here remain heterogeneous, with at least two distinct cell types
in regard to DNA repair. It is interesting to note that the increased variability in JL BTL29 cells may be hints at there being more than one type of stem cell or progenitor in this
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population. Indeed, the breast has multiple progenitor cells (Hwang-Verslues et al.,
2009). Further molecular analysis and sorting based on more and/or different markers
may shed light on this observation.
Most obvious is the need for further confirmation of these findings, and repeated
experiments have already been completed and are currently being processed by our
laboratory. While only based within a single experiment the trend continues across all
three cell lines. Upon confirmation of these findings, not only would we support the
theory of resistant more aggressive tumor we also intend to find the molecular basis by
which stem cells increase their resistance.
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Chapter 6
Overall implications and future directions
6.1 Exploring our in vitro model system for the factors that control it
We investigated possible epidemiological factors associated with how well
primary cultures from non-diseased breast explants formed secondary breast ductal
structures in culture. We found that African American women developed these
structures, on average, in half the time of European white women. Based on this
observation, we compared gene expression, stem cell compartment size and stem cell
potency between breast explant cultres from African American and European White
women
We found that African American reduction mammoplasty cell lines had increased
proportions of stem cells, defined as CD24-/44+/49f+ cells relative to European White,
and that these cells were also more capable of bi-potency than those from European
White derived cell lines. Although preliminary, we also found that in samples from
European White women stem cell compartments are more consistent with those seen in
post-menopausal derived cell lines. However, this aspect of the study is limited by the
lack of available post-menopausal cell lines. The present results rely on a very small
number for post-menopause analysis, one African American cell line and two European
White cell lines. Another limitation of this study is the that we have not determined the
percent admixture in the self-declared African American and European-derived White
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subjects. We have additional samples that may reflect patients that have more European
White lineage than African American lineage, so all cell lines need to be validated for
admixture.
We know that there are “windows of vulnerability,” for genetic mutations, in
breast development that coincide with breast developmental phases (Martinson, Lyons,
Giles, Borges, & Schedin, 2013). During these windows, women are more sensitive to
genotoxic agents and this may affect their risk of developing breast cancer (Martinson et
al., 2013; Russo & Russo, 2011). African American women’s stem cell characteristics
are different then European-derived White women and they develop ductal structures in
culture, differently, as well. African American women go through thelarche, one of the
“vulnerability” phases, at much younger ages than European derived white woman. They
may therefore respond at different times and differently to factors that influence breast
cancer (Bodicoat et al., 2014; Cabrera et al., 2014; Martinson et al., 2013).
We have developed an in vitro model of thelarche where we can test various
chemicals and how they affect breast architecture. The Latimer tissue engineering
system is a model of thelarche when it spontaneously undergoes ductal development, in
which breast stem cells play a role. Our first attempts at using this system as a model for
the thelarche utilized the simple characteristic of formation of epispheres. Episphere
formation is an active process that has been documented in time lapse movies in the
laboratory.
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We have shown that the development of JL BRL-14 epispheres is responsive to
estrogen and BPA in a dose dependent manner. With further validation and use of other
estrogenic and antiestrogenic compounds this early work lays the foundation for the
development of a medium throughput assay. The use of high throughput instruments
such as the Thermofisher CellinsightTM will allow us to turn this assay into a medium
throughput assay. Additional work is already under way, and it is our hope that we can
test additional chemicals for their putative role in hormone disruption of breast
differentiation. RNA sequencing will be used to determine the gene expression changes
and potential mutation that are present as a result of these exposures. In addition, predisposed cultures that are already on the path to cancer can be used instead of reduction
mammoplasties in order to see visible steps towards cancer.
Episphere formation from women of different ancestries could also be tested
when the system is optimized. The two cell lines tested were both European White, but
they had the capacity to form architecture over later passages. Only one was
reproducible and another approach to chemical testing might be to use only one for all
chemicals in the tradition of the ESCREEN.
An interesting experiment would compare nucleotide excision repair function of
normal stem cells in African American and European-derived White women to their
respective non-stem cell populations with the unscheduled DNA synthesis assay. Then,
using the Latimer tissue engineering system, we would expose the derived cells to
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mutagenic chemicals. This would give us valuable information. First, can non-diseased
stem cells be transformed in this system to malignancy? Then, do African American and
European-derived White women explants respond differently to insult? If malignant cells
are formed, do we see differences in the malignances of European White and African
American women, i.e. the resultant breast cancer subtype? This can be taken further by
testing the resulting transformed cells by again sorting and measuring the nucleotide
excision repair capacity after malignancy, in the parent, cancer stem cells, and cancer
non-stem cells. A major obstacle in this experiment would be maintaining the stem cell
state during the transformation process. Historically, it has been shown that
transformation assays are extremely difficult to make work in vitro and the long period of
time necessary for exposure to cause enough somatic mutations would cause the stem
cells to differentiate (Tralau & Luch, 2012).
6.2 Cancer stem cells and treatment resistance
While breast cancer etiology through exposure represents one part of this study,
progression and treatment resistance represents the other. We have shown that there is an
intrinsic deficiency in both nucleotide excision repair function and nucleotide excision
repair gene expression in sporadic stage I breast cancer (Latimer et al., 2010). However,
more recently, we have shown that there is an increase in nucleotide excision repair in
late stage breast cancer cell lines (Appendix A). Only cancer stem cells from late stagederived cancer cell lines have been studied in the literature, therefore, our use of a stage II
cell line is novel. It may be that early stage breast cancers have cancer stem cells with
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very little intrinsic treatment resistance. This has never been explored in spite of the fact
that the majority of breast tumors diagnosed in the US and Europe are stage I.
In order to control differentiation, groups have transfected cancer stem cells with
constructs that limit differentiation (Kim et al., 2012). The study found the opposite
result with ionizing radiation as we found with UV radiation. They also used the less
specific comet assay, as opposed to specific repair remediated by nucleotide excision
repair in the unscheduled DNA synthesis assay. To limit differentiation, an OCT3/4
transfection was used in MDA MB231 and MDA MB453 cells. We also used MDA
MB231 in addition to two JL BTL cell lines, however these cells were not transformed.
The addition of the OCT3/4 promoter may explain some discrepancies between our
results.
Not only do commercially available, chemotherapy resistant cell lines show
increased nucleotide excision repair function, but the chemotherapy naïve stage III cell
line JL BTL-12 does as well (Appendix A). These finding suggests that increased
nucleotide excision repair capacity may be an intrinsic quality of the progression of late
stage breast tumors, and not necessarily only the result of in vivo selection for
chemotherapy resistance or adaptation to cell culture. However, the chemotherapy
resistant cell line MDA MB231 is overall higher in repair than the chemotherapy naive
JL BTL12 or JL BTL29 (Appendix A). Suggesting that chemotherapy can cause
selection of even higher treatment resistance than the cancer stem cells intrinsically
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possess. Analysis of the cancer stem cells of additional cell lines will clarify this.
It is possible that cancer stem cells are the driving force behind the increased
nucleotide excision repair capacity observed in the cell lines derived from advanced stage
tumors, but it has been shown that the non-stem cells can convert to cancer stem cells
upon treatment and with hypoxia in vivo (Ansieau, 2013). While based on only a single
experiment, this is the first-time nucleotide excision repair specific function was assessed
in breast cancer stem cells. We have already completed a second experiment and
included an additional stage I cell line, JL BTL-33. The nucleotide excision repair
capacities are being calculated and will be added to this data upon completion.
While targeting cancer stem cells for therapeutic treatment may seem ideal it has
proven to be elusive. This is due to the epithelial to mesenchymal transition pathway,
whereby epithelial cells lose their polarity and adhesion and become migratory (Ansieau,
2013). In cancer, epithelial to mesenchymal transition is highly associated with cancer
stem cells and a mechanism of metastasis and increased resistance. Furthermore, under
certain stressful conditions, i.e. hypoxia, radiation, or chemotherapy, non-stem cells can
convert to cancer stem cells (Lee et al., 2016). This makes them extremely difficult to
target. It may be possible that by targeting nucleotide excision repair genes we can lower
repair in cancer stem cells to be similar to the rest of the tumor. In theory this should
sensitize cells to treatment.
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6.3 Conclusion
Although we are limited in the number of cell lines we determined that African
American derived cell lines had increased percentages and potency in their breast stem
cells compared with European derived White cell lines. The literature indeed has shown
evidence of increased breast proportions in breast stem cells of African American women
we now also show differences in behavior of these cells. This dissertation then lays the
foundation for development of a medium throughput assay using a unique culture system.
While this work is preliminary we have shown that structures termed epispheres can be
measured and are responsive to estrogen and other chemicals. While this relied on
microscopic analysis of chamber slides, the use of high-throughput instruments will now
be implemented. This assay will be vital for determining the effect of chemicals on
breast development. Finally, we showed that breast cancer stem cells are increased in
nucleotide excision repair capacity over breast cancer non-stem cells. Again, this work is
preliminary and is still being completed, however, we see that in to late stage breast
cancer cell lines there is increased DNA repair capacity in cancer stem cells that may not
exist in early stages. This is novel and explains the increased resistance seen in these cell
lines and late stage breast tumors in general. Prior work by our lab also shows that
nucleotide excision repair is modifiable (Appendix A), therefore, decreasing this
mechanism will allow for increased sensitivity to already existing chemotherapy.
Targeting nucleotide excision repair in breast cancer stem cells is a vital pharmacological
point of intervention in breast cancer treatment.
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Appendix

Appendix A

The following section is a study completed in a joint effort with prior members of
the Latimer laboratory and myself. This section is an excerpt from a thesis that has been
submitted for publishing by Homood As Sobeai titled “DNA Repair Capacity in
Commercially Available Breast Cancer Cell Lines Compared to Primary Early Breast
Tumor Cultures” 2017. The subsequent manuscript is being submitted for publication to
BMC genomics by the following authors: Jennifer M. Johnson1 , Homood As Sobeai2,
Nancy Lalanne3, Omar Ibrahim2, Stephen G. Grant4, Sharon L. Wenger5, Jean J.
Latimer2; 1Thomas Jefferson University Hospital, Philadelphia, PA; 2Nova Southeastern
University College of Pharmacy, Fort Lauderdale, FL 3Case Western Reserve University,
Cleveland, OH; 4Nova Southeastern University College of Osteopathic Medicine and
public health, Fort Lauderdale, FL 5West Virginia University, Morgantown, WV. Work
in this section completed by myself includes microarray of breast cancer cell lines. This
work is pertinent to my dissertation in that it established nucleotide excision repair as
increasing in both function and gene expression with increasing stages of breast cancer.
This work sets the foundation of our hypothesis that breast cancer stem cells are
increased in nucleotide excision repair function.
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Elevated DNA nucleotide excision repair capacity in established breast
cancer-derived cell lines relative to primary breast tumor cultures
A1.1 Introduction
Established stage IV breast cancer cell lines are the most common models used to
study breast cancer. There are several reasons behind their popularity in breast cancer
research. They are easy to handle, provide an unlimited regenerative source of breast
tumor cells, and possess a high degree of homogeneity that allows researchers, under
well-designed experimental conditions, to generate reproducible and reliable data. The
use of these cell lines has enriched our knowledge of breast cancer features such as
proliferation, invasion, angiogenesis, metastasis, and drug resistance (Holliday & Speirs,
2011). Utilizing such knowledge in preclinical and clinical settings has yielded
breakthrough discoveries that have improved patient outcomes over the last 50 years
(Lee, Oesterreich, & Davidson, 2015).
There are more than 60 human breast cancer cell lines that are commercially
available, 20 of which are widely used in breast cancer research (American Type Culture
Collection, 2017). There are many concerns regarding using these cell lines to study
breast cancer. First, the vast majority of these cell lines have been derived from
metastatic breast cancer cells that are isolated from the pleural effusion of stage IV breast
cancer patients (Cailleau et al., 1978; H D Soule et al., 1973). Metastatic cell lines might
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not reflect the cancer cells that are present in the primary tumor. Second, these cell lines
are stage IV tumor cells which are not true representatives of the majority of breast
tumors that are diagnosed in the clinic now, which are stage I tumors (Howlader et al.,
2013). Lastly, these cell lines may have changed some of their fundamental cellular and
genetic characteristics due to culture condition adaptation. For instance, a number of
MCF-7 cell lines that were obtained from different laboratories have been shown to have
significant biological and genomic parameters such as growth rate, hormonal response,
and karyotype, despite the fact that they all had the same origin, suggesting that MCF-7 is
a highly mutable cell line capable of altering fundamental cellular and molecular
characteristic that might not reflect the original tumor from which this cell line has been
derived (Bahia et al., 2002; Wenger et al., 2004). Thus, researchers should constantly
characterize the established cell lines they are using to ensure that they maintain the
cellular and genetic features necessary to make them appropriate and representative.
Our laboratory has developed a novel tissue engineering culture system to
overcome the flaws of the established breast cancer cell lines. Using this culture system,
numerous breast tumor primary cultures that represent all stages and molecular subtypes
of breast cancer have been successfully maintained and established novel cell lines
without the use of human telomerase reverse transcriptase or exogenously transforming
agents. This system provides the laboratory with a set of invaluable research models that
can be used to study a variety of cellular and molecular characteristics associated with
breast cancer etiology and progression (Latimer, 2000; Latimer et al., 2003).
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Genomic instability is a hallmark of human cancers that can be caused by the loss
of efficient DNA repair function (Vogelstein & Kinzler, 2004). We have shown that
sporadic stage I breast tumor primary cultures exhibited a significant loss of nucleotide
excision repair (NER) function compared to non-diseased breast tissue primary cultures
(Latimer et al., 2010). Gene expression analyses of the 20 NER canonical genes using
RNase protection assay showed that 19 out of 20 genes were significantly downregulated
in stage I breast tumor explants compared to non-diseased breast epithelial tissue
explants. These data suggest that loss of NER plays an intrinsic role in breast cancer
etiology.
In the present study, we extended our investigation of NER function and gene
expression to a series of widely used commercially available breast cancer cell lines to
determine whether the loss of NER function that was observed in stage I tumors is
maintained in these cell lines. We hypothesized that the well-established, commonly
used breast cancer cell lines that have been derived from late stage breast tumors that
survived chemotherapy treatment have been clonally selected for an aggressive tumor
population that has acquired high DNA repair capacity during tumor progression.
We believe our study is clinically relevant since it examines whether the widely
used commercially available breast cancer cell lines are true representatives of the
majority of newly diagnosed breast cancer cases, stage I tumors, for an essential genomic
characteristic, NER function, that is associated with genomic instability and breast

160

carcinogenesis. Also, our study provides a new potential NER targeted therapeutic
approach that might be used with genotoxic agents to avoid chemotherapy resistance,
especially breast cancer patients who at a high risk for being chemoresistant.
A1.2 Materials and methods
A1.2.1 Established breast cancer cell lines and culture conditions
We selected five established breast cancer cell lines, MCF-7, CAMA-1, SK-BR-3,
BT-20, and MDA-MB-231, and a variant of MCF-7, MCF-7/LY2 (Table A1.1). The
selected cell lines were chosen based on their popularity as models in breast cancer
research and because they represent different molecular subtypes. MCF-7 is the most
commonly used breast cancer cell line, due to its estrogen receptor expression profile (H
D Soule et al., 1973). MCF-7 strongly expresses the estrogen receptor and is used to
represent luminal breast tumors, which represent the majority of U.S. breast tumor cases.
MCF-7/LY2 is a stable variant of MCF-7 that is resistant to the antiestrogenic compound
LY117018 (Bronzert, Greene, & Lippman, 1985). We included this cell line in our study
to investigate whether antiestrogen resistance impacts NER function. CAMA-1 is
another estrogen receptor positive cell line that is used to study luminal tumors (Fogh,
Wright, & Loveless, 1977). SK-BR-3 strongly expresses HER2 and is thought to be
representative of HER2-enriched tumors (Trempe, 1976). MDA-MB-231 is the most
widely used triple negative breast cancer cell line that is used to represent basal type
tumors, especially highly metastatic claudin-low tumors (Cailleau et al., 1978). BT-20 is
the oldest breast cancer cell line, and was derived directly from a primary breast tumor,
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unlike the majority of breast cancer cell lines, which were derived from lung pleural
effusion (Lasfargues & Ozzllo, 1958). BT-20 is also a triple negative cell line used to
study basal type tumors.
All the selected cell lines were obtained from the American Type Culture
Collection (Rockville, MD). MCF-7, MCF-7/LY2, and MDA-MB-231 were cultured in
Dulbecco’s Modified Eagle Medium (DMEM) (HyClone™) (Cat# SH30243.01)
supplemented with 10% heat-inactivated fetal bovine serum (FBS) (HyClone®) (Cat#
SH30084.03) and 1% penicillin/streptomycin (Corning®) (#Ref 30-002-cl). CAMA-1,
SK-BR-3, BT-20 were cultured in Roswell Park Memorial Institute medium (Corning®)
(#Ref 10-040-CV) supplemented with 10% heat-inactivated FBS and 1%
penicillin/streptomycin. All cell lines were cultured in uncoated 25 cm2 flasks (Corning®)
(Cat# 430639) and maintained in Forma Series II Water Jacketed CO2 Incubator (Thermo
Electron Corporation®) at 37°C in 5% CO2. Cells were plated on two-chamber slides
(Lab-Tek®) (Cat# 177380) one or two days prior to the unscheduled DNA synthesis
assay.
A1.2.2 the primary culture and cell line of a stage III breast tumor JL BTL-12 and culture
conditions
The study included a chemotherapy naïve advanced stage (stage III) breast tumor
primary culture, JL BTL-12, which was established in our laboratory. JL BLT-12 shares
much of the gene expression profile shown by the commercially available breast cancer
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cell lines. We included JL BTL-12 in our study to exclude any artifacts that might be due
to our unique way of performing culture and establishing cell lines that might influence
gene expression. JL BTL-12 was obtained and handled in the same way as the nondiseased tissues and stage I tumors to establish explants and a cell line (Latimer et al.,
2010).
Upon delivery to the laboratory, the tissues were washed with phosphate buffer
saline (PBS) (Corning®) (#Ref 21-030-CV) supplemented with 3% AntibioticAntimycotic (Cellgro®) (Cat# 30-004-Cl) containing penicillin, streptomycin, and
amphotericin B. Tissue was then minced into small pieces in MWRIα medium. MWRIα
medium was developed in our laboratory. The novel medium consists of Dulbecco’s
DMEM, 10% heat-inactivated FBS, 10% heat-inactivated newborn calf serum
(HyClone®) (Cat# SH39118.84), 2.5% whole embryo culture rat serum (Harlan Sprague
Dawley®) (Cat# 4520), 5% nucleosides comprised of adenosine (Sigma-Aldrich®) (Cat#
A4036), thymidine (Sigma-Aldrich®) (Cat# T1895), guanosine (Sigma-Aldrich®) (Cat#
G6264), cytidine (Sigma-Aldrich®) (Cat# C4654), and uridine (Sigma-Aldrich®) (Cat#
U3003), 5% non-essential amino acid (Corning®) (#Ref 25-025-Cl), and 0.0035% βmercaptoethanol (Sigma-Aldrich®) (Cat# M3148). The tissue pieces were plated on twochamber slides that were coated with basement membrane extracts (Trevigen®) (Cat#
3432-005-01). The primary cultures were grown in MWRIα medium and maintained in
the cell culture incubator at 37oC in 5% CO2 for 7-10 days prior to the unscheduled DNA
synthesis assay.
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Table A1.1 Clinical and molecular characteristics of the selected established cell
lines and our laboratory culture explants that were included in the study.
Cell line/culture
explants
MCF-7
(H D Soule et al.,
1973)
MCF-7/LY2
(Bronzert et al.,
1985)
CAMA-1
(Fogh et al., 1977)
Cell line/culture
explants
SK-BR-3
(Trempe, 1976)
BT-20
(Lasfargues &
Ozzllo, 1958)
MDA-MB-231
(Cailleau et al.,
1978)
JL BTL-12
(Sajithlal et al.,
2010)
JL BTL-8
(Latimer et al.,
2010)
JL BRL-6
(Latimer et al.,
2010)

Stage and site
of isolation

Patient age
and race

Molecular
subtype

IV, pleural
effusion

69,
Caucasian

A stable variant of MCF-7
that is resistant to the potent
antiestrogen LY117018. Used
as a model for antiestrogen
resistance
IV, pleural
51,
effusion
Caucasian
Stage and site
Patient age
of isolation
and race
IV, pleural
43,
effusion
Caucasian

Molecular characteristics
ER

PR

HER2

P53

Luminal-A

++
+

+

-

WT

Luminal-B

+

-

-

NA

Luminal-B

+

-

-

Mut

Molecular
subtype

Molecular characteristics
ER

PR

HER2

P53

HER2-enriched

-

-

+++

Mut

IV, primary
breast tumor

74,
Caucasian

Basal

-

-

-

Mut

IV, pleural
effusion

51,
Caucasian

Claudin-low

-

-

-

Mut

III, primary
breast tumor

35-40,
Caucasian

Luminal-A

+

+

-

NA

I, primary
breast tumor

50-55,
Caucasian

Luminal

+

+

NA

NA

Non-diseased
breast
epithelial
tissues

60-65,
Caucasian

Normal breast tissues

A1.2.3 Unscheduled DNA synthesis assay
NER function was determined using the autoradiographic unscheduled DNA
synthesis assay. Newborn foreskin fibroblast explants (less than 10 passages), which
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exhibit a high level of NER function, along with MDA-MB-231 were used as positive
standards in every experiment. Newborn foreskin fibroblasts and MDA-MB-231 were
plated on four slides each, two days prior to beginning the experiments. Four slides of
each established cell line were analyzed in three independent experiments. At least two
slides of each primary culture or explant that was derived from non-diseased breast
epithelial tissues or stage I breast tumors were run in one experiment. The stage III
breast tumor primary culture was run in an experiment and the cell line that has been
derived from this stage III breast tumor primary culture (JL BTL-12) was run in another
experiment.
The unscheduled DNA synthesis assay was performed using a UV delivery
system that is specifically designed for this functional assay (Steier & Cleaver, 1969).
The delivery system has three UV germicidal bulbs that are placed at a distance of three
feet (91.4 cm) from a turntable platform where the experimental chamber slides are
placed. A six-inch diameter photographic shutter that is electronically controlled opens
to deliver a precisely timed dose of UV radiation. UV light bulbs were warmed for an
hour before performing the experiment and the UV fluence rate was checked before
irradiating the chamber slides to ensure delivering an adequate UV radiation dose. The
optimal UV fluence is one Joule/m2.
The unscheduled DNA synthesis assay was performed as previously described
(Latimer et al 2003; 2010). All experimental slides were fed with fresh culture medium
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one hour before the beginning of the experiment. Then, the chamber farthest from the
ground glass end of each slide was irradiated with UV light at a wavelength of 254 nm
for 14 seconds in the absence of the culture medium, for a total UV radiation dose of 14
Joules/m2. The left chamber of each slide was shielded from the UV radiation, serving as
the unirradiated control for each slide.
After UV exposure, all the chamber slides were incubated with DMEM
supplemented with 10% FBS and 10 μCi/ml [H3] methyl-thymidine (PerkinElmer Life
Sciences®) (#Part NET027W001MC) for 2 hours in a Forma Series II Water Jacketed
CO2 Incubator that is dedicated to radioactive treated cultures at 37 oC in 5% CO2.
Labeling medium was then replaced with unlabeled chasing DMEM medium
supplemented with 10% FBS and 10 mM non-radioactive thymidine (Sigma-Aldrich®)
(Cat# T1895) and incubated for another two hours to release unincorporated radioactive
thymidine from the nucleotide pools inside the cell nuclei.
After incubation in the chasing medium, the slides were washed with 1X sodium
citrate (Sigma-Aldrich®) (Cat# 1613859) in PBS, then fixed in 33% acetic acid (Fisher
Scientific®) (Cat# A38-500) in ethanol (Sigma-Aldrich®) (Cat# E7023) and 70% ethanol
in distal water for 15 minutes each. Slides were rinsed in 4% perchloric acid (Fisher
Scientific®) (Cat# A228) overnight at 4 oC. Slides were dried the following day, then
dipped in a photographic emulsion (Caresteam®) (Cat# 8895666) and packaged in tightly
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sealed slide boxes in a dark room. Finally, the emulsion was exposed in complete
darkness for 11-14 days at 4 oC.
The length of the emulsion exposure was determined in each experiment using
two slides of each experimental control, foreskin fibroblasts and MDA-MB-231. These
slides were called “tester slides” and they were dipped and packaged in a separate slide
box. After 11 days following the dipping process, selected tester slides were developed
in (Kodak®) D-19 developer (Cat# 1464593), fixed in (Kodak®) fixer (Cat# 1971746),
then Giemsa stained (Sigma-Aldrich®) (Cat# G9641). The incorporated radioactive
thymidine in the nuclei expose the photographic emulsion directly over them and
ultimately appear as silver grains that can be seen and quantified at 1000X magnification
under oil emersion using a Zeiss Axioskop microspore. If the silver grain average counts
per nucleus were 50 or more per nucleus in foreskin fibroblast cells on the tester slides,
then the rest of the slides in the same experiment were developed. If the grain counts
were below 50, the experimental slides were left to expose for another day before
developing.
Grain counting
After developing the emulsion on experimental slides, nuclei were stained with
Giemsa and then slides were dried overnight. The slides were ready to count the next
day. The silver grains were counted over 100 non-S phase nuclei on both unirradiated
and irradiated sides at 1000X magnification under oil emersion using the Zeiss Axioskop
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microscope. S-phase nuclei were not counted because incorporated radioactive
thymidines in these nuclei reflect DNA replication, not DNA repair. S-phase nuclei were
easy to distinguish by their high grain counts, usually at least 10-fold higher than non-S
phase nuclei. Local background grain counts were evaluated for each microscopic field,
over an area approximately the same size as adjacent nuclei.
Unscheduled DNA synthesis statistical analysis
The grain count in the local background of each field was subtracted from each
nuclear grain count in that field (local background). The average grain count per nucleus
was quantified for each side chamber, unirradiated and irradiated. The final grain count
that indicates NER function was calculated by subtracting the unirradiated average grain
count per nucleus from the irradiated average grain count per nucleus. Data from all of
the slides for the same cell line or primary culture were pooled together and expressed as
a proportion of the final grain count of the concurrently processed and analyzed foreskin
fibroblast control slides. The relative NER values for the same cell line or primary
culture compared to foreskin fibroblasts were averaged over all the independent
experiments and normalized to the average relative NER values of the 23 primary
cultures of non-diseased breast epithelial tissues.
Normalized NER values for each of the established cell lines and JL BTL-12 were
compared to the normalized NER values of both non-diseased breast epithelial tissues
and stage I tumor populations using the statistical z-test. Also, all the established cell
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lines and JL BTL-12 were compared as a late stage group to both non-diseased breast
epithelial tissues group using two-tailed unpaired student’s t-test. For all statistical tests,
a P value < .05 was considered significant.
S-phase index analysis
Besides NER function, cell proliferation (replication) was assessed in each
unscheduled DNA synthesis experiment. Cell proliferation was evaluated by calculating
the S-phase index, which is the percentage of S-phase nuclei in all counted unirradiated
fields. S-phase indices were calculated for the established breast cancer cell lines and JL
BTL-12 to investigate the effect of proliferation rates on NER function in these cell lines.
The association between s-phase indices and NER capacities was examined using a
simple linear regression model. P values < .05 was considered statistically significant.
A1.2.4 Total RNA isolation
A representative non-diseased breast epithelial tissue explant (JL BRL-6), a
representative stage I tumor explant (JL BTL-8), JL BTL-12, MCF-7, CAMA-1, SK-BR3, MDA-MB-231, and BT-20 were subjected for further molecular analysis, to quantify
expression levels for 20 canonical NER genes using a microarray technique.
Total RNA was harvested from three biological replicates of JL BRL-6, JL BTL8, and JL BTL-12 and at least one sample of the five-established cell line using the
RNeasy mini kit (Qiagen) (Cat# 74104) following the manufacturer's protocol. Cells
were seeded and maintained in 100 mm petri dishes (Corning®) (Cat# 430167). RNA
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isolation was performed when the cells in these petri dishes reached 80% confluence.
RLT (700 uL) lysing buffer (supplied) was added to the petri dishes. Cell lysate was
scraped using a cell culture scraper (Fisher Scientific®) (Cat# 8100241), then
homogenized by passing 15 times through an RNase-free 20-gauge needle fitted to an
RNase-free 5 mL syringe (Becton Dickinson®) (Cat# 309635). An equal volume of 70%
ethanol was added to the cell lysate and mixed well. The total volume was transferred to
an RNeasy spin column placed in a two ml collection tube (supplied) then centrifuged for
30 seconds at a speed of 12,000 revolutions per minute (RPM). The eluant solution in the
collection tube was discarded. RW1 (350 uL) washing buffer (supplied) was added to the
spin column and centrifuged for 30 seconds at 12,000 RPM. The eluant was discarded.
DNase (10 μL) mixed with 70 μl RDD buffer (Qiagen®) (Cat# 79254) was added directly
to the spin column membrane and incubated for 30 minutes at room temperature to digest
DNA. RW (350 μL) washing buffer was added to the spin column and centrifuged for 30
seconds at 12,000 RPM. The eluant was discarded. RPE (500 μL) washing buffer
(supplied) was added to the spin column and centrifuged for 30 seconds at 12,000 RPM.
The eluant was discarded. The spin column was placed in an autoclaved, RNase free 1.5
mL tube (eppendorf®) (Cat# 22363204). RNA-free water (50 μL) (supplied) was added
directly to the spin column and then centrifuged for one minute at 12,000 RPM to elute
the RNA. The RNA eluant was added to the spin column and centrifuged again for a
minute at 12,000 RPM to increase the RNA yield. The RNA samples are kept on ice at
this point.
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The total RNA concentration for all samples was determined by measuring the
sample absorbance at 260 nm in an Ultrospec 2100 pro spectrophotometer (Amersham
Biosciences®). RNA purity was obtained by calculating the ratio of the sample reading at
260 nm to 280 nm. Pure RNA sample has a ratio of 1.8-2 (Matlock, 2012). Samples
were flash frozen in cold ethanol (with dry ice added) and stored in a – 80 °C freezer
(Van Waters & Rogers®) (model# 40086A).
A1.2.5 Microarray gene expression analysis
Two μg of total RNA from each sample was used to perform microarray gene
expression, which was done at the Clinical Genomic Facility of University of Pittsburgh
Cancer Institute by using the Affymetrix Human Genome U133 plus two chip. Five
publicly available Gene Expression Omnibus (GEO) datasets: GSE41445 (Groth &
Politz, 2012), GSE20713 (Dedeurwaerder et al., 2011), GSE34211 (Hook et al., 2012),
GSE12777 (Hoeflich et at., 2009), GSE36133 (Barretina et al., 2012), representing the
five established cell lines were utilized to complete the microarray analysis (Table A1.2).
Raw data for each sample was downloaded as .CEL files and then processed using
GeneSpring software (Agilent, Inc). The probe logarithmic intensity error (PLIER16)
algorithm was applied to normalize the sample files. Gene expression data on 51 probes
representing the 20 NER canonical genes were extracted. Data on multiple probes for a
single gene, when available, were averaged.

171

Table A1.2 Source and the number of microarray .CEL files that were processed in this study.

Culture explants/
cell lines

Our
laboratory

GSE41445
(Groth & Politz,
2012)

GSE20713
(Dedeurwaerder et
al., 2011)

GSE34211
(Hook et al.,
2012)

GSE12777
(Hoeflich et al.,
2009)

GSE36133
(Barretina et
al., 2012)

Total

JL BRL-6

3

-

-

-

-

-

3

JL BTL-8

3

-

-

-

-

-

3

JL BTL-12

3

-

-

-

-

-

3

SK-BR-3

1

-

1

2

1

1

6

CAMA-1

1

-

-

2

1

1

5

MCF-7

3

3

1

2

1

1

11

BT-20

1

-

-

2

1

1

5

MDA-MB-231

2

3

-

2

1

1

9
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Gene expression statistical analysis
NER gene expression was expressed relative to the average of NER gene
expression in the normal breast epithelial biological replicates of JL BRL-6. We
performed a one-tailed unpaired Student’s t test in order to identify individual NER genes
that were significantly increased in expression in the established cell lines and JL BTL-12
compared to JL BRL-6 and JL BTL-8. A P value < .05 was considered statistically
significant.
Gene expression clustering analysis
Using hierarchical clustering, samples were divided into clusters and sub-clusters
forming a tree-shaped structure (dendrogram) based upon their gene expression profile.
The distance to the horizontal lines reflects how similar two samples within the clusters
are with respect to their gene expression patterns. The larger the distance, the less similar
or related these samples are to each other.
Supervised hierarchical clustering analysis based on the 20 NER canonical genes
of JL BRL6, JL BTL-8, JL BTL-12, and the five established cell lines was performed
using GeneSpring software (Agilent, Inc). Multiple probes for a single gene, when
available, were averaged. Euclidean algorithm and the average linkage method were used
to generate the dendrogram.
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A1.2.6 RPA3 silencing experiments in late stage high-DNA repairing breast cancer cell
lines (cell line selection and experimental design)
Three high-DNA repairing cell lines, MDA-MB-231, MCF-7, and JL BTL-12,
were selected for RPA3 loss of function experiments. MDA-MB-231 and MCF-7 were
selected because they are the most commonly used established breast cancer cell lines in
breast cancer research and represent two completely different molecular types of breast
cancer. JL BTL-12 was selected to assure the any results that are obtained using MDAMB-231 and MCF-7 are attributed to intrinsic characteristics of late stage breast cancer
tumors and not to artificial phenomena in these long-standing established cell lines.
RPA3 gene expression was silenced using the small interfering RNA technique
(siRNA) (Dykxhoorn, Novina, & Sharp, 2003). Four transfection treatment groups were
assigned for each cell line: blank, mock-treated, negative control, and RPA3 siRNA
transfected. The blank sample was maintained under the optimal culture conditions in
which the cell line is handled without any treatment. This sample was included in the
study to ensure all optimal cell culture conditions during the experiments were
maintained. The mock sample was transfected with only the transfection vehicle,
lipofectamine® RNAiMAX (Life technologies®) (Cat# 13778150). The negative control
sample was transfected with the transfection complex that is composed of lipofectamine
and fluorescein isothiocyanate (FITC)-tagged scrambled RNA (BLOCK-iT® Fluorescent
Oligo) (Life Technologies®) (Cat# 2013). The fluorescent-scrambled RNA duplex
mimics RPA3 siRNA duplex structure but does not have any functional effect on all
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human gene transcripts. Both mock and negative control samples were included in the
study to exclude experimental artifacts that might affect RPA3 gene expression and NER
function. The RPA3 siRNA treated sample was transfected with the RPA3 siRNA
transfection complex, consisting of lipofectamine and a predesigned, commercially
available RPA3 siRNA duplex (Invitrogen®) (Cat# 4392420) (ID# s12133) that was used
to assess silencing of RPA3 gene expression and the impact on NER function. Three
independent transfection experiments were performed for each cell line.
A1.2.7 Lipofectamine transfection
Four RPA3 siRNA doses 20, 40, 60, and 80 pmole were used to optimize
transfection conditions for each cell line. The 60 pmole dose was selected to be used in
this study for two reasons: this dose had a higher transfection efficiency in the three cell
lines compared to other doses, and this dose was used in the miR-145 experiment, which
allowed us to perform comparative gene expression and NER function analyses between
RPA3 siRNA and miR-145 experiments.
Two hundred fifty thousand cells of each of MDA-MB-231 and MCF-7 were
plated separately in 60 mm petri dishes (Corning®) (Cat# 430166) for each treatment
group 36 hours prior to transfection. Two hundred fifty thousand cells of JL BTL-12
were plated in 60 mm petri dishes for each treatment group 24 hours prior to transfection.
This number of cells was found to allow the cultures to reach 40-50% confluence by the
time of transfection.
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On the transfection day, transfection complex for each sample was prepared as the
following: 60 pmole of FITC-tagged scrambled RNA (negative control), and RPA3
siRNA were diluted with 250 μL of Opti-MEM® (Life technologies®) (Cat# 31985070),
which is serum- and antibiotics-free culture medium. Ten μL of lipofectamine was
diluted in 250 μL of Opti-MEM. The diluted FITC-tagged scrambled RNA and RPA3
siRNA were mixed with the diluted lipofetamine and incubated for 10 minutes for each
negative control and RPA3 siRNA sample, respectively. The diluted lipofectamine was
mixed with 250 μL of Opti-MEM™ and incubated for 10 minutes for each mock sample.
Five hundred μL of the final transfection complex medium mixed with 3.5 mL of OptiMEM and incubated with cells in each assigned treatment group for 6 hours in the cell
culture incubator at 37 oC in 5% CO2. The Opti-MEM medium was replaced with regular
culture medium, 10% FBS in DMEM for MDA-MB-231 and MCF-7 and MWRI for JL
BTL-12 after a rinse with PBS then maintained in the cell culture incubator.
A1.2.8 Transfection efficiency
Transfection efficiency of the FITC-tagged negative control transfected samples
was evaluated using fluorescent Olympus® IX51 microscope 24 hours after transfection
in each experiment. Bright field and dark field images of five representative 20X
microscopic fields were captured by a Hamamatsu® digital camera (model# C848-03G02)
using MetaMorph® software 7.7.4.0v (Molecular Devices, Inc.). The total number of
cells in each field was counted on the bright field images while the number of transfected
cells was counted on the corresponding dark field images using ImageJ 1.47v software
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(National Institute of Health). Transfection efficacy was calculated by dividing the
number of transfected (fluorescent) cells by the number of total cells in each field.
Transfection efficiency for each experiment was obtained by averaging the transfection
efficiency values of the five representative fields.
A1.2.9 Total RNA isolation (RPA3 siRNA experiments)
Total RNA was harvested from the treatment groups using the RNeasy mini kit
(Qiagen) 48 hours after transfection. The extraction process and RNA concentration and
purity measurement of the samples were performed as described in section A1.2.4 in this
chapter. The samples were flash frozen and stored in a – 80 oC freezer.
A1.2.10 Northern RNA gels
The harvested RNA samples were run in mini-northern RNA gels (1.5% agarose,
6.3 % formaldehyde) to evaluate RNA quality and adjust the total RNA concentration
that was initially measured using the spectrophotometer. Ribosomal RNA bands were
densitometrically scanned. RNA concentration was adjusted with these ribosomal bands
using an MDA-MB-231 control RNA sample that was run in triplicate on each northern
gel.
One μg of total RNA was diluted in 10 μL in diethyl dicarbonate (DEPC) H2O
(Cellgro®) (Cat# 46-000-CM) to obtain 100 ng/μL final concentration. Each diluted
RNA sample was mixed with 15 μL of denaturing buffer that consisted of 64% deionized
formamide (Sigma-Aldrich®) (Cat# 11814320001), 37% formaldehyde (Amresco®) (Cat#
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M134), 0.01% of 100x northern gel buffer stock solution (1 M Na2HPO2) then denatured
at 65oC for 10 minutes using Matercycler EP Gradient S (Eppendorf®). Then, 2.5 μL of
RNA loading dye, which is comprised of 90% orange G (Sigma-Aldrich®) (Cat# O3756)
and 10% bromophenol blue (Sigma-Aldrich®) (Cat# B5525) dyes, was mixed with the
denatured samples.
The samples were loaded in a 44 mm 1.5% agarose gel that was prepared as
follows: 1.125 gm of agarose (Lonza®) (Cat# 50070) was dissolved in 59.29 mL of
DEPC H2O then heated until it reached a boiling temperature. The agarose solution was
cooled to 80oC then mixed with 12.75 mL of 37% formaldehyde, 0.74 mL of the 100X
northern gel buffer stock solution, 2.22 mL of DEPC H2O to obtain the final northern gel
concentration (1.5% agarose, 6.3 % formaldehyde). The final agarose solution was
cooled to 60 °C then poured into an RNA gel-casting tray. The agarose solution was
allowed to cool for 30 minutes in order to allow agarose polymerization. The gel was
transferred to a northern gel electrophoresis box, then immersed in 100 mM Na2HPO2
buffer. The gel was run at 120 volts for two hours.
After electrophoresis, the gel was rinsed with distilled H2O three times to dilute
the formaldehyde, then incubated with distilled H2O containing ethidium bromide
(Sigma-Aldrich®) (Cat# E1510) for 30 minutes, covered with foil, under a constant low
speed shaking. The gel then de-stained by washing with distilled H2O for 30 minutes
under a constant moderate speed shaking four times. The gel was exposed to UV light at
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365 nm in AlphaImager MINI gel imaging system (Cell Biosciences, Inc.) and several
images of the RNA gel were captured at multiple exposure times using Chameleson®
digital camera (model# CMLN-13S2M) and AlphaImager MINI software (Cell
Bioscineces, Inc.).
Total integrated intensities of S28 and S18 RNA ribosomal bands of MDA-MB231 control replicates and experimental samples were measured using the ImageJ
software. A local background below each band was assessed and subtracted from the
total integrated intensity value of that band. Background subtracted values of S28 and
S18 bands were combined for each sample to obtain a final intensity value. RNA
samples concentrations were adjusted based on the final intensity values of these samples
relative to the final intensity value average of control replicates. RNA quality was
examined using the ratio of S28 band intensity to S18. A good quality RNA sample has a
ratio of 1.8-2.2 (Ausubel et al., 2001).
A1.2.11 Reverse transcriptase polymerase chain reaction
The efficacy of RPA3 siRNA transfection on RPA3 gene expression was
evaluated in three independent experiments for each cell line using reverse transcriptase
polymerase chain reaction (RT-PCR). Two μg of total RNA of each sample was
converted to a copy DNA transcript (cDNA) using the high capacity cDNA reverse
transcription kit (Life technologies®) (Cat# 4368814) as follows: 10 μL of 2X reverse
transcription master mix was prepared by mixing 2 μL of 10X RT buffer, 0.8 μL of 25X

179

deoxynucleoside triphosphate (dNTP) mix of the four DNA monomeric units
deoxyadenosine triphosphate, deoxythymidine triphosphate, deoxyguanosine
triphosphate, and deoxycytidine triphosphate, 1 μL of MultiScribe® reverse transcriptase,
and 4.2 μL of DEPC H2O. The 2X reverse transcription master mix was then added to 2
μg of total RNA of each sample that was diluted in 10 μL of DEPC H2O to obtain a 100
ng/μL final concentration. RNA was converted to cDNA in three thermal steps: 25 °C for
10 minutes, 37 °C for 120 minutes, then 85 °C for 5 minutes using Matercycler EP
Gradient S (Eppendorf®).
A predesigned RPA3 Taqman® gene expression assay (Invitrogen®) (Cat#
448892) (ID# Hs01047933_g1) was used to quantify RPA3 gene expression in the
samples. A predesigned GAPDH Taqman® gene expression assay (Invitrogen®) (Cat#
4453320) (ID# Hs02758991_g1) was used to quantify the housekeeping gene GAPDH
that was used to normalize RPA3 gene expression data. 200 ng of three technical
replicates were run for each sample. An RT-PCR reaction volume of 20 uL was prepared
for each technical replicate by mixing one μL of 20X Taqman gene expression assay, 10
μL of 2X Taqman gene expression master mix (Applied Biosystems®) (Cat# 4369016),
two μL of cDNA (200 ng), and seven μL of DEPC H2O. The 2X Tagman gene
expression master mix contains AmpliTaq Gold™ DNA polymerase, uracil-DNA
glycosylate, dNTPs, ROX™ passive reference, and optimized buffer components. 10%
access volume was considered to compensate for volume loss from pipetting. The 20 uL
RT-PCR reaction volume of each replicate was transferred to an RT-PCR 96-well plate,
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then sealed with an adhesive cover to prevent cross contamination among wells. The
well plate was loaded into StepOnePlus Real times PCR system (Applied Biosystems®).
The PCR amplification process was run using three thermal steps 50 °C for two minutes,
9 °C for 10 minutes, then 40 cycles of 95 oC for 15 seconds followed by 60 °C for one
minute.
The average of GAPDH cycle threshold (CT) value was subtracted from the
average of RPA3 CT value of the technical replicates to obtain a ΔCT value for each
sample. Then, the ΔCT value of the reference group (mock sample) was subtracted from
ΔCT values of negative control and RPA3 siRNA transfected samples to obtain
logarithmic relative gene expression values (ΔΔCT). ΔΔCT values were exponentially
transformed using the equation 2-ΔΔCT to obtain relative fold change expression values.
The significance of RPA3 gene expression reduction in the RPA3 siRNA treated samples
were evaluated statistically compared to RPA3 gene expression in the mock and negative
control samples in the three independent experiments for each cell line using one tailed,
paired student’s t test. A P value < .05 was considered statistically significant.
A1.2.12 Unscheduled DNA synthesis assay (RPA3 siRNA)
The impact of silencing RPA3 gene expression on NER function was assessed in
the most transfectable cell line, MDA-MB-231, that had the most significant RPA3 gene
expression suppression. Forty thousand cells were plated in each chamber of a twochamber slide 36 hours prior to transfection. Slides were transfected with either negative
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control or RPA3 siRNA with a dose of 12.6 pmole. Three replicate slides were used for
each treatment group. Transfection efficiency was examined 24 hours after transfection
as described in section A1.2.2. Unscheduled DNA synthesis analysis was performed 48
hours after transfection as described in section A1.2.1.
The final grain counts of the RPA3 siRNA transfected slides were pooled together
and expressed as a percentage of the pooled final grain counts of the negative control
slides. One tailed, paired student's t test was used in order to test for the significance of
silencing RPA3 on NER function suppression in the RPA3 siRNA treated cells compared
to in the negative control cells. A P value < .05 was considered statistically significant.
S-phase indices of both negative control and RPA3 siRNA transfected cells were
calculated to assess the impact of silencing RPA3 gene expression on replication
(proliferation). S-phase indices were evaluated by calculating the S-phase cell percentage
on all counted microscopic fields on the irradiated sides. One tailed, paired student's t
test was used in order to evaluate the significance of silencing RPA3 on cell proliferation
inhibition statistically in the RPA3 siRNA treated slides compared to the negative control
slides. A P value < .05 was considered statistically significant.
A1.3 Results
A1.3.1 NER function in the established breast cancer cell Lines and JL BTL-12
We evaluated NER function in six widely used commercially available breast
cancer derived cell lines and a chemotherapy naïve primary culture of late stage breast
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cancer (stage III) JL BTL-12, and compared to NER function in primary cultures of 23
non-diseased breast epithelial tissues and 19 tissues with stage I invasive breast tumors
stage I breast tumors that have been previously published (Latimer et al., 2010). All
repair capacity was expressed as a percentage of non-diseased breast tissue (derived from
23 primary cultures of breast reduction mammoplasties). Our goal was to determine
whether these established breast cancer cell lines reflect the same DNA repair capacity as
stage I breast tumor cells, which is the most diagnosed breast cancer stage, in the context
of NER capacity.
The six established cell lines and JL BLT-12, as a late stage breast cancer group,
exhibited a significantly higher NER function by 2.35 times (P < .001) and 5.15 times (P
< .001) compared to the non-diseased breast epithelial tissue and stage I tumor groups,
respectively (Table A1.3).
JL BTL-12, CAMA1, MCF-7, MCF-7/LY2, BT-20, and MDA-MB-231 had a
significant increase in NER capacity by 1.60 (P = .019), 1.68 (P = .002), 2.20 (P < .001),
2.71 (P < .001), 3.40 (P < .001), and 3.63 times (P < .001) compared to the population of
non-diseased breast epithelial primary cultures using one-tailed z tests, respectively
(Table A1.3). SK-BR-3 had 1.27 times increase in NER function over the average of
non-diseased breast epithelial tissues but this result did not reach statistical significance
(P = .087) (Figure A1.1; Table A1.4).
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When compared to the primary cultures of stage I breast tumors, SK-BR-3, JL
BTL-12, CAMA1, MCF-7, MCF-7/LY2, BT-20, and MDA-MB-231 had a statistically
significantly increased NER function by 2.79 (P < .001), 3.49 (P < .001), 3.67 (P < .001),
4.81 (P < .001), 5.93 (P < .001), 7.44 (P < .001), and 7.94 times (P < .001), respectively
(Figure A1.1; Table A1.4).
These data suggest that the established breast cancer cell lines consistently
manifested higher NER capacity over both normal breast epithelial and stage I tumor
populations, and that these cell lines do not resemble stage I tumor cultures in terms of
NER function. The primary culture of the stage III breast tumor primary culture and
established cell line JL BTL-12 showed NER function similar to the established cell
lines. This result indicates that the increase in NER function that was observed in the
established cell lines and JL BTL-12 was attributable to molecular characteristics of late
stage breast tumor and was not due to intrinsic differences in culture conditions.

Table A1.3 NER capacity results of one-tailed unpaired student t test values of the late stage
breast tumor group compared to non-diseased breast epithelial tissue and stage I breast
tumor groups.
Group

NER Capacity

Standard
Error

T Test vs. NonDiseased Group

Non-diseased breast
epithelial tissue

1

0.084

Stage I breast tumor

0.46

0.045

< .001

Late Stage tumor

2.35

0.347

< .001

T Test vs. Stage I
Group

< .001
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Figure A1.1 NER function in the established breast cancer cell lines and primary cultures.
Established cell lines and JL BTL-12 (n=7) compared to the primary cultures of non-diseased breast
epithelial tissues (n=23) and stage I breast tumors (n=19). JL BTL-12, CAMA-1, MCF-7, MCF-7/LY2,
BT-20, and MDA-MB-231 had significantly increased NER capacities relative to both non-diseased breast
epithelial tissues and stage I breast tumors. The increase in NER function of SK-BR-3 was statistically
significant in relative to stage I breast tumors but fell in the range of NER values of non-diseased breast
epithelial tissues. NER capacity was presented relative to the average of NER function in non-diseased
breast epithelial tissue group. The dotted line in each group represents the mean. Standard error from at
least three independent experiments is shown in the established cell lines.

185

Table A1.4 NER capacities, standard errors, and one-tailed z test values of the established
cell lines and JL BTL-12 compared to non-diseased breast epithelial and stage I breast
tumor primary cultures.
Cell line/

Relative to non-diseased breast
epithelial tissues

Relative to stage I breast tumors

Primary culture

NER
capacity

Standard
Error

Z test

NER
capacity

Standard
Error

Z test

SK-BR-3

1.27

0.055

.087

2.79

0.121

< .001

JL BTL-12

1.60

0.324

.019

3.49

0.709

< .001

CAMA-1

1.68

0.162

.002

3.67

0.355

< .001

MCF-7

2.20

0.245

< .001

4.81

0.537

< .001

MCF-7/LY2

2.71

0.279

< .001

5.93

0.611

< .001

BT-20

3.39

0.284

< .001

7.44

0.621

< .001

MDA-MB-231

3.63

0.546

< .001

7.94

1.196

< .001

The association between molecular characteristics and NER function in the late stage
breast cancer cell lines and primary culture was evaluated. The triple negative breast
cancer cell lines BT-20 and MDA-MB-231, as a group, had a statistically significant
higher NER capacity by 1.72 times (P = .020) compared to the luminal type breast
tumors group consisting of JL BTL-12, CAMA-1, and MCF-7, and MCF-7/LY2 (Table
A1.5). This suggests that triple negative breast tumors might exhibit a highly efficient
NER function that might play a role in the tumor aggressiveness and chemotherapy
resistance that have been observed in such tumors. Although the antiestrogen resistant
cell line MCF-7/LY2 had an increase in NER function over its parent by 23%, the
antiestrogen sensitive cell line MCF-7, this increase was not statistically significant (P =
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.231). These data suggest that increased NER capacity might not be involved in
antiestrogen resistance. Hormonal therapy resistance is associated with tumor
aggressiveness and cancer progression (Viedma-RodríGuez et al., 2014).

Table A1.5 NER capacities, standard errors, and two-tailed unpaired student’s t test value
of the late stage luminal type breast cancer cell line subgroup compared to triple negative
breast cancer cell line subgroup.
NER capacity
Molecular subgroup

Standard Error

T Test

(relative to non-diseased tissues)
Luminal type

2.04

0.258

Triple negative

3.51

0.114

.020

A1.3.2 S-phase indices in the established breast Cancer cell lines and JL BTL-12
S-phase indices were calculated for the established breast cancer cell lines and JL
BTL-12 to investigate the possible effect of proliferation rates on NER function in these
cell lines (Table A1.6). The association between S-phase indices and NER capacities
were examined by a simple linear regression model (Figure A1.2). The model was not
statistically significant (P = .274) and yielded a low coefficient of determination value
(R2 = 0.232). These data suggest that proliferation and NER function are independent
biological mechanisms in these breast cancer cell lines. These results are consistent with
a similar analysis performed on stage I breast cancer primary cultures. No association
was found between proliferation and NER repair capacity (Latimer et al., 2010).
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Table A1.6 S-phase indices and NER function in the commercially available cell lines and
JL BTL-12.
NER capacity (relative to nonCell line/ primary culture
S-Phase Index (%)
diseased breast tissues)
SK-BR-3
42
1.27
JL BTL-12
34
1.60
CAMA-1
36
1.68
MCF-7
27
2.20
MCF-7/LY2
39
2.71
BT-20
35
3.39
MDA-MB-231
27
3.63
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Figure A1.2 S-phase indices in relation to NER function in the commercially available cell
lines and JL BTL-12. No significant association between S-phase indices and NER capacities in
the late stage cell lines and JL BTL-12 was found (P = .274) (R2 = 0.232). NER values were
expressed relative to the average of NER function in non-diseased breast epithelial tissues.

A1.3.3 NER gene expression in the established breast cancer cell lines and JL BTL-12
Gene expression analysis of the 20 canonical NER genes was performed using
expression microarray analysis on the Affymetrix Human Genome U133 plus 2 chip. A
previous study in the Latimer laboratory on stage I breast cultures showed there was a
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strong correlation between NER functional capacity and gene expression (Latimer et al.,
2010). It was therefore hypothesized that overexpression of NER genes would be
associated with the increased NER function that was observed in the late stage breast
tumor cell lines represented by the established cell lines and JL BTL-12 when compared
to the non-diseased breast tissues and stage I tumors. The non-diseased breast epithelial
tissue explant JL BRL-6 and the stage I breast tumor explant JL BTL-8 were used in this
molecular analysis as representatives of non-diseased breast epithelial tissues and stage I
breast tumors, respectively.
NER gene expression of late stage breast cancer compared to the non-diseased breast
epithelial tissue explant JL BRL-6
As shown in Figure A1.3, microarray analysis demonstrated that the NER
pathway was generally overexpressed in the established cell lines and JL BTL-12
compared to JL BRL-6. Fourteen out of 20 NER canonical genes were upregulated in the
HER2-enriched cell line SK-BR-3 in comparison to JL BRL-6. Five of these genes were
individually significant. The luminal type stage III breast tumor explant JL BTL-12 that
was derived in our laboratory had 13 genes overexpressed seven of which reached
statistical significance. The luminal type cell line CAMA-1 had 14 overexpressed genes,
6 genes were individually significant. The most widely used luminal cell line MCF-7
also had 14 genes upregulated. Eight out of these 14 genes were statistically significant.
The oldest triple negative, basal type commercially available cell line BT-20 had 13
genes with increased gene expressions, six genes were individually significant. The triple
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negative, claudin-low MDA-MB-231, which exhibited the highest NER function among
the established cell lines, had 12 NER gene overexpressed six of which reached a
statistical significance
Taken together, three genes, XPA, GTF2H4, and RPA3, were significantly
overexpressed in all the cell lines relative to JL BRL-6. These data suggest that these
three genes may play a major role increasing NER function in late stage breast cancer in
advanced breast tumor cell lines. Two additional upregulated genes, ERCC3 and RPA1,
reached significance in both of the triple negative cell lines BT-20 and MDA-MB-231.
These cell lines had the highest increase in NER function among the established cell
lines, suggesting these two genes might additionally and/or specifically contribute to
induction of NER capacity in this aggressive type of breast cancer.
NER gene expression of late stage breast cancer compared to the stage I tumor explant
JL BTL-8
As also shown in Figure A1.3, the majority of the 20 NER canonical genes were
found to be upregulated in the established cell lines and JL BTL-12, ranging from 13 to
16 overexpressed genes, when compared to the representative stage I tumor JL BTL-8.
In SK-BR-3, 16 genes were unregulated seven of which were significant. A total of 14
NER genes showed an increase in expression in JL BTL-12 and seven genes were
individually significant. CAMA-1 showed 16 overexpressed genes eight of which were
individually significant. The expression in 15 genes was increased in MCF-7 and 11 of
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these genes reached significance. BT-20 had 15 genes that were found to be
overexpressed, seven of which were individually significant. Lastly, MDA-MB-231 had
13 upregulated genes and the upregulation of nine of these were statistically significant.
Taken together, four genes, ERCC3, GTF2H4, RPA3, and RPA2, were
significantly overexpressed in all five cell lines and JL BTL-12 compared to the stage I
tumor explant JL BTL-8. The upregulation of two of these genes, GTF2H4 and RPA3, in
the established cell lines and JL BTL-12 were found persistently significant when
compared to both JL BRL-6 and JL BTL-8. These data suggest that GTF2H4 and RPA3
may play an important role in the increased NER capacity that late stage tumors exhibit
relative to non-diseased breast and stage I breast cancer. In addition, later stage disease
may acquire the high expression of these genes and they may assist late stage disease in
resisting genotoxic chemotherapy agents.
RPA3 was the most overexpressed NER gene that was statistically significant in
the commercial cell lines and JL BTL-12 compared to both JL BRL-6 and JL BTL-8.
Theoretically, RPA3 might be a potential therapeutic target to suppress NER function,
and therefore, decrease DNA repair-induced chemotherapy resistance. To test this
hypothesis, we designed a series of RPA3 loss-of-function experiments to examine the
impact on NER function of loss of RPA3 gene activity.
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Figure A1.3 Comparative expression of the 20 NER canonical genes in the established breast cancer cell lines and the stage III explant JL BTL-12
relative to the non-diseased breast epithelial tissue explant JL BRL-6 and the stage I breast tumor explant JL BTL-8. The microarray molecular analyses
of NER genes are shown in four subfigures. (A) CCNH, CDK7, DDB1, DDB2, and ERCC1. CDK7 was significantly upregulated in JL BTL-12 (P = .033) (P =
.018) compared to JL BRL-6 and JL BTL-8, respectively, and in MDA-MB-231 (P = .003) compared to only JL BTL-8. DDB1 was significantly overexpressed
in SK-BR-3 (P = .021) compared to JL BRL-6. The upregulation in DDB2 reached a statistical significant in JL BTL-12 (P = .009) (P = .022) and MCF-7 (P <
.001) (P < .001) compared to JL BRL-6 and JL BTL-8, respectively. (B) ERCC2, ERCC3, ERCC4, ERCC5, and ERCC6. ERCC3 was significantly upregulated
in SK-BR-3 (P = .004) (P = .002), CAMA-1 (P = .009) (P = .004), MCF-7 (P < .001) (P < .001), BT-20 (P = .008) (P = .006), and MDA-MB-231 (P = .001) (P
< .001) compared to JL BRL-6 and JL BTL-8, respectively, while in JL BTL-12 (P = .045) compared to only JL BTL-8. ERCC4 was significantly overexpressed
in CAMA-1 (P = .001) compared to JL BTL-8. (C) ERCC8, GTF2H2, GTF2H3, GTF2H4, and RAD23B. ERCC8 was significantly unregulated in CAMA-1 (P
= .005), MCF-7 (P = .008), and MDA-MB-231 (P = .021) compared to JL BTL-8. GTF2H2 was significantly overexpressed in CAMA-1 (P = .036) (P = .013)
compared to JL BRL-6 and JL BTL-8, respectively, while in MCF-7 (P = .023) and MDA-MB-231 (P = .043) compared to only JL BTL-8. GTF2H4 was
significantly upregulated in SK-BR-3 (P = .012) (P = .010), JL BTL-12 (P = .013) (P = .006), CAMA-1 (P < .001) (P < .001), MCF-7 (P = .003) (P = .002), BT20 (P < .001) (P < .001), and MDA-MB-231 (P = .005) (P = .004) compared to JL BRL-6 and JL BTL-8, respectively. RAD23B was significantly overexpressed
in BT-20 (P = .043) (P = .015) compared to JL BRL-6 and JL BTL-8, respectively, while in SK-BR-3 (P = .021) and MCF-7 (P = .014) compared to only JL
BTL-8. (D) RPA1, RPA2, RPA3, XPA, and XPC. RPA1 was significantly upregulated in JL BTL-12 (P = .006) (P = .002), MCF-7 (P < .001) (P < .001), BT-20
(P = .011) (P = .006), and MDA-MB-231 7 (P < .001) (P < .001) compared to JL BRL-6 and JL BTL-8, respectively, while in SK-BR-3 (P = .049) compared to
only JL BTL-8. RPA2 was significantly overexpressed in JL BTL-12 (P = .009) (P = .003), CAMA-1 (P < .001) (P < .001), MCF-7 (P < .001) (P < .001), and
MDA-MB-231 (P = .003) (P = .002) compared to JL BRL-6 and JL BTL-8, respectively, while in SK-BR-3 (P = .003) and BT-20 (P = .008) compared to only
JL BTL-8. RPA3 was significantly upregulated in SK-BR-3 (P = .019) (P = .014), JL BTL-12 (P < .001) (P < .001), CAMA-1 (P = .001) (P < .001), MCF-7 (P
< .001) (P < .001), BT-20 (P = .004) (P = .003), and MDA-MB-231 (P = .001) (P < .001) compared to JL BRL-6 and JL BTL-8, respectively. XPA was
significantly overexpressed in SK-BR-3 (P= .011) (P = .017), CAMA-1 (P = .020) P = .027), MCF-7 (P = .004) (P = .007), BT-20 (P = .027) (P = .040), and
MDA-MB-231 (P = .027) (P = .039) compared to JL BRL-6 and JL BTL-8, respectively, while in JL BTL-12 (P = .031) compared to only JL BRL-6. XPC was
significantly upregulated in MCF-7 (P = .008) (P = .022) compared to JL BRL-6 and JL BTL-8. GTF2H4 and RPA3 were the only two genes that showed a
significant increase in the cell lines and JL BTL-12 when compared to both JL BRL-6 and JL BTL-8. NER gene expression values were expressed as relative to
JL BRL-6. + and * indicate a significant increase in gene expression compared to JL BRL-6 and JL BTL-8, respectively. P < .05 considered statistically
significant using one-tailed unpaired student’s t test.
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Gene expression clustering analysis of the established breast cancer cell lines
Overall NER gene expression patterns were examined in JL BRL-6, JL BTL-8, JL
BTL-12, and the five established cell lines using a hierarchical supervised clustering
analysis. This analysis revealed two main clusters; the first cluster contained the nondiseased breast tissue explant JL BRL-6 and the stage I tumor explant JL BTL-8, while
the other cluster included the five late stage breast tumor derived cell lines and the late
stage explant JL BTL-12 (Figure A1.4B). This clustering demonstrates that the
established cell lines and JL BTL-12 have a widely different NER gene expression
pattern, influencing the NER function, compared to the early stage breast tumors and
questions the use of these cell lines to study early stage-related molecular or biological
features. Interestingly, the late stage, luminal type JL BTL-12 clustered closely with the
most common luminal type cell line MCF-7, suggesting that MCF-7 molecular identity as
a luminal tumor has been maintained despite that it has been cultured in laboratories for a
long time.
These results were consistent with previous supervised clustering analyses based
on 521 probe sets covering replication and DNA repair genes using a larger set of cell
lines that have been created by Nancy Lalanne, a former graduate student in our
laboratory, including non-diseased breast reduction, DICS with matching contralateral
and ipsilateral non-tumor adjacent explants, stage I, stage II and JL BTL-12 as well as the
late stage commercial breast cancer cell lines (Figure 3.4A). In this analysis, JL BTL-12
clustered with the commercial cell lines, away from the other two clusters containing the

198

non-diseased reduction cell lines, DCIS, stage I, and stage II cell lines. For
replication/repair genes and many other gene sets this is the continuum we see based
upon stage. The clustering of our JL-BTL12 with the stage IV commercial cell lines
demonstrates that the discrimination of our early stage tumors lines from these
established cell lines is not an artifact of our culture system, and it is due to intrinsic
molecular differences between late stage and early stage breast cancer.
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CAMA-1 (VI)
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MCF-7 (IV)

JL BTL-12 (III)
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Figure A1.4 Hierarchical supervised clustering dendrograms. (A) Based on supervised analysis of 521 probe sets covering replication and DNA repair
genes. This figure shows three major clusters: On the far right, the commercial stage IV pleural effusion cell lines and our late-stage lone JL-BTL12; 2. In the
middle, stage II cell lines created in our laboratory; 3. On the left, stage I cell lines, DCIS cell lines with matching contralateral and ipsilateral non tumor adjacent
explants as well as Breast Reduction Lines (BRLs) on the far left. (B) Based on the 20 NER canonical genes. This clustering analysis yields two main clusters,
the first cluster is comprised of the non-diseased breast tissue explants JL BRL-6 and the stage I tumor explants JL BTL-8 while the other cluster included the
five established cell lines and the late stage explants JL BTL-12. The <5 percentile of expression is the brightest color green and the > 95 percentile of
expression is the brightest color red. The Affymetrix HGU133 Plus 2.0 Array was utilized.
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A1.3.4 Silencing RPA3 gene expression
RPA3, as mentioned earlier, was the most overexpressed NER gene in all the late
stage established cell lines and JL BTL-12 relative to JL BRL-6 and JL BTL-8 that might
have a significant impact influencing NER function in late stage breast cancer. We
decided to examine such impact experimentally by silencing RPA3 gene expression in
three late stage cell lines.
After evaluating the transfection efficiency in MDA-MB-231, MCF-7, and JL
BTL-12 (Figure A1.5; Figure A1.6), we assessed the efficacy of RPA3 siRNA in
silencing RPA3 gene expression in these three cell lines using RT-PCR. RPA3
expression of the RPA3 siRNA transfected samples were compared to two control
groups, mock and negative control (Figure A1.7).
In the most transfectable cell line MDA-MB-231, 97% of RPA3 gene expression
was successfully silenced in the RPA3 siRNA treated samples compared to both the
mock (P < .001) and the negative control samples (P < .001). In the second most
transfectable cell line MCF-7, 85% and 83% of the total RPA3 gene expression was
suppressed in RPA3 siRNA transfected samples compared to the mock (P < .001) and the
negative control samples (P < .001), respectively. JL BTL-12 RPA3 siRNA transfected
cells had 69% reduction in RPA3 gene expression relative in mock cells (P = .006), and
68% when compared to negative control treated cells (P = .003). These results showed
that we were able to efficiently suppress RPA3 gene expression in all three cell lines to
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an extent sufficient to allow us to examine the effect of such reduction on NER function,
especially in MDA-MB-231, where the RPA3 gene expression was almost completely
silenced.

Figure A1.5 Lipofectamine transfection efficiency of MDA-MB-231, MCF-7, and JLBTL12. MDA-MB-231 had the highest transfection efficiency followed by MCF-7 then JL
BTL12. The transfection efficiency percentage for each cell line is shown. Error bars represent
the standard error of three independent experiments for each cell line.
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Figure A1.6 Representative microscopic fields of fluorescent-tagged negative control
transfected cells of (A) MDA-MB-231, (B) MCF-7, and (C) JL BTL-12. Transfection
efficiency was assessed 24 hours after transfection using an Olympus® IX51 microscope. Five
20x microscopic fields were captured for each negative control sample using a Hamamatsu®
digital camera (model# C848-03G02) and MetaMorph® software 7.7.4.0v then evaluated for
transfection efficiency using ImageJ software. Representative microscopic bright field (left) and
dark field (right) images are shown for each cell line. BF; bright field DF; dark field
(fluorescence).
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Figure A1.7 RPA3 gene expression of the RPA3 siRNA transfected samples compared to
mock and negative control samples in MDA-MB-231, MCF-7, and JL BTL-12. JL BTL-12
was plated on matrigel, which was later shown to reduce transfection efficiency. RPA3 gene
expression was significantly reduced by RPA3 siRNA transfection in all three cell lines. The
percentage of reduction is given in the figure relative to the concurrent mock treated controls.
RPA3 gene expression was expressed relative to the mock samples. Error bars represent standard
errors over three independent experiments for each cell line. + and * indicate a significant
decrease in RPA3 gene expression when compared with mock and negative control samples,
respectively. P < .05 was considered statistically significant using one-tailed paired student’s t
test. NC; Negative control samples.

A1.3.6 Impact of silencing RPA3 gene expression on NER function and replication
After we validated the RPA3 siRNA efficacy in three different advanced stage
breast cancer cell lines, we selected the most transfectable cell line, MDA-MB-231, in
which RPA3 gene expression was almost completely silenced, to assess the impact of
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such silencing on NER function using the functional unscheduled DNA synthesis assay.
Processed grain counts derived from application of the unscheduled DNA synthesis assay
on three slides transfected with RPA3 siRNA were compared to three slides that were
treated with negative control scrambled RNA duplex.
RPA3 siRNA transfected cells (n = 300) had a 16% decrease in NER capacity
relative to negative control treated cells (n = 300, Figure A1.8). This reduction was
found to be statistically significant (P < .001). These data suggest that RPA3 is
significantly involved in the increased NER function that late stage breast cancer
acquired.
Since RPA3 has a role in replication, we evaluated the impact of RPA3 siRNA
transfection on proliferation by calculating S-phase indices for both negative control and
RPA3 siRNA transfected slides. RPA3 siRNA transfected slides had a significantly
lower S-phase index by 25% (P < .001) (Figure A1.9). These results indicate that
silencing RPA3 gene expression significantly reduced MDA-MB-231 cell proliferation.
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Figure A1.8 The
impact of silencing
RPA3 gene
expression on NER
function in MDAMB-231. NER
function was
significantly reduced
in RPA3 siRNA
treated cells (n =
300) relative to
negative control cells
(n = 300, P < .001).
The percentage of
NER function
reduction is given in
the figure. The NER
function was
expressed as relative
to negative control cells. Error bars represent standard errors of the pooled grain counts over the counted
nuclei in three slides of each treatment group. P < .05 considered statistically significant using one-tailed
paired student’s t test. NC; Negative control cell

Figure A1.9 The impact
of silencing RPA3 gene
expression on cell
proliferation in MDAMB-231. The S-phase
index was significantly
reduced in the in RPA3
siRNA slides relative to
negative control slides (P
< .001). The percentage
of S-phase index
reduction is given in the
figure. Error bars
represent the standard
error of the pooled Sphase indices of total
counted fields in three
slides in each treatment
group. P < .05 was considered statistically significant using one-tailed paired student’s t test. NC;
Negative control samples
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A1.4 Discussion
The established, late stage, commercially available breast cancer cell lines have
been the predominant models in breast cancer research. In order to improve breast cancer
patient outcomes using these cell lines, especially with downstaging of the most
commonly diagnosed breast cancers, it is essential to ensure that these cell lines are
representative breast cancer models.
Our laboratory has previously shown that sporadic stage I breast tumors had an
intrinsic loss in NER function and gene and protein expression compared to non-diseased
breast epithelial tissues (Latimer et al., 2010). However, this low repairing phenotype
was not shown to be present in the most commonly used late stage established available
breast cancer-derived cell lines (Figure A1.1). In fact, the established cell lines instead
showed significantly higher NER function by a factor 2.35 and 5.15 times, when
compared to primary cultures of non-diseased breast epithelial tissues and stage I breast
tumors, respectively (Table A1.1). These results indicate that these widely used breast
cancer cell lines are not representative of stage I breast tumors when it comes to NER
capacity, which is a fundamental molecular characteristic associated with genomic
instability and carcinogenesis.
There are several factors that might contribute to the increase in NER function
that was observed in the established cell lines compared the primary stage I tumor
cultures. The first factor is the tumor stage from which these cell lines and primary
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cultures have been isolated. The majority of the established breast cancer cell lines that
were examined in this study have been derived from pleural effusion of women with a
stage IV metastatic breast cancer (Cailleau et al., 1978; Keydar et al., 1979; Lippman &
Bolan, 1975; H D Soule et al., 1973; Trempe, 1976). Therefore, the observed increase in
NER function is likely associated with cancer progression and/or drug resistance. Late
stage tumors from the era that produced these commonly used cell lines may represent
the most abnormal subpopulation that has survived in culture. These cells have gone
through a serial of cancer cell selection rounds due to the natural tumor selection process
or as a result of chemotherapy treatment. This aggressive subpopulation of tumor cells
survived chemotherapy treatment because they have an efficient high NER function.
Another progression-related possibility for increasing NER function in late stage
cancer is that the tumor itself has evolved and restored NER capacity either by altering
NER gene or protein regulation or amplifying some of NER genes since cancer cells are
genomically unstable. This would assume that most stage I tumors, if they progress,
naturally become higher in NER capacity than they were as stage I entities. In fact, JL
BTL-12 that has been established from chemotherapy native stage III tumor had already
high NER function (Figure A1.1). This finding supports this possibility and indicates
that the increased NER function is an intrinsic phenotype in late stage breast cancer.
The second factor that might play a role in driving the significant difference in
NER function between the established cell lines and the primary cultures of stage I
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tumors is the culture conditions in which these cultures are maintained. Established cell
lines grow as a monolayer on plastic culture flask, while the stage I tumor primary
cultures our laboratory created are maintained on a reconstituted basement membrane
that allows the cancer cells to grow and communicate with each other in a threedimensional environment, which is closer to the tumor in vivo microenvironment as
compared to the classical in vitro cell culture methods (Lee, Kenny, Lee, & Bissell,
2007). For instance, the HER2 overexpressing cell line SK-BR-3 has been shown to
respond significantly better to trastuzumab grown in a three-dimensional model
compared to on plastic (Pickl & Ries, 2009). A number of MCF-7 cell lines that were
obtained from different laboratories have been shown to have significant biological and
genomic parameters such as growth rate, hormonal response, and karyotype, despite the
fact that they all had the same origin (Bahia et al., 2002; Wenger et al., 2004). The fact
that JL BTL-12 manifested high NER capacity consistent with what we observed in the
established cell lines, when compared to both non-diseased breast epithelial tissues and
stage I tumors that were maintained under the same cell culture conditions indicates that
the increased NER function in the cell lines was not due to culture technical artifacts; it is
most likely an intrinsic progression-related characteristic in late stage breast cancer. JL
BTL-12 explants that were derived from a patient with a luminal type breast tumor
clustered closely with the most common luminal type cell line MCF-7 in the hierarchical
NER supervised clustering analysis (Figure A1.4B), demonstrating that MCF-7 still
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exhibits the luminal molecular characteristics despite it has been maintained in culture for
a long time.
The established cell lines that were selected for this study represent different
molecular subtypes of breast cancer that allowed us to examine whether the molecular
subtypes have different NER function profiles. Triple negative breast cancer patients
tend to have more aggressive tumors that are less responsive to chemotherapy, and
subsequently have worse clinical outcomes compared to patients with other molecular
subtypes (Bauer et al., 2007). One possible mechanism by which triple negative breast
tumors are less responsive to chemotherapy is by acquiring an increased NER capacity.
The triple negative breast cancer cell lines BT-20 and MDA-MB-231 had significantly
higher NER capacity compared to luminal type cell lines CAMA-1, MCF-7, and MCF7/LY2 and the luminal type breast tumor primary culture JL BTL-12 (Table A1.5).
These data indicate that NER might be a molecular factor contributing to tumor
aggressiveness and chemotherapy resistance that is seen in triple negative breast cancer
patients.
However, these results contradict a recent report that has showed that NER
function was low in triple negative breast cancer compared other molecular subtypes.
Matta, Ortiz, Encarnación, Dutil, & Suárez (2017) examined NER function in peripheral
blood lymphocytes as a surrogate for the tumor cells, which might not reflect the actual
repair in the primary tumor. In fact, the unaffected distant tissue would not show a
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progression-related event such as acquiring an increased NER capacity that occurs only
in the primary tumor. In addition, Matta's group used the host cell reactivation assay that
specifically measures the transcriptional-coupled repair to assess NER function in triple
negative patients, which might not be indicative of the total repair function. Therefore,
we believe we addressed the repair in triple negative late stage breast cancer represented
by MDA-MB-231 and BT-20 in a more specific approach compared to the study that was
discussed.
We also investigated the possibility of an association between antiestrogen
resistance and NER capacity. Advanced breast cancer tumors manifest acquired
antiestrogenic therapy resistance (Broom et al., 2009; Kuukasjärvi, Kononen, Helin,
Holli, & Isola, 1996). MCF-7/LY is a stable variant of MCF-7 that is known for its
tamoxifen resistant phenotype. Although MCF-7/LY2 had a higher NER function by
23%, compared to its parent antiestrogen sensitive MCF-7, this increase did not reach
significance (Figure A1.1). Therefore, NER is as likely as not be involved in developing
resistance to tamoxifen. Such resistance might be explained by other tumor progressionrelated phenomena such as altering tamoxifen pharmacological target or loss of estrogen
receptor expression (Viedma-RodríGuez et al., 2014).
After we established that the established breast cancer-derived cell lines had a
higher NER function relative to non-diseased breast tissue and stage I tumor primary
cultures, we evaluated individual NER gene expression to identify the genes that might
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play an important role in increased NER function in late stage. Supervised analysis using
NER genes showed that the stage I tumor cell line JL BTL-8 grouped together with nondiseased breast epithelial tissue explants JL BRL-6, whereas the established stage IV cell
lines and JL BTL-12 formed another cluster, indicating that even though JL BTL-8 is a
tumor, it is still more related to non-diseased JL BRL-6 than to late stage cancer with
respect to NER gene expression patterns (Figure A1.4B). This supports that early stage
breast cancer has widely different NER molecular characteristics compared to late stage
breast cancer. An extended clustering analysis utilizing more than 500 probes
representing genes involved in DNA repair mechanisms and proliferation revealed
similar results (Figure A1.4A). Thus, the established cell lines that are derived from late
stage patients are inappropriate models for studying NER-related features in early stage
breast cancer.
NER genes, overall, were increased in expression in the cell lines and JL BTL-12
relative to JL BRL-6 and JL BTL-8, as we hypothesized. However, the number and
identity of upregulated genes that individually reached statistical significance varied from
one cell line to another, even amongst cell lines with the same molecular subtypes.
GTF2H4 and RPA3 were the only NER genes consistently significantly overexpressed in
all the established cell lines and JL BTL-12 compared to both JL BRL-6 and JL BTL-8
(Figure A1.3), indicating that these two genes might play an important role in the
increased NER function phenomenon seen in the late stage breast cancer.
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GTF2H4 is a member of the TFIIH complex that is essential for opening the site
of DNA damage, stabilizing the repair bubble, and initiating the repair process. GTF2H4
is a non-enzymatic protein that has a structural function maintaining the stability of
TFIIH complex (Compe & Egly, 2016). TFIIH also plays an important role in
transcription initiation of protein encoding genes (Compe & Egly, 2012). Therefore, the
increase in GTF2H4 gene expression could be also impacted by its role in transcription.
RPA3 is a subunit in replication protein A (RPA) complex that binds to the
opposite (i.e. undamaged) strand, preventing premature re-annealing of the DNA helix
and protecting the undamaged strand from degradation by nucleases. The RPA complex
is also involved in replication, playing essentially the same role as it does in repair . The
RPA complex has been an appealing therapeutic target in cancer drug development due
to its essential role in replication. Several compounds have been developed to target the
RPA complex to inhibit cancer cell proliferation, such as NSC15520, HAMNO,
MC113E, TDRL-551, TDRL-505 and fumaropimaric acid (Glanzer et al., 2013, 2014;
Glanzer, Liu, & Oakley, 2011; Neher, Bodenmiller, Fitch, Jalal, & Turchi, 2011).
MC113E, TDRL-551, and TDRL-505 have sensitized cancer cells to chemotherapy
agents that are associated with NER pathway, such as cisplatin, illustrating the important
role that RPA complex plays in NER function (A. K. Mishra, Dormi, Turchi, Woods, &
Turchi, 2015; Neher et al., 2011; Shuck & Turchi, 2010).
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Here in our study, we showed that silencing a subunit in this complex, RPA3, in
the high repairing MDA-MB-231 significantly reduced its NER capacity, although by no
means abrogating the ability to perform NER. Silencing RPA3 also significantly
inhibited MDA-MB-231 proliferation. Although these two processes have been shown to
be independent, the dual impact on proliferation and DNA repair may make RPA3 a
potential therapeutic target in breast cancer treatment. Silencing RPA3 might synergize
the genotoxic effect of chemotherapy agents by directly interfere with the ability of
cancer cell to replicate and suppress NER repair-induced drug resistance mechanism.
However, such statistically significant reduction in NER function and proliferation needs
to be evaluated in the context of the biological significance. Future experiments should
involve RPA3 siRNA transfection accompanied by DNA damaged-induced
chemotherapy agents such as cisplatin to see whether this reduction in NER function
caused by silencing RPA3 is significant enough to sensitize cancer cells to this classical
NER remediating genotoxic agent.
In summary, we demonstrated that five commonly used established breast cancer
cell lines and one similar cell line our laboratory established from a primary culture had
significantly higher NER function relative to primary cultures of non-diseased breast
epithelial cultures and stage I breast tumor primary cultures. In addition, the established
cell lines had widely different NER gene expression profiles compared to stage I breast
cancer. It is a clinical reality that cancers of increasing stage are harder to treat
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effectively. This study suggests that with increasing stage, breast cancer may become
more resistant to chemotherapy because of increasing DNA repair capacity.
These findings question the use of the established cell lines as models to study
genomic instability-related phenotypes associated cancer etiology and emphasizes the
need to develop better and more representative in vitro models, especially stage I breast
tumor-derived models, since stage I is by far the most diagnosed stage, 62% of the total
breast cancer cases. Our laboratory has successfully established novel cell lines from
early stage breast tumor primary cultures. Hopefully, the availability of such models
would be the start to shift the focus from the traditional use of the late-stage established
cell lines to utilize our cell lines or similar early stage models in the field of breast cancer
research. In fact, some early stage commercially available breast cancer cell lines have
emerged (Gazdar et al., 1998).
Finally, this study also provides early evidence for the development of a new
NER-targeted therapeutic approach via precisely inhibiting RPA3 gene expression in
concert with genotoxic agents to suppress cell proliferation and reverse chemotherapy
resistance, after recurrence.
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